var title_f13_60_14272="Mediastinal lymphoma PA and CT";
var content_f13_60_14272=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F77617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F77617&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 480px\">",
"   <div class=\"ttl\">",
"    Mediastinal lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 460px; height: 250px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The PA chest radiograph (left panel) reveals a lobulated mass in the upper portion of the mediastinum (arrow). A CT scan obtained at the level of the great vessels (right panel) shows multiple enlarged lymph nodes in the anterior mediastinum.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of William Travis, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14272=[""].join("\n");
var outline_f13_60_14272=null;
var title_f13_60_14273="Nail melanoma dermoscopy";
var content_f13_60_14273=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F85618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F85618&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Dermoscopy of nail melanoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 405px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14273=[""].join("\n");
var outline_f13_60_14273=null;
var title_f13_60_14274="Forceps of aftercoming head 2";
var content_f13_60_14274=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F68911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F68911&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Forceps delivery of after-coming head",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 426px; height: 308px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Pritchard, JA, MacDonald, PC. Williams Obstetrics, 16th Edition, Appleton-Century-Crofts, New York 1980. Copyright &copy;1980 McGraw Hill. p.1071.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14274=[""].join("\n");
var outline_f13_60_14274=null;
var title_f13_60_14275="Carbetocin: Patient drug information";
var content_f13_60_14275=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Carbetocin: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/45/33491?source=see_link\">",
"     see \"Carbetocin: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F239715\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Duratocin&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030700\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692184",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to stop or treat bleeding that happens after a birth.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030699\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705255",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to carbetocin, oxytocin, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705289",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have not had your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030703\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030704\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697891",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698088",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Flushing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698189",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Irritation where the shot is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030706\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698648",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bleeding a lot (soaking 1 pad per hour).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698655",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A fast heartbeat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699008",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad belly pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030702\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695989",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein over a period of time.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030708\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11548 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-188.40.116.55-6D8648E745-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14275=[""].join("\n");
var outline_f13_60_14275=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F239715\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030700\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030699\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030703\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030704\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030706\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030702\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030708\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?32/45/33491?source=related_link\">",
"      Carbetocin: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_60_14276="Iodoquinol and hydrocortisone: Patient drug information";
var content_f13_60_14276=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Iodoquinol and hydrocortisone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/53/24403?source=see_link\">",
"     see \"Iodoquinol and hydrocortisone: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183856\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Alcortin&reg; A;",
"     </li>",
"     <li>",
"      Dermazene&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10016783\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692076",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2692075",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat skin infections.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10016782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702317",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to iodoquinol, hydrocortisone, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are using under a dressing or diaper.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10016787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697343",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have thyroid disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697666",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may stain fingernails, hair, and skin.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697585",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect clothing and fabrics from staining.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696817",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use coverings (bandages, dressings, make-up) unless told to do so by your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10016788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698344",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Skin irritation.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10016790\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698659",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired, weak, or touchy; trembling; having a fast heartbeat, confusion, sweating, or dizziness if you missed a dose or recently stopped this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698988",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Numbness or tingling in your hands or feet.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699086",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight, eye pain, or irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699049",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very bad skin irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10016785\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694772",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take this drug by mouth. Use on your skin only. Keep out of your mouth, nose, and eyes (may burn).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696257",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wash your hands before and after use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694623",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Clean affected part before use. Make sure to dry well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694440",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put a thin layer on the affected skin and rub in gently.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695110",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If using on the groin, use a little bit. Do not wear tight clothing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694785",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not use diapers or plastic pants.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10016786\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696441",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Put on a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696452",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not put on 2 doses or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10016791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699340",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature. Do not freeze.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10016792\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11788 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-197.136.42.3-071942397F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14276=[""].join("\n");
var outline_f13_60_14276=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183856\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016783\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016782\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016787\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016788\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016790\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016785\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016786\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016791\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10016792\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?23/53/24403?source=related_link\">",
"      Iodoquinol and hydrocortisone: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_60_14277="Nephrology pattern 3 answer";
var content_f13_60_14277=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F63425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F63425&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 3 answer",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 243px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCADzAXoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDrfBfjjwx8WNLn0XXrJbHUpV2v5YwHPHzKezcd66b4feCIfDGsrbrOLi2hUmA9G57n8DXk2leDotDuJX08PHdL+8Rwck45x7dK9h8BaudZgE9yxTWILfaImcrvTs2Oh+orrrQcIvkej6Hv1MPOjScoy0ejPPvjk2oa5czQQRySGFwBCgJJRev1PfFVvgdpFyLi/nn86KJgHVCcHPTPtn+lcb4/8T+IdR+ITxWkctvAJQqLCGwx4ySe9e7eCozY6XGzn99K2+VAMduvtW1VunRUEErRpaKzWhuWZvbGwkRQrK7b/LfnqfUfyqjeBLLVLG6SaWIPIEZYpeHPUKR6ZyP0qzqYuREHVSo4X5ZMEg8cfSs/XopZdQtLQRtPHHNHJ5nmDJHcEdscVyR1+ZzQSvd9Tc0a8e58SX87I8LTQIqK64zs3H+tZZ1E3l6sepxiMW75V1P3h2Oe3U8UlxrAj8QyJI+N+3yYTjfwMnHrW/qVhZavpb3UaqshGdy8MCOCP5/Wp+BpyW9ifdg05Le3yOR8WaXdXizzW6iQ2koZPJJIZe5weFPHNc38RdYitfF+i3sEMcsUECmVGfbgHjnHUV6LplxB/YxSR3QxAby2eTjg479K8Av/AApqN1rF1d3MwnXcxRQcM6ew9OtdWHXM/e6afedNC8nZ7L9T1/XfHHg8WcV1q2pB2uY8CCJxIyHuPbkVVuX0vUdP+0aVaTlFKqD90sDx+PX9a8rt/g+2q3STJdvbgfOVnjIXt0b0r1DULebQ/DS28xEfzgs6EdB6fkPahwhBpQeo6dPklyp9drmHrF/NdMLYyIkMRKqhHH4+9V9PURK8/wAoEabi5GAOucD8RWHHqCxXsjSxNJuYqiM2Rn1Jq20/nsEv5Qlokqo+wfKCTwOPrXTy2VketKMacbPRDbfU2S83WyB5M43Hp17e5rYjtobZWP2cfaJmLzTNgk7hyP51reIItDs5wNKgbyIv3eVXO+TGOKxUGpNGg8tlZjvO4YB9/pUKXMr7GfPGolJK3qcvq+uBr8wwwk2+7YpAwu7AP8jW1ZwyagwjghdpAmcZ649BWza+Fz9nkvJ4GZNwlxglQQMZHrxU2veE9R0nxHpWsaPqyR2ksWHiI6Hucdwc03Vh8KOd4m3u31Ma9SCGKO21CZf9KXay4C4Pv6dSPwqDXNFvJ7GOxu9Uiuog4mPlLjcyqQuW9lCiul13QbHVNQju79sCMYRYxl2b/wCv/jWRrrSadYW+IASpZIgCNxA7f59aIyva25MOWo05dDzrwva6hcXZkSLfbljGileADx17cbua7/TrLTdFTWk05pLh7mYRefIoB8rILbQP93GeKybDVng3iKBoUlwHRgSjDrg+nfn3q80gkm+4yIMEYcNx3HQfh7VrO7epvGjGUrt3J7jUL3UVMNzdTTJHwiyMX6j3+lbuh3E9r8PfEZjL7SQg3L8rA4DYPrg1zYWFrkHz9kbH77L2+gzWvq99BcaPpWk2bSNbWkrSvK42iRjzjbn3PWspxvaKRriIqUVTgtLp/dqVINOu4PElpqV3C0WmIA0cuQwmIfPHOegXHFcjoum3V5e6ydZt1aKa4crG3IXk/dJ/D8q7d7uLyLZJXKLv43ElYuew/E1bsZNLa5AgtLq9fHMhAjRmJ4AA5xT52lqjnhFUnzvVmZpWmW1mkFrptrEjuCu1QAG6ipdW8Em6vLBdZuZJIxGJY4S+5IucdPoK7e38ITwCO91S/trTYCFV+AnoN2feq8mn6FHI7vrxu7oHnyXBAxwBkHpWHtk37r/AwlioSlaP5XOY1jwYF0OWHTbjT512eYIdu0qvTnj14xXnlx4Kkllto3j8lh8sgTOD9c8g17IItI2NFIlzDuU+XcnJXcOeWzVVrK41CO7ujF5nlAO0oPLDpj37VcK0o7lxq9JnGaLDFpljJayrHHdkBgi84QkdPevoTw+gj0WzVTkeWD+fNfPkFqn9uo4bMrAK3UnGcgc17NpLXK20ICycD7mSR71jjI8yWpz5jTvBK5nXlzeWw1+bT7X7TdMu6FGwMFs/lxXjngf4XauNam17Wo4YogzSJEyglnY9/wATXvmvwQJFE7O1vPIPnKvtLcdzXJ6/Jcz3ItbdzKrqqKAfu9/x+tRRqO3u6XM6DU9Y6f8AAMG607yNSjnMiku20eWAVHOMDHpxUOo7LBpXmyXjOFeXkAn09KyfjDrE/hXS9N0/RXb7RMWe5mXkhugAP51yfhLxPJq8E+ma3G8srDdHMxAJI7e9dlODnHm6HXCreSH3i6hqOuvK7ymJyroM/Koz19Ogx+NRa54a1vXvEsUs8/maJGQwQHCKAMlcevvXXWGkyhIo7eF5IcfdweR3J/Wr1x4pi0ZZLKxgabUNnmvGq70gQZGZMfd3HgDvg9gTVyqWtyl1+RJHXXniDQdK0Dw7pt1JFbkqpEKNuK7QDgfU1d16C8vNHSa1aP7FOTcF0JBOeR+H1/8ArV414T8Bav4y8bpf6s0tvYRgzyybdoBycKo6DP8AjXruoeI7K10+60rSIJJYoSYwW4VCOwJ4I+lcdSmoSShq92eeouM1GOrv+ZxtsrvcpGzIqsxG8n5cY7D8TWN4vN5Hol/dRXKRiFwqGNsMcZ5+nFU/HOtyaIunfZG2yK4Z1IyrD0NSahAPE+g7rGVcsNyAH81PvXWk1aXQ9S93YofCfXNQ1PVb3TL3zZrdYHmwzfNkDpk+uaxPivp91puoWV9bK0cOdrYP3X4P+NUrm1m0WaGKOV47lz+8AyGwD0/SvUdVgbWfDtp/aMayi5zOdwIJAOMetVO8ZKS6mXK7uN9zNsr5n060nV2G4Iz5b72ef0rY8N6fPB4t1rxNrhZ9Ns4fOhBOQxC9cfSubvLi30spAsMhKr8qJggAcA81saT4jhurOe02zI6IYZopWwQD2K+lRUi2ny9R1oOWiOp8N6tqHihbLxFo0UsOwgSWxcoJU3c/XIr0lvEGnIxV7qFWBwVZ8EH0Ncz4ft0fwa0Glf6NcTIwJGcIcYB/CvJbr4S67PczTPNEzSOXLef1JOc9a4JRp1JNSdktjzJUo1XaTtbQ6v4nSf8ACMwnUH2tYSSbScbmyB/KsXwzrtpqqRX2lyD7SitFG6kB1OBwfy7+te0a1oGn6zo0ulajF59pMCGU8Ec5yD2NfMni/wCC3iKz8SRW3hiEtZH5llEgXbzwSc9elaUK0Jw5ZaNG1HFXjyv/AIc9Xl0qGHTJdZkS6+0O+PLCc5z374JrV0zUIbawhhuZ0gzCrhmwqfN/Dk1LqKT6Z4W07TUk36j8vnybtxGOTnPXJryrxxY6xrt3oulxokNhLKTKI/8AWgqQcZ+nQ0U0qqvLYbk6qu++h7HKwubqOCYtJFLtWA44JI5J9u+RXPePr6PwrcRvcEmOZdqzY5Q9MH2+ldPaWkupSwOVMSxjbgOQwI4BDY61yniS21bURc6f4m0kT26tuhuQdxC9MbhgZ9jWdFrnV9uqMoN8ySZMwh1iwtdct/JuHMscccwQ4VmwOM8Ec9RW9eyJpM1vbx3ChpmEU0LEcsOfNGOnJwR6Vyng6x/sDR9S0Oa4WaBlaeESHIXPTGenIH51Re1nl1DUtb1WffC0BFvCv8b4wN3GOea05OZ2vp0/Q19m27S2X9I7TXp4raC5VMSOY1iIHOFGScfnXNaVBc3mrq9rDBaE/JEGG/AGOvHWsu5FzZ6VaXyTYa5jMewnOMjGCfxrWhSW6uhYW8wspFjSWOdsgkjsPaqUFCOhqoezi7O5u+EdUN34z1/w1qttva1RLm3lcfeRhhuOg59Kk8beF2utNhhtZWeNcjBPI9BmsnwE2o3Hi2a78RFYrgQGOB4wBvAK7txHB6DH4113iu0ZLKSWzmdA5A2ofU81hJuFVWfb0OO8qVZK/wDkeF2+m3sd9iziLBSfnkHTGeufWo554g1lp1y8azEKXZV+9JgjIA6Zz3r0CTSr2CJp5ARCwJO4YGeOtc1oel2EviQ3V5A9yy5Y+WeM4+UZr0I1U02epJ+19/ex1PgNbbTNWe41eVSwhX7PEQSVznkA98CtOzu7bVdaur27RRaxsHWMjOBngkenBrl9YU2zPO4KPMm1RznHPr296wLQ3M7tElxtEuPMLHt/WsXSU7zvuL6p7a9S+rPRdf8AEn2/U/sWjzILeJt0tyQApA42j16msTUp5r28Etw7Ts4Ck7SceyqKn8OaRA80ke5PMOF3nov0Hc/40zUr+HwR4ila5WaSwc5WcDkZHKnJx3GD9amKjF8kFqY2pUXyw3SMq/t7tbuWJbe7Rk7lGXA9apalo96LeCa5ilR3+dCj5OfbBru9M1u6vtTiuLa4Ettc24eISfKzKSMkDuRnFa3ivVINENlJqzW8Qnlwpx3xz/8Aro9tOMlG2ofXJwtFpHCeGfAV/qDkXc09pbMN25iCc+wrq7H4cW0N2yHULl4RhuAFyccdKNX1W7urVbbQJzLezAMgjIIAPrVq/wBS1Lw34ZOpa/cWkcsaZaOLdl2xwuc/mRWU6lWT3tfoclSvVk7xdr9DkvEnhSKz1BxZvPNaxLuklkAwjehPGax/EeqeF/DNtDJeXn2smPdEkHIZzjIPrgfzrG0SPXfi34vaQzy2eg2pUyFcqrY7Kvv717Jrvh3QdGs49Yk0iC8udPh8uN5QDtXOc46Zz7VrOp7NxhJ3f9dTWWKnDlpt3ZgeHEu/HNtaNd6DNo+iwKHgMhUPNnvjqBjHaug1fWPDvgiMIsYN26/LFFy7duT2rnNS8fz6npONKjMaFvLZ0fa4wOQOw7c1zdutrrGlXj3VuPtSkNFNklmPfcc8/wD16j2MpP8AeaLsgp4WpUjzVNIdkXta1yTxTqdvcSoYLVF2rCzZwT1NV7bwjImrNpFgD9skbz57mXq2QCD6bQOgHrTPCOlpLNA2oBpbXOODjc39388VLqeqzu/2O3uLqCMFo5ALhnVl4IAJ5GOQee9bW5XyQ6HZb2cuSitvw/zL2va9oHhXS49KvvEMdzdpKAUiBcRjOSGxnH0rC1TxVD4d0WFzclI2DRuwORKpOVwPcEdKzF8EaPrLKJbtYJ7kEFQMBcHPX1Nblh8NbTxM9jqV7qLQWFhcGOONQCJNgAB5+mKb9nTXvO5zyfsk3N3+XU63wP4Wt5tJttavnx9oQShCpBRT0znvXY6jq9jo1qhLKGYfKD/FjjrU1/dw2disIZWOzG3phQOuO1cdqOmWlxodtf3Mz7UciKPgBiTyT7VwX9tLmntc4ot4iSlWbtc53xrqd9qPmCOQRhhuLqM7ccYB9OK3bbUrCz8PWktmjTTHCtOeJN3RiSR9ao6npMMtor28iOS33ugxgk//AKqoyTW4thbRNttIslsnjOcfzrrspRSXQ9B06copR6D7TQo/EWoGOe4hWJz8gnZTIwx1C/561zXjTwFqOiXiSeEdFt7+5RN8jSz/ADKefupuHpx161Y0vQdT1rxGLiK+trXT4IWkkQqWk+UZDZ7c4/KvPbT4zzahq93olokRkmlENpe3DfKDjBdjkNwfuqD8xwOKcpuEvdl8jGvUcZW5vkdH4a8TeNte1eTw5daWItSjhyJZ4zHHZxE4MkvqowcLwWPHTJHpHg7R9N0nw2I9NTz55Llnvby5UO9yxBXe54x2wBwBwKi8IeGtMsNBupdNvLu8Mrb7ye5bEskpHLOBjPsOQAMDiplmKWjW0aeWz4ZWA6gdazfvvsZxg5632/A2pbybTb6LR9IRPI8kklhgGRs8E45GOa4s2NzoOmzJPHHObna6yrLnHPzAD9OldX4caO5tJ47oyefGfkmVyeOmD+nFc/ryqmtCJTtihTduV85I6H/63anT0k4/f5m1BJTcPv8AM4/xHon9t2SGEIbpvlRXU8MfftR4S0K68OxyWepPGWcltkYJ2Hp1I9q6VbYySCRLl4JHyCMHv6iqc/mrKSJcZIV/lBJP/wCsV0qTat0Ox7ivZRNb3ErR7pYv4jHktz3PXFZPiHxGmj3unWWoRSRiRSpAwcDOT07Hg10VtC7xt8+wrwwzkEZxmsjxP4YtdSFq9zCjujExyMSCc9sg4pJq+pOre4t/pMet7ZLXBuIMOhzguCMYAA5/+tVDSNGENxd3M8rTXly26VicLn2GMVqaZPPpVzbs8Q2KMKM7cjpjIq5LayiOW4liZbdlyGJyM07uOnQez1NLwTfz2F+YpcmEnYwzkV6KYkYlvkGeen/1q8q0sxtEt1bypIUkwrk9WwM8d/rXpCSLsXfJCWxycdTXHiI+9c8/Fw9/mRhW3j2PUdJWbSIPMdDtclwdp7Y7mrkUtzq+mzvLeTxKreW8advpxXi2jXk2g69e6H4XZr+2jZvOhkgbbBN6CRckgZPJr0/wrp11NDdT67cLDNGCfIiOBCCOx9T606lKFPb/AIJDjBRvFWL2gJbWCvdTRrHEBtRp2JdvcA9ay9S1O3GrG+iUrI3ABHHucfQVK+n2ltpolDy3E7rtV5pS4QEngZ6fWs+ztklu/KmRMMx5JxkCnFRbcmdVKEHecj0XwvE0tp58oO5zuBAxzW4yJKpV/njYYII4OaislEdnBHGOFUDn6VBqupw6XbCWZWc8hVQcsR6flXnO85aHjSvOeh5N48tJLaW+aBwbi2UqqseqvwOPbmuU+HUesaDp3iK98UmVIry3VraMkOrgn72OSCBVn4taxc3XgnVNXgjeCaW5EIPYIOgHvnOTUHwDmTVvBGsNqavfXgbykMyF1jjIB6+hP8q9e7VL3u6PVcrKMZ9NzcGrWuq6TDutFgSGZV+9gHgAH6jHNdBrmoaa+pWqJPGPKg8sANgs5xxnuMj6815t8UvEcfh61itbK1RZmH7oKMRx46tjv1xiuG8Fz3/i7xdaxsSWtsOR6c5q1STXM9DepySn7uh9J2V1afbFDecYmiUqVPyxngEEDrUms6qbKBUaJI5+GGQWWQA8fjwPSszTb1U1j7I0canhXVvoP1rVv7ZreORpIlZw5YORnA/+tXI0lJXOZxSmuYS3h1HxLbq+qSxw2W0EwxDGBnqa528Wy0fUJGtHXy4fkUt/Ee9L/bx0CK6lm+ymKRuZ5M/Lk8D3rW0rR4LyJbjUHa5uHUuuHGCCewHGMe1Urw1exsn7Fvm+HsjldRW51KWNLWN5JJQTkHGCfXNdb4c8KWNpITcuk86oGz1Bbp/OrwjZRJHGx3RgBAF247DP5VUOqtDfWXkxonkN5bxg8MS2eRjJxyc0pTlNcsdBVK9SpHlhojS1lbfw3bPqsreXaB1MqSjoScDBP1Fc/qd5p/irw9rckEC3QMasp6bDzz7VH8UvD+reMNElaPUVgtrZTKbTGNzqCefU4zj61yHw/wBLbwvZLPdyLJC8JLlZOPMBGN3OCOtOlBOHNf3jCjFyjzN6r+rF7wd4Z1DQJtK1F7try12F4YXcgwIWBcAGpPiXZ2vjfxHZSxfamtraIoyR9HJOevatDQZJfGV/KYz/AKNHgZiG5DzyM16lZWdlouns5SGCKJdzPsA2gDuaKtZ058z1kOtUjRknJXl29TzXwfby+FIJBY6a7SPkbpSWOAeBntW9c6C3ieZLzxXIIbAZMVpv2qfqT7VBrXj2a5RovD9sHfcdtxLjYF9Rnqc9q8r8ZWuua+tz9vuzezImFhD4EZzksBwPY1Uac6kuaXuv8S1RqVV7Syi/xPcpdW8OeE9HRLOS0igX7sMDBmf6AZJNeReN/jKlv4xisZNMkl0WFtt0kylXZSByF9RnPPWuA0rwjd2dzFNKywNEysCj5II57f5FegXh07XLprrxBpNtq4VQpdWMcoA/2xycehzVxw0Kb5viFDBOPvPVkjtpEA+0eGrqC80jUAJPJYn92RxhuhB/+vWf4wvZ9DutGR7Zl0q/Jy4zjdkjj0wfWroTQVi0630TTW09luCu1m35jPT5vXP867P4lX1ppc2j6PPapc2cnzyh0DbVzjI9Dnmq53GUVa977nQpVFyU0tXf8DBvLiO38OactlPt2XZD4GG9mHtWvrFpDZX+i6dBZxy2V2oee7bqAepBHTHWua1DTlt9XvNOaUGJNrwvjsy7gAM12GlaPpV1YL9kvdVSSMAOqqDgk/3cfqKibSSd/wCmOq4wSlfTX8dvuPNEM9vfXAyxCyFEIHvgfSvVfhffxLp9zpd4yiRZTIm48MDjIH0I/WuP1bTxBrV1BFK0wLKqsB98YB+YVr6bp5jFvIMOVlV5SoOQBzj+Zqq1qkLBiFGtSszpfin4t0nwv4UuLrUCZg7CJYoSN7k9ge3HevMofE58VaXDc2KG2sY4ysFru/1eAAcnHLE/yqH4ueGbrVtG1VbY75LeSMxxehbOAB74I+pqP4VaC2jWFlYXMhE9xJukQgAx7sfLz0qaNOFOnfdnPhqXsndapajdY1m6svDV0qSFLhYiMv0HHFWPgd4Kubrw1dap4jupYbGZt6qW5IHU5OcCtjVdJBsdV81GeeGRsoVBVUDAfhya7XxTb/Zfh1aWELCHzI4oz2GMAt+Zp1KtoqMOrNK81KUY03Zt2OI8eXWsS+HZ9G+Gl8dUu9SjeGRjGFa2hA+eQy4HODgDqd2RnBrhNN+BeleH/A8uvx3Y1rVkUEb02Q27g8/J1JHv9cCvQvBOl3Daxbagjm3sbRx5szEKrY6j8elbnhmeLUvEniqKCESaTKwmMZX5WOMMR7tisJQUJcyd7a/8A58Rh40qvNF81rf8N6nnvw+8TSXsM1sJwl0q+XMh4D++K9Agne7EdnfRGJolOHAxnpz+QrxrUb3R7L4gxx+FrS9WAuRNvJKr6Y7gV7Zo9+t3pUN453yQvtdT129sf4V011tJLc2ntzWMvQdKbTLDUmlldbOe5yrbidmR0bj1/pTb+2ltNTiZ23K+3bK53Bu4ya2YbrOoS2EkZijvQV8tgQr9+3Q44qHxZfM+krCltFH5MgLISdwAH8JHb1rFSk5eooSkp2tucv4I1A6qLht22+S48rygQcKSf4u/T9RUeqSRyXsqQR5Te2Ni9QTnmprT7LplhusYdk0zbmkUfd7n9MVz95NcNFcxwb1kZMIwPBOPXP0roUbybR104tts3bOfDZZQC2Rj9MVLLMTtB3M8Z+ZeTtHNYHh5buMK1xM7OpBTzOvb07c1q6hevp13HM1uskU0Ycq38fO1lHvzRKOuhS3JtQiluIYXgWJ5cnPYg56Vhprl5LYS6elqVSU8ebk7D0OO2SBWprDmxihicsXlCssQBJUEdGbp/ntVG4naaa2n48xHBc5+Yr0/TPanFXWo1qvImZW0260iwkWM3VwQUibG5lBAyf1r1D+0NGXh4pgw4IDsAD9K8u8crZWvimHX7qQMunWKbB2yMn8euKgs/HUU9pBMzEGRFcjHqM+lZuk6yTRwVlz2czZ8Ha4mpeHLgadJFa311iY3TcliMDHA69ua7extpLSKSC8ZHZo18wgcMdv/ANavPfh7o6aRbqY4pPLXdEU7kHPP/wBevQLqZ9jIwZsgDDc/qOvSueqkpNIeIilPlj1MrUJDcvFDHz0Zto/T/PrVyw0eCyR5oo1SaJCRxtB4yAf896XTIdpe4eM4jwBz1NT6rdImlzKHVpXHRT+FS3f3UTUk9IROk0+6uJbZWQRkHGSO/TB9P61keKIby6udPbcsFvDkysOQ+RgD2rjpf7ftII20yW5a2IBjEbFlxjofQg11819dp4UhlvIyZ1wZSgzyT7d+Rms/Z8kk01qYSo+zalFp3OO8b+F59U8MyWpj32p/eRoh+bj+vpXE/C4N4Y8Q3Oj2STNaXOwSrICzKw78DnrXr9hdvcziKW4+UoDEoGCpA4FeMfGCe/8ADuvQ6lpjtHMzFmIHQ8du2cGuyg3NOnI6ack04zR3nxL0W212ytdM021F1KT5sZRfmUr1PPT3pPBXhvSNPhabTLOK3vbhA0r53NjPzcdVGRiuH8M/Eq4k0q9ufsUl1qZhMSrBwQXb73fpUHwZt9Qs7/Vb7U3lhe7URqz5J3bsk+tVKlKMHFvb8Q5ZcvKtu56zrenpcsLu3XZcRgkhh94fWqj+I5ICkWrQyCONFIkhb73Gc/41pq7tA8TuDKqbXJGQwPII/CpoUtreGOSEmO6271zyG9QQfWudSVrNXJukrSV+x53rniO21jS9V0D/AIRS9WW9QrC7fMNx+64I7ZweK6P4eaVq3hbQ003WrpL+NJALd48lolxzGT7GtS51rQobKQILcXBfLpFwS3px0qMa2liEiSRSHw7Kwz5fHrWjblHlUbC9m57L7zVDCMiMWqtbBwyu7YZOTnnPTqKlaC1i1GPVNLiEzg7njVsjdjBAPPI61Q/tBWmjkUAxStjIB6nsB36VHrl49ksDSyKsafOEj44PrjqeQKxUW3Ynkle3cf4n1w2qSiZ0Mjx7ZCF6c8j8q8Z1yPxB4n1iHTdFhka2YhHRBgKM8k+leq+BtDbxHdnUdSH+gRnMcfP7xvU+1ej29hpmjie6ihgtVIzI/CgAVf1iOH92KuwnXp4dezSvIg8JaHbeHdAtdPto0jESDeV/ibuTXDavrD+I/E5s2cto9tL5T26PhpSByzDPK54ArZ8WeL4z4Ye68P3Ec4lbyVukwUU85x74rwjwXrskevXSzztLEznaxfo+eoPpRhqEpc1SW5nhaEpN1Z7s9X1KXRY9UVhOEi2hRbA42kdOe1cxqCzPePc28bG2dsFyCAxHoar69DGtwJ05WRg+Og3AVYtr2KWxlFzIAxkQhWbjoema6oQ5Umj1IRlBXuY+oRSsUwAEiPO3+McH9KtadbxSx3BSGRQvOVGfqPb6/Wt/RLKLVrwBhuheMl3EmPLYZwu3qcnH1rpo5NP0fR/JiCyPM5Z9pz0GAD+dKdbl91LUipVs7Lc4eCxkGkTal5UlvCLhVhZ2BIUdeR1PI5rU1W7i8R6lb3MhDvGFRmUZYoMnp6n+tcrrfi1bvWrPRYzPdXEk2xYIh8kbMenvgV6B4cubSw8S22ifZ43LDZLMM7i+M49gP6Uql4rma1/QfNa8lrJX+SMW8Ml9dXl7Kio00g8tSRuVQAAPwA/WrFpq0lvfxS2+Wlg27ifutgEVH4nlFhreoQxlGnD7lGMjj1/CuSMep6lfi2tJWBnGSEOOcdSfQCnGKlG72LS5qe2h0Z1GSfWnuZSouJQSwK4GSRgVty3DzRrdeequYwWAO3OTtArn10yO1sUmgn86NQ6HA/iUAkH6560/RLmW6nhtRsRGO5nYfKiqCST9BniiUU1ddAlBW5o9DT1GYwXsQlieO2maITYPClCMsf1qfWtBuW+Iq3WmxKbGSWCRnVgcA4yevTg1Jq0EN54S/tWzd57eJwk6uMNt6Ej868B06w1K+8WGO1u50YyZGGO7GTxn6UU4e0u07W0MIzlBtw31TPpV1j1CS/iDqsF/cvJJKvaCJhz9WYYFWvFTNd6TJdKEksI8KARlcdv171k63E9j4D0+az5d5E8yVeSE2ng/pWp47vIdO+HH7kKkEyxIrE8KGIJP864/tRt3sciXK4yXV2PJPF3jmeygi+0xobdWIjtbdfLUdBn3+td5o7nSNO0rUrK5jhu9QiE32GX7swx93f2Pp714/rVppnihoba2vBJNaMsjoM4MeeR/n1r3rVvD9v4l0XT7nTJorazsoSkAZcDAAHPoBt7/AKV11+WCjF6J7nRWlFSUW7Qf9fmcX8OPiHpOt+KtT8P6x4Xj0u7nlbc5+fe2cEOSBg+lbviGxTwzrEcFuS1pcDcinnbz0rjdbEqajLq9hatI7Th42C/eZduW98kE16X4gVfFPhKy1eBcSIu4pnJU9/yI/WspJU5Rktno/Uz9m6M4tv3ZfmTavJbahZpCsJF6UUxeUDwx4Vs9setUvFVvLqUottPtXkbHlPIg+8w6k+gyDVTRU+0acrSSSRMFLI4JGdv3h+ldBpsd/Y6THfWZM8UgLujcuFyeRzzxzisX+7enQzf7p3T1Xc8+kgaDT7kTApNCyJjHQ5Oc/gKovbQLqLSWhDWu4YZvlz2NX9Sml1XU5BARIs8hlaQjhhxzgA4oZxOx8iFYZ4uwOVyB0x/WuxN9T0Yt2KkVsJZCicliB9cUzxJqUlvdwx2RIWCERSSoucMSSRz3GB+daFv5dxG0xDBlBYgH72fT6VVkEZj8mJCpG4sjDPzdPx4FO+uo0uaWvQyXadz5xneR1wQ03zk9uf515xrVrrmmeP7JZ5rhkuJFNuyncjRsRkLgkf8A6q9M1OGaONAI/wB2SE3RjGB6mr+gRrsN3cR+fFZIWiDcDJPHP1PSq5+X3kKtG8dDE+IM0Vx4N1p5vllKrDFCcFjhgMn9SK4Kw0K6extmEQwY1PT2Fbmj6VqPif4qSrPbyHTIiBIWU7AAO3Y8mvaP7Ptof3SWyBU+UDA6DihVlQ+ZzSknKxJoADWtwqYQuoO0/eOR1H60sURZcmQllPf8s1dtJ7NpPtaSRxh1x97APSqk9k9ukk6SK0DSNIpDfdyc4PtzXn31MVL3nfQ0HVbfTMb8EnIPck/yriPD0V9LrV5AQwsUJYPMwwp/umtmdLrZFLIxWGTJRy+eB3xVrSNh0+a7niy0v8IHzPjvg9+lWvdi/MdlBN7tnJ3WpXlnDPBb6k1tao2CFOxc9SOB1q14u+Mek+E20/Rre3a/OxROxOAFK9eOprkPjDb/AGfw4yKHSYhWkAGee30/wrJ0zwDF4o+z6pe3EluWijRwVzltoxg+tdPs6ckpTN6tONWKdtj2LR5rfVbOyvbUqqzBdoyeOc/WqPjzwhLr1lIwcAop2dWJOTjA/wA/pWloGnW1ksNrEpSO2ABYdMgDkg+3ateyvJp4JmvLOWzmVmQEjO8L/Ep9DXLzuEuaJyym4y908C8C6Fd2GvFzDIjWxw4KFRz0+tew6TplkkcD3EI8wA5kPr1B4+tXtOmjv45hK8c7gsQwTa5wcHcB25pwaNLRzGxBUhfoOla1azqPXQ0lUduUZq4DXKiLmRY84HDE9qg0Sfz9Fd51LlmYeWhwQuOfx61dtzAoudTlJEMMZDZbAIXq2fyql4bbSG0cXdjdRy21wWkGWDEA8Y46EVlf3bE8y5eXqrGVqGiWY05bm2hO9WE7swLcAdP5ZqlFFKbhYBGDdSny+SR1we/O3t+Fdjb4FmbUDdE+QMn7oH9KwrzVtKs9bitLKVXvVyMD7uMc9+cc1pCcndG1OtLVF+10sxyRxK6GeGNpeThASMHp+NedfFjW3ma3soJBHNdOIhjjanA/Dr+td/dXawOjrI85kRk2R8GRicc+3tXi+r28/ir4i2emCOYP5m0bQenUn2A9a1oR97nl0Ek/jkfUvhnTodI0Cw0+2ACW8Spx64yT+ua8g/aovdaTwzp9no4k+yTzEXbRdeBkKfbvivbbWMwWkMbvuKIFLHvgda8A+J3xRa18bz+H9KtLO4hWVRM88XmAyBQOBnjHTNcOEjKdXmWtjy8PD2tUzPCfibRPDPgfTNE8fyXAa9b7TBHChDQxEABmxyM84HpVSy8MeCdbmlu/Bfixo3iXc1peJ8x55wcA46evWu18U+CrL4i+G7bXILVIdVgwkgUYWQDHA/z0rybwb4R1LTvibDBp9jL+4JkZc4G0g5BPYc16EGneSdmtz0YxldyUrWeq7f13PQJ7eW3uVg1J1Kx4QAElT9D+IrlbiRrmK4jjdFvmkCq0ke5bdAxBO08EnA9a6fxBpwurE2Vvqls93GMlVZtnDEkB+5rmIL/+y3uodVilM9szLPKrAqhBzg+uOOn61vT1V1udk5OyUtjufBWnNGscssscMOWUyzHaJHPOFA/PHanIJG1ae33nZFNtcBc8DPNJC6S+H9MZmA8wma0ckDjd8wYH1PIP4VoXFjcaRDNfXV1YQ21yRI7yzqd3U9fqT0rBy1bZDkl1OG1G8sfA2rSz6bYG51O6jMq39w+4xKxP+rUAY6EZrsPDmu28Nhb6wNOb+25EKoG+4pbOGI/vYx+dZ2q2eky6Wt7erFeXYULEwk3KEGSeB1Gc1zGl+IZftkUAXEqyCaFsdSO2O/StORVI7Exgrtd/xLHgXVrzxTfa2dWcQyRSsiSOPmaQ7vl5+n60/wAVaVqa6Vd3GkhzPZSx79p+YA9MevSvQNO0uz1zV4dZWeZoIlLy27KCARknHA4/AmuD0vxXe6d8UtVsr4RNZXOY2ikQgNGxG1h6jnOaiM22+XddCpVOWPJe76+XkdJ4UF8vw6utR1uDbe3Uht7eMqUIUgZbHqRmsLU/FFt4au3WSB5rdYkhuJYyMxq/DEeprs/GH2i1v7m2BYWltbbrSPPBDAEnPfkY+grzS00vTdSuY7i/vmWylkVbiEHJwpyc45p0rSvKWzJhGU4OSe+p6ZrEsUXhgWWjyfaLe4t1kLLwpBA+f+VY/hLTbee7s2k+W7nkZYZAvAaMA8/pxVzVrqytrC8nTZb2Ri2xoW6RJg8fpXP+F/Ea6uk66RN8ig7gVGckY3LnkenGKiMXyOxUbqDV9Wanw1n1GHVb2w1JZrixu2ZChGU2EHLD8h+ddz8RNOt7n4fXGmAiIRRAovUqo4H481Df6zF4dh0NraOPyZrUjd78d/xrnrjxtp0d+txrc7xwzERtnAVd3BOO44rCSlVmqiX9I5FQnN+1S91ank+nxW+kwTaxfyRrHtFqBGhXngk474Fdvpdyl3o7zQXMrWrNjCudmPVh0NR+OPhtHqd1Y2mnTB7C+ffZ3ET/ACfMcnPGDwc/SjW5dD+GslnoV5dvd304LtFGo2omMZbPTOBgda7HVjUtbdnQq0EklazN66WLUfD0EbuLW5iV0hlf/VzLkZU+jDg1b+FfiXTp9cuPC1tdR3hFsZJZIxlN4IBAPfg8/SuS0zxpp14ZfDbRyhLkCS2E6gYb/ZYHjIz1/wDrVneHPCln4a1k6vp+p3jXyBmt4QgTGR0fnn6DrWUqV4yhL5EVeapB01tc7e7jv9KurjTdQKFkBZWj+6ynuPz/AAr1qwQQaTbxhNyrCoCr34rz74hxS/b9PupowBNByP7rDGR+tejWDBrG2YdDGpH5VwYiXNCMjixcualCXc8PudUfwN8R73TJnUpPbvcWR3YXawPyt7hh+VeR+Dtb8Qap4pcXtzOwLvJLEw/dr1J47V778ctAa9ttO1WFQJ7a4QF+Btiw27n3zXJWzRQ2gWCOIOzbi4HLDtz6ev4V3YealBT67fcduGftIqpfU1rFWt9yMqqrRgNjqDyQPzpj2skkZnhUGFOJOmVz7fpUtrdW0s9rI7lQoxKoG3kDgj1J71zHiPxDML6PTtLKowy29x78DI+tUouTsjqUne504jjkMSL5jB02ybugznGMc/8A6qrwSeVDqNuip9nccLtwVOR2/DNZvhXxNNqeqQ2uprb/AGjICTKMK3XBb2yD+ddfpNireJrpZlRxAxVuMDgcfzqJ+5dSJlUUU7+pp6Bpf9ieH7i4YIL2RS7BjgHjIX/PrSQW0t3BHcyajErzKJGXy+hIzirHjVHi0WGVWXymdVK+ueOtZ7aTBIxcSIu4527yMe3WuKU21z932OKD5lzyerIYokmZVtY4kG3CRqobYvTn0q0LGYrLPEXJiBzjGCPXFdfpdjbWNoohVfmGSSB1rO1LVLayvoreZ1xM5VgrDcP972pKq5O0UZKs5O0UcpPKFhaa5O6McRqM9fp78Vqws9tp9u0aYDx5JccgnGKy7hG1HVQ5VTbxOQgVfl9vfgVrIHkkEWR5ESbflBznp0IraXQ1nqlc5fUYbjVL0LDatcKjHcwblscYP51a0torWZBKZlS3YtsggyF993OT1pNFuzpmqzowlaOTcd6KeG4/oK3mle8vIlRgYupweg/yauUmvdexrOUkuXoc6niWSLW5WktWWCXG44OSPXke1dHN4j0+3VJzIstsT83qB6YNJeWqC2c3jKUPAUr29cjoa4b4kxz3PhIyaTBKxiOdqc7+3SiMYVWlaxny06ltDp9P1bT47iU29wEWd2Ah+6SuOOe/OKxNWsLhA9x5kpfOHULkYPI6V5x8N/EOtXN3Ja3WnxmKPIaV4cNGfckcV63e3NwNNZoLiJGK4LRoM5+hyPzFayi6UtDaPuu8evc85+Kh8RXXhOzstIMgtRK0VzEhwGB5Un/x6tP4c+GV0Pw5C+qSbrhQWWNDwM9M+vPam+L9S1C10pJrVFmIYKxXIKk+39a0Ib2SXToJrhTEyRhdp4Ct7n8c1q0+VJGypq7a3N/TtWZJpluod8TMMYbGFIxUfjTwb9iaPU9ERC0eJyuecZ/hJ/DjNYVpctcWLvG0UsIj3iRJAxPPOR1B69q6rR9ba0t47adBK8eCm8kjrx1/AVhJShLmh9xFak4tTp/NBeWt1JbrfSWvkXR2yqjjCjI5/nVL4X2McnjOS6CAmGBgM87CxB/Pkiug1TVnvbdjPZt9qQZKbsoAATnP4fpWb8FAb3+07/Bj2zeUcdHI9/bpWcpSVGTZzzm1QnzaHqLxrIBuAJU5Bx0NfMHiPwiIfiLrV9cShXN25jBXPDDdux9K+oh+leE+PrkL4n1JtpXE23zC2B0Ax7VngJNSaRhletRryGeE9Z1PRdXs5FmMumPGfMiQZA55YgV2Os3dnpniGPWFYTaffwG1uXQZMf8AtcdDjqK8c0XxC1zdsrWnkIJGRZg53qfoPwBr0TS9csl0q4tdWtp28wDJQhgcHqvoeRXZWpe9zWOypTU5e0S30Z5l/ZXieHx7NaRJC+goSEuXKrHJH1DBu56cCt7xVpMF7rF7d282TMio644kYKAW5GcE5rrLjUdMtNMH2LSLpJScRzykEEc9Rn5c/jTtJ1a5uNWsredrRklZWKxIC3UdT0z0qlOXxW2NeabTlK733FtPAxXR7N7u/S3dEKRwysF4AGMc55rzDVfCOpX/AIv+walbSw20ZA37N3ydcoO5PP6ZqX4qaZqXiXxhfyR3TovnMoWQnasYOBjHbivVPCdlL4e+FzS3NxJc6o8fkQSyElgueFUnoOTS550opt3b/UycqqS5utvxOT1zRTpti9jDaNZ2zRGOMFizLkHO4/3sHJH0rOt9FvZ47W8kt9kdkhWN927cT1OfpXVNPezaGbK+RAkkpkiL8yMxBGfp71m/EXVhofgFkt5fLniZNqDqVzgt+YH6VUZy0ibTap25uhf8Jak0RvbCWGb7LOpaUwPho8cZHqPaofEGjWWva/Yq0AlubCIKLyElS65JAOOvXpXH+BtavRYrdypmW4geLeCQWycZx6YGa9Q0OwcyafbInki6Bfef7o4z71NRezk5BNRV5taP/Il+Ix0/TvC0GuahK8PmKLeRk+b5SDgAHvxXl3wr0Xw1eapJcnXXupY8uIRE0e1O5c8juP1r0z486Bd6z4Ht9K0iIvciYFUyAoUfxHngfWuf8M+H7LwT4cFjGLWW8jiT7S5AfzbqQHAPqqjoOmeayoT/AHVk9WcNGcpRSX9ah4gtNPvrJ4xdiZHMizpGDiNGAA2569P0Fcn8MrBPDup3c0UrSyDJH7sY2jI5H1NdDZWl4tvfXGpyLHJJ8oG4Et/wEdAPXjFJp8MUTyi3gl+0yrsYJyc+uO/NdEXaLielOmkrXvY7Xxr4fvbnQ9EmtYzstbfbKnVhwDnHQ9PWuB1Xw5DqmiNBcXMYupYd4j24wCeBns2AD6VtaL498W6PeJpmpWNvf2qHas0waOQr2ye56dR/jU+q2lwZZr2dEj82TmEfejGMjIH3cVjTU4e7LboYYapVjD2U9vzH+GmOleGfC+k2we9uYJ5WdWbo4z37AZrmtV8F2OrazP4gu4XvWj3NPsmLYz91scHaDjpWp4UuYrK7M9wCY0kljbH3troRkfia6DTdB1HS9OttVmlsrUlNkscj7VdDwQeo5Bzjt605P2cm+r/UnkhBO+nb72ecQeFbL+0YrvULlQsAEieWMPnsM57da6rVZ7o+U+SLaYs0UEScLjqS394nnFc1rM0GpiSPSZjLbxz7WCjcSgP3ev8AkVX0dri21Hy4rWfT7RULSxSsGjdz90qOQDn0rocXLVmnuqS0uj1q/upNa8BW91dKxubSYwszDluMZ/UZrsPBl4Lzw5ZtvDPGnlP7EcfyxXCFjZ+Ao5Wn85L24Rw4H3Tjlf0rXlW58LXUd/YL5unXKKZYc98DkH1rzKkFJOK7ux59Wmpw9nHu7f5HXeItOXVtGurNx/rUK9K8w8M6II9Pexu4SRDJlWLHeDzkfQ8GvQbXxZpd5rVnpVjJJdXdxAblhCm5bePs0p/g3EEAdSQeMAkZuuRi31K5ktrfLBPMLocHPp+lZUJyjeBjhKko3pnMavpGIIBpcBmldN55zn256YIrj9W8MXC3LnU4yk5II2np2HINeqaVe21nBai9SRXiDMzHkDJzn3ySKl1PzzfxXFsu8rHllLcDOOf16e1dMa8oOx2wxMoPla0PHNJ0CGCbdbFjJkfOzE49PocmvYfD2liOydFBaV/mmeU5LnA6e31qu+kWNsIrq4gAwzTmYMFAPXkVNLqco0e3NtJ/rpAgcnDAEE1Naq6qViK9Z1klBaEHjeaGTTYY0Y/Z4WV2I/QfXmuGbVtRiYxxX0flodq5IzgdO1b3xAngt9IXcx+YmQ8/wqOuK8afxpb72xauRnjDCt8LSvDa50YWEVT94+hdR8QW9v8Au7KYSALz1b8q4l5JoL6W6vYGmQnBlyDtJ6fL6c9PesTXrLxBqLWm/UbW1t3nTIgjZf4sdR2/wrV8Taxb6T4nGl2wSWVlXbtcMQSBnIqYUlH3Y6tmdKCj7qWrN241DEIRFWOLduL42gf7Rxz3qw80k168ouCYtmxzjbu9CPauMh1S41bxHFYRW0cdtZ5mmwMKccZJ78nrW/PNNMk2nRJm4nZNrKcqv4+/9aTp8ugclnYuuywahp7QbUkM+WAUHI5J/lVjSrqIvFtBYyORIMZ7kEevavIpfFF7P8QrPTrEyGK2maNhnO4KCGyfoM16roASC3MxaQtGC5A7cnP0706tLkWopxXLc4zxB4tbRfFmp2VzbzyLc+XLFzxnGCM+natLwzq2oXcFzJfaelpZg4jidixbPc8cVoR+Zq2ovc6lpkZWGUsh2/MsQOR+P+NPvr9Q4ghRRHyvPGe+c1baa5UtS4RekbEiTqlvKVjgUSfKzgfMR7/yrA16d7OMTM4OVJZQTjjPH6U25ugxWIfKmzIJH3j7H60TXEctmLG72jByoUDcmOpP51cY2dzqhT5HdnD6H4s1bXtfjtUtY0teRtjTG33J7811niO1jurSXT1kIM0DLuHBDHp+uB+FR2en/ZpC1lHHCueNgILE9+nJx/Kuwl0/TZvDzzXd273igiPaRjdjj8MY9Kqc1Fpot2ppc2tz518G2+pWXie3hIkD7/LePnkdD9RXuj3AglbzFUkhQTjJU5BOP1rmZtd0q01K0sFlL6vJJ8yhAvl98EnqT/hXTuvmazb+bGYgEWZlBB4I4OKdR33JSUVyp6HSO8M9xcncohEeFdVwDuHP+I/GpvgdIU0HUrJl2tbXz84+8G5B/wA+lViIBLCnmYtpoiXDL8yso4/DPSr/AMHHD2Gq/IUYXOWHvyc1xVf4UvkediEvYSfoehOwRGZjhQMk+leRaxBpfjWaSISfYdTcEwTt8qzjsH98dO9emeJIpJtA1GOFS0jW7hQOp+U8f0rxiSfbc/2hAsEttJIgSB13Y2Ltww9OcVlhIXTktzLLoN804u0lsc/d+D59G1EyX1pJaylsCQkmJiR1Dfd/rUrxi1cNck567VIbP4V3Muv3c1xZaYDBbW16gdY3QuDu6BsnhT09qj1a/wBMGhoqaTYw6iJPs6QxxB3Z8YZsDkAfzrvVWeikj1FiKsVaUd+35nIaIb3VY32AREAhfNIXLduvt/St+1sI9MsJLm7ni83nKRMrEt2GcY/I1nJaHTbea51hX82KNppoBIilR7jsMkdq4CTxLNqs0lrZRyxNJnydrY3DH8I7fw/gTWij7R6bClO6tc6dL+zm1H7NHIst05O5V4we49zXa6lqs0ejQ2bfNllVdw+7gdf5V594K0C7l1mG/mhaIKP3UIIXLgYLHnr1/wDr16DeeVpmtabDqasECebIQQFG709gD1qavLzJLUTknbm6amd4k3aXZILq4tre4miD7ihaRxnucEj9BXPeIdEbxLpttbvcIHRSWJXoOp7cn29an+Mmr6fb/EKHTS17dX0qKx2lViiDY2Dpk/nXQLaQWfhaLUnmkE9yzAjsB2x9Oc1MJcsIy6scalOdKKW73/yL3w68N2OmaJFdXCedn5LaJj/COMn8Qf1ra1KWS8vLgp/x8Rxja2SAAewHaregqq6Ro0cq7YRCCHBzuDNknp1qC7s7fS9dnthftLdzQmRYGjwAuTzuz6iuVz5ptvc41Pmm29+gyz8QyWek2trZwpqF9On7x5JAiZxyuTyxGegryP4haPqHiu6e48+O2cuUlgRCQpA649sY/Oul0yylvNesLO7G2G3k8ktxhUVi5znjua5PxYt1qkz3dnMUDzuCijAIJJ7f56V1UaahPTc6Y4eFPzbWpo+HtHbQNAt7FZ451Ri8hUc5IGcnHT0/GqGt6xe2OrT29nEEeFBIHkO1+eQV56jj/wCtV74bhkiuZb35obQvP5QPGVA2qfqSK2rH50Oo6hFFdWBkMRhkjWQO5Gccj5fqK1b5ZO+paTcPd0t/Vip8P/G+ta6l9pPjEGfKLc6fe+WArMh3Bcj+8P8ADvXf+GL/AE/Tr3V4tUffPdSmeB9m4PGQTlffr+Vct9hszdr/AGj5kMRyTFaIBsHYD07Cr15Z6Vo1ravp8uoyvKwZZZ9pVAeoyB/SuacYy0Stfsc3sYpcmtpB4wgsghvIXWG2lIc7QMkf459a871+e71wRwRarIsAH+pYMApHHUHB/Kuk8WtdXWhNHJKi3TM3EvGcEAD9K5+w0yfdG06fJCfkdiCzFhznHGO9dFGPLG7Z0xg1aD1L3hnw/DpVh5TMZFnP7xnb5icHkDtzxWjcWPnQwr5TyTxyDZHg5Y9jirNnNc/ZbgW1srSRxskbCPeFfnr24NYejXeuzajJDerPIduT+7A2nGOCKerbdx7O1tDtoZWk8GPpN6u2e0k+0xEf8tF3fMPZhk/ga2fE3iN73RLHQfDUcd3rs9qkzFhmKxixgzS/kQq9WPoASPC/DnxMgvvGMmgaWlrBLLOLezvbxgYd20qzycg4GW2qPvHaOM5r1L4aahpnhpLzQDcxTm6mcyXu9Wllk+6TJ3HbA7DAGBXn1I89+TpqebWSqy/cu9nf/M6b4NaTDoNnqdirtLPJMJ5biXHmzuRhmY/gMDoAcCu51WD7RbtHGB5p5B47VwVrA0Fz50cpt2R9u5c5Ujjn1/lXY6DfNczXUNxn7XERkkY3r2P/AOqsK0LS50YYilyy9pDYwXQqPLnBGMgOq9eaba3f9mNcXFzmQxj93GBy46DrXVXmmwzo+/hSCSO1cEL61tIpn2M1sxIRhycgkdB1GRVQaqJmlKSqpo1006bVLK3k1a62RhmkjgU8Jk8ZwOcD1qlpsTXniVrLAS309ASQM5yOPx/wrV8P3bzyQwTx7S2XU7uT/nFZEu+01/U54xtWXZFvycklcj+VNN3cfIqHNeUfuOW+ICx6re31osyqRCYVy2AW5z/OvGG8I+IkYqLFyFOARMuD+tei/E3WzDdpcabGkGF8tgRnOCRke/NccPGuoAAFZSR3z1r0qEJqCsejGLjFI9A0nxhpuu6X9jhVX8g4OOAD69M1FN4dspfGGm31zfMuoy20ly0RyRt+6pB/D1rj/hzox8Lm+ttQmhGo3agxW7N8xQc7sY4z7130t5BNZpJNAP7TQiPzj18ocgD2zz+FZtcrtHYnkckuVW7mxB5VrYzTJHAlwzDzJowQ8ijs/OM5x7VR08GLU/OkcM0ilyQRsHPUfSi3LXHmwRSGEuA0+SP3g4A/Gq+tSDTrWC8vSCjy+SqKBnnjpz0Pr6VCXTuQlytp9SloHhhNK1DU9WufJkmuJfMiGPupg9/U9DXU2F4bg3VwbRonK7CsZyDxgfTrXPtrQeIRRRlmBw7SdD6fpXSWblYluGkYORtwnI79u1E7vWW7FKHLHVFmS6mWOKGVoowqBdmMtx61yscW+9yUO0sQx3HgVqNK1xdyIsY25+RsgEj1NYWoa5YQ3KWaXUUblsks/wAzj0Ht/hRCLWiNKUeXY86+Lmp6loHi6C2srmSJEgDoQB8xJJz6Gu404NPpdi90W+2NGGlJHKkr0Yf571s69omneLr7Tb/VrYefagKZVJwQMlcj8OlPhhP7wBQzod4AyWGCSTz1zWntLxSe6KpOSu5M2IWtNDt7XU75RdXMqD7PbR5VdygqXJx0x/Osm+8Tz6kskWoW8CkfNCIV5Q+o9eKv+P4hB4fsdXhDTlF2x+W2ATjgY9PpXiXg/wAWajqmt/YtSWMrKrEFUCtHtGccduO9TRpqa53uFJ05WlLVv8D2PXvAui+JbRfFentKdStIAXHAMzKvO4dmAzXLWF/cv4uhuZiWtrmBAWVs429vY8frW78N7260rxDLapIJNPvUw3m5VS/bHuc4qbxDanStUGmvbhcnzI/LAJ28nORye4og3GTpvXt6BGPspypN36r0H+J8Ra3pYjf5WtTKuQFzhmHI/Wt74P3UaXur2RJ8xmWUZHXqD/OszX7X7RPpF3sXAtJYl3Y4PBH4ZNO+F0Ev/CY3MibhALc7geh5HT8azqJSov8ArqY1UpYaSf8AVmevMe20sD16V4dqvh97DWbnayrAZG27mIJGSR/P9K9zryLxT/pfjKeOeaQJBgIirnI69P61y4NtSaOHLpuMpJdjl7vUZ7NYY5UQTW5KwyOh3RBskYPcc5GQcdsVpaaLXTtNW9ErNeyAkyYyxDZ+6T0781g6osc10UmzJE7KTk4IwOv5U2BYH8s3UksdnBl3OeQqj7q56selem4po9p07ryNNbaC9tbizsoJHWaIi5lmfOVzk9Og4HPevGtPstSGs282iF47h5Nke35tgzz26DivSrjx5psFt/ZcmmWUWnu4ZpFLecvod3Vm9sYrofBFxof2S61lYjPNagfudv31bjIHfDYz9elOM3Ti20Riabh/E3JtdRdM0y4uLtV+3TQIbW1Z/wB6SAB5jAfdzgn8a2dMW58UfDdL/UIdmp2HmASMnEkYBDD3yp/PFclc6te/aTJ5iyN8wCuFdDz90KRwBXdPdyf8Kd1D7GGhuLOF0dEGSWByePQgmueqnFR73RzV4ShGEnvdHmmpaLp13Pba5JcTx3NtFHG0bEsrumdhDHkcEcV1010o+GFw4zk3axqnZc815V4a1O616KGFUkWO2B3nPBb1r0A+Y8UNkSYYGnDKm3eoOAAc9zW9SGyb2OmNOLtba9x/9p6poep+Y5urrRmhjNxYoN8lsCgzLCO+MgtH/F1HIw3UXunSanBZa3YXn2uDCta3kD70dccDHpXG+IftEWoLc/aJfNkJ3HPcfy4xW34Uubvw7YS69pEE1zorMRq2mRKWaBzybqAdz3eMdeWHzZDclVOmvaROOvGWH/fR2e5e1e5itd7XkADH96UZT+8Oen06D8a4qK4gto1h8yI3DnKpuwQO529cdq6vxrqmnalHpeo6XdJeW8x3xbn3CQYz+PAzgelcVr2iPrDWV1Z5t9dsZwgYKf30RIOwgd1OSD6H6V0UWnFN9TpptqmqiR1dhZ+RLLcwxqbaRCCCPv54OPcHFTG0aaCO0Y+Vbef55RVwxbaQOnQYzXWvpobQ4oGtx9q09Y4j82M5AYnHTv3rIvR9iYGQEArwAQfoPzrJVOYyjW9psZs9pI8CGK53SF2DK5B3dKy9Y8W6RaQQ6NfPC9xISAyK2UPTk/h6VMC4uyHK2y4L5br0J4xXBah4MudV8Utq1xdLHZ7huwMuSoGR/wDX963hCLfvGkkzrtStzdxQu21kKBQc9R2JH0p1kPtMiWqgiWTCjbjA/wA9K2rC2gXxNa6Vdw7YZgIdqkkpleOe5HHNZ8cZ0zX4pBljBcqrAr1AYA4FJTvoa8+lutrodrV1PbajDa6Zc3FraW8IVVhmK5JGSxA75Jrn/EX/AAlviZUsfCyPNrU0bW0l8CI0ihIAZ5H9QM4/iJORkrW147tIrTxdqKwEeV8rhcdCwBIHtnNd18IbdbPw/e3cgbfNKGOBztA4wPrmsaslGjzLd/qZ4xxjg1OK1dvXU4HwZ8EPCPw300a14umXWNTjxtMifuY37eXH/EfdvrgV5Z4v8Iaho0z6/wCHdRkvLGaYszr8ssbEk4de31r2P4p22reK/E1qdPaQ6Jp5w7xkYL8FjgkZI4FWvANl5nhzXdNu0Hnz4khOQd23jHqDnHB9amgvYw9pfV7ryPPoUVSp80t3Yo/CHWptd0WZNRMjywD5mxkH68da7I3txpd7BdWWZg2FlDDgx9semDXM/C7UIbbxfq3h6SMR4G2Rcfx45/XIrq0gLXV5aXMbBYSdkqnqpNKtb2j003NJuPO4vVCeKvE/2yzvLLTGjEiIXkO7kIOTx9K8b8K+OodS8SRaX9ndInzClw75w3O35ccc9s11/iCG08MtNqmqTI817MEVY2wrKQcj8sdKiTw5p080erR2lnp9243wlSQ8p7NjOAPc1pSjCnHTZ/mXTgoQ5Y7HZ+H7l2u0juYibhIsSBCAN2c5Ge30rat9LtZ9NeS4ZmlmYuMtnPYfkK8ZvL3xZ4Y8SWFzLi5tLkZIaQEhc4zu9uveuv8AH2ratbaPbto8lsl4gLx9HdgRxknpwaxqUW2uV7mU6UnNKD3MTxJocxv3kvoJbdWdmQnjPqPx96xP+Ebb+C3yvY+YnIrtPB3/AAket6EJPFTl7l1chU8vB4+XIHeshhbqxHyjBxgqeP0rppza9y+q7HbRquSs1qjzSfSL+++J73jw3RtVculyASjqqgKAw4POBivUtItnmuk82LIhUvKkgx2/SuG8K6Dquh297/xM0nEw2pGpJC/Nyyluh47etei+FpJ44L2fUpiGuIyrEjcMeuexp1paaCV4U2Vzfr58iaesI3oVxx19c/0qu+hzRoH1C7ikg3+aJfM34J4P9fzrm/F1r4knIbw5aN5MTBt6Nhjg9wcZridV17xajyRag8iK3ysixgbR6Yq4Um/hZDaT0PWNZ8Kw6jPZT29zstImDbF5zn3zx2rUnvUIjRD+5tztCk4zgfrXIaN4xjEvhrSY4SDcc3JkBz7E49+a67xfbSaffm3GyRPL8xHRSBznisne6jIcVefKyeOxGrWt6dNliaaKPmE/KxGc8A/SvANW0TULvx3c20cchZmUgkcAHH/6q7vxXqt3Y6d59mSJ8fI393jn/wCt9a3fhZqVv4ourS71Il57bPmSn+LacjPc1or0ouW6NZR5LpvRanpGraVDofw/jDzrB9lVZ55ZPYfNn8MivDvCnjy41jX9TntoNtlExEDszFivOM89x2xXu/xcsf7Y+HWrWsUwiMsP3jn2/wABXgXgrQl0GyW2Q+a1wxaSRuFyuBgfmawwfvQbl3OTBc9TV7XZ2Wl67dX1jBaX8EiCNtyIFBX29e1ZOr6Do2iXN3reluZrlY2lljZCMkg8DrjPANad34em13ULGOCae11CdGuIJFO6Lao4BX8Md65rSbzVHvJIr+KP7RbkoMEKsw9Mden4V0xSveL+R2x5W7LczvAfjW41HUIrSeCFLppV8qRCQB16j+telfG/xFBoN7pUkxLy+UFkKD1OT19snr3rj5fA0UF5aeK9PtpbewR1d0yOG5yAOOARiun/AGoNJbV/Buk6pbbd0Thtm3BZWXPP5VlNxdWLXn95y1KslOL3eps6DMur2KTrIslqFVohv4MbYz1/zxW58Nl8rX9TjZRvVdu76NXBfCCQ2nw7guJCoaMjaZBnByf8a7X4bOZdfnlU5URkMfcnr+ZrKtH3Zomtd0pvoeoV4d4hmm0zxVrD6bEGnQkx4IwD/XvxXuFfO+r6qNW8WT6ssoSG3nPyp13AOu0+nWufAq7l2OTLU3KS8jm7XxDq914kjg1W0jUXL+SuIQAvHBGOMZxz6V0F5BG8Bttqy7MlmXjoMce1Z1j42sNR22TRStDFMVhmVUVFkYHrnkjrzXQuttN9isyi26h8XN2p3Ahj/QV6ctOlj16M+V6HlfjCztY9RQPK8TmLPlpGGwpJ6nIrsfBdpbDw7BJa71mALfMeSQeentg1u6x4e0u+u0t7E/b5clQ/l7QoHHJPTjv0pLu1jsg1lZSRSvFC2HiOVL46KQOf/r1XtFKKiiW71Oe+5yOq232rU5kuGZbeFlkjJ5BUkE8fnXofhK5OnfC28Mys7X880UAznahyAMnqcVh6fpES6ZAt3EjXGC+T8xUHB2/1x7103i24TTLXw/p0bxqbKNnnAGQrHGQffrWdaXPyw8/yOeUOaUV3/Q5TSdF+yzyfZgqC2Xzmw2BzwQ2OD1FaF3eXMjF7Ywm4j/eAIuF9D8vStXwnJZ38F66SxzExny1HZifun/PpWHpKCbUrj7diNk6MV2/Lxkf59KV7t36HZCUXJ8xa1GGWTR7a6uFbzy27pyc8cVq+AdRuNP1GQoWS2ZhuTOQR3NRPqEOpWUsNxDI8crbbVguCqqQNw/Drj1qvouTrccMbGPd8qkEevr7iofvRaaIl79OUZLQ8O+Mmg+MvCXj6XxLcaUkOkLetdWpswzWce5hlSD9wtxuyAGJOK+mPD3jrwnceG9J1LRo7cT3kKyJCT/qTyGV2524IYe+OBXo17HG1jMksSzRbCGjZQwcY5Ug9c184T+FLPQYn1HTYPs1pfSNI0MYxDDKSSVVcfKcYGOny8AVw4ePtXaWx4+BofWKnI3aJ3niG+1db1ru7R47SZhzCQ8GMYU7h149cVjeLvFsNhZ3E8cZk8iIRxNj5ZXz1/AE/lVfw3eMkq2JlkNlfAxSQn5hvIIDD0IODVO+tmvrRLPf5YkKkOy7lRlYYY/lg13wgk0n0PVnh3S93tsZPh7Wlv7ee6mRPM2pIsgYtjcT19OhrrdFhhnjuZZ93kxxu6NggB8Dj36VyXh3wtN4cWe2umV5pWVvlVtp2E47cg5PNemXsMUXha3uLWFI57smHG3kswx0+neqrSin7vUmc5cq5t2XfDWltP4ie5ndmjQCUSEgYOAQAfasX4ifYRr9nqNhcwTQzEed5ThxuUjnjv0rd1e2k13wRrun6PO8WpRxeUjQ8M5RR8oHocY/Gvnf4ZaXqcOrTR3kU8NuqsJYpAUw49j7isKEeeTm3a3Q56cpTrcz6aWPW9ZhNz4knvLmNZ7dkMqBWOWbbwMD/ADiunudUj0H4W28u4x+YNrNnB+ZiTj86868VSarpPhwanZLuZmEfEm9gO52jnGK53UPGes6v4YtrW+sVY22EC8JlWOAcdSOPTitPYuolbZP8jesudxT2j+h2+ty2114KiuYsgQMwIYcYJznHb696d8PNQiXU9EEJjlmSQwsAvUOBxnuV5P41xfhfxF/akUunXUJhuIco6BjhgK6XRtPm0jV7K40rJ/ebxvPfBGKucLRcWaN89Jw6am38TbSTw58RdH8RaYMG7YQXMeM7sYO8fpXVaxeLY6Fe3JRwJIWkRyM5UjnPuMk1wWua1fX/AIva21nzfs1usZtT5fyklfnJbHXcpOCemMV6JqEcep6WbGUxy/a4vKwo6hlxkH1xXFLSEb9DhceSMeb+rHgV9FdeMfDFhqNjcTTxwagZJfN+XyR3XHQ9R09a9FutDvPEfii3t4cQxwWMSbs8EDJz+RqC/jt/ClpZ+FILIQQyYlDjli+cc+vIH51seHtS/s7U1vPstzcTrF5OE/hHU5Hr0rplN8vNFd7G8OZL2kfiRzX7SKyaf4e0HTraVVMa7XccHYAOo/CotJkd/hBBq8aj7ZLF9nEhbPKuQD9dox+Fcv8AFC6u/FepvbLdWiXbEBrdpPnUDnb7Y616L4R0qwuPAuj6FDPu2gu7CEgMwJyST3pWdOjFS73f5mbi4ct3tv8AmP8Agm+oLoN6t/KZAXAjLc445Arrm0aNmJYR5JyeR/8AE0yxktLJI7OGDy443MYCr/EPr9aeDKw3Lc3IB5A2muWo3Um5LS5jK6k2tD5r8c+INWk1kW+myPb2ikBSq4LFif8APFew+HoEu9GEbOXUHnPOffHSuS0q4g1nQrWC8toop4WLr+7BYsM4GTz3rt/CJuZ7WZXt/LsoMpu46454798+ldtd6aaWO2q3BbklzZfYBbvavLHF5xLFnJUr3OM8fhUb6pp81/FaXURd52Ijcw8MQMkA1nTeLNOv9eOgW06PcR27GFpMbGkAOAR9ccVz/h238YS+PLO48QaellYQ5PmxRARk47Fs/U4rNR0fNo0jJvT3ty4/hqG48SXWqCdbZmwkMaqcoOmRzx0xmuh1eYNi5vfMZ2jO1uudoxgdvrUzWNvLPdPFL96QHcrbsgnqD35zWV8VIp7XQ4RapIzGI7Np5Jyfz6dKalzzSZrBpzRmahbQ6lZxq9orLxwfm6+3QV0/wl0uy03Vo4be3WJpEkZkA5HQA9frXC+ALm/bQZE1fD3MjHCuoBVeRz6GvQvBuyx8ZQxuv2ctG0YRmBL98/jTr35JRNcQ+alJeXzLvxvuJrPwLfW+no3nzhWj2nleecD2x+teN/A3Tr7Vre4OqyTmPeWVpG5AHUjPvxXtfxwtwPB/9p7Wb7C4lYIDkqeDj05xXkXgjxNHJd2tvIzxyzwnaBjoTwB6mpw13Q905MGv3fNGVnqdwbu88O6klxDBKYLVlSBZNp3wsW3gHv0B9sV4r8QopbD4gy3KtLDtkWRMcBQDz/Kvf7/W7ey8PiTVBaiOLB8yU85z2H4GuV8TaPYeIfCUE5lMk99GXSZBkDDHP1zwce1aUZqMrtb6Gl3L4tyK68Spq/gvTLbTkxbGJnORzu3EEHt6n8a2Nc1Iap4H0S1EjSvAm643rkhs4Uc/X6V5TpPiKaDxXZaLCEi0lZRaRRhRuI6bieuSea3o9dik8QT6ZLOv2oPsK5wGwf6Y6VbopNeWpvCEZJd02/mz0DUYxZ+BLUuVNxqF1GuxF2gKo5wOw4FdD8KYj5+oSbfk+7kfUf4VQ1+K1uItOmd1M9ugRIVJGc98dj/jS/C7xBaweIdR8P3H7q7kAnhLH/WAdR9R6VyVLyoyscVZv2EvM9Tr5We0lj+KnjDSoId0a3El2sQOMjG44/A5/CvqW5EhhYQuqSEcFuleM2Emlal8UW161cpdurQOpU7XKoVBB75/DtWOCk48z8jlwPNFuceiOG0bwVYyapbyaWbqZCzTLCXAXfjg9M8eldPosNwJrmaSJ5oIJN1xtxuVcehPPFXp00+DwhYizuvK1ZSwniDYdWz8wZT0A/wqDRbqW1nmvbWRbcECFNzjDseoOevAr0HNyTPXi7wcoHNeL5NYl0e6fRrSe5kJ3P8AZoy2yPsSFHNO8HeFPFlrodte3VlM63J/cRbcyAEZyw7Z9zXoPw01a9vPEtxaiKOG3K+bII1wCRwOO1dl4y8WWnhyKNGPm3suNkI64z1PtWNTEVIy9lGNzjrVqsKypwWpzng7wDcW94mo+I5YpZF+dLaPlVb1Y98VyvxCeO98TXyW4QxCMRkpjhj3z361sX2t6lrsZvNRnGlaGAWSMPia5xxhQOefyri2mSUXKv5VtuYGFFUsGwQCCeucZ5PrRSjNz55vX8jowlCpKbqTd3t5Il8KW0Gl3SRea0lxPwV27QoPNaXiaOS51aytrOOQySZDqOCRkd/THOazdMiSTxJDLFgW8W5jg5AyOBnvyRV0Tv8AaLiaR3W42bWI+8f7wP1xW0vi5jqqQ5J6PoV9Z1MxxzbHLi3iCsyjChR/Cg5wM8k9T1qz8IbXWNa18Xskqiytgr5dMrknOF6Z71qeFvBkmvEXl0rQaWDkLkkzYJzwOfpXp4l0bwzZrE0tvaRAcKSNzfgOT+Fc9bERjF04K8medjMTGP7qlqy9qV1FaWkjzOigqcbmwOn+fzrzS1nktBIAIpo5uJoJl3RSDGAcdmHr3rqr3xJper6VdRWzSSsQF2mMg8nGQD6VV8N6lok9w2lS2UlteED5b1ArTfT/AArlpJ04u8TkoJ0qbcos861i+/s14mj061tDPIyB4EYbCMdMnGMEc1W061mkVZIrQ3EZJCMxIBx17811njPQYv7Tt7bzZPsYeNJHLf6tWYk/4Z+lc/47YJrk1rGhWO2CxQIDjYmBjp1B4Nd9Oakkl1PXw8vbNRi90RSfbYhb2/mtukG3C54GMnI7YH8q6LxTrG2SKCBYxb2ybIgOFDYxuPvzmuc0m6hPh/UWupQtzbqPsb4yxLAhk91I9elT6Vpsmp6ZaT3sPl5lCRsZOXUdeO4A70SSbvLoE4RjU/edDQ8MX8tiXuo5ZAydFbO1yerEDk9c9v6VShtbrUtSmuo7mCS4klEgRkK+b3IHA546E5NYPizx5Hb+KR4dsIg1tIiI0ycfO3T6jpWvZNb2WiSrHcmTUpJ04QHEO08Et0//AF0crXv21ZOk+aotG9DT+zx20VxdJdxS2k7gPCsThtwPC/MOD14yay9c0y3UwPqOliIkAhXGwup9uo6V0tx4gFvMJpLaN9Q4AZDmMPjG/A7nPFcb4g1EjVZpNUcvcKFzEWyzdMDjoMdfypU+a4UYzqys1/X9dTkvFUll4Z1C31qKxWDf8gSNdocDqeOPxrsPh/qFx4n1Jbia3a302EbwMYJPaq1la3njG6TT5F+1wlt6xNHlIQOhGeFr1TQ/CMOg6an228WG0hXc0aKAD67m/wAKK1WMI2luTiJLDNwbV+yOT8TIJbzzFjLOWAHbccV3Gi6VLFp1mLkMWtwH3xk7g3oPbB/SsPTtvibxRJOqCKzgjKwgjkdMNj/Gty/1SCPUnsrWYfaYovMc5IIHQAf571yVJNpQW5x1pyklTW6C/wBDsda1O1uplbzbYliAvP689xx7Vy/xSvZkkh0LRGazuLiMs1zCmZBjhQPr61twava2CCfd/pBO5lzlmB7nPf2rKu9duLi5MkRRJjwrhQcUqcZXV9UiaVKSne10jkPAnw08P+GJU1DxfeC61Vm3LCzfc9yASc/XivU4LizvbHy7SNYLFchFXCj8B0FeXvZlNWLmUu8ijJY9W9zXY6M0d9EVuJFDxEZjQ4zgYwPyrWvFy96Tv/XY1q4dRXNczvGVje28trPpWoTi4zlkkfIK9hg9DTE1G+CKJoiZQPnOF5PetnW2EFqYkVfOkX5txzjHpWOsFiVBeRy56kORzRB3ik0VTtyq55x4EXX4fD2mXVvaRXU9uzbBOSp8n3+nJFdbf+O9Gs9KWyFz5d00eXhjB3AsOh6evWtDxLcQWNvb2duzGGYsMrngZAAwO5Oa5OP4fzN8Sb7V9QRG0h9kseDncu0DbgdwRjmt04S96aCbTSbR5hH4W16axa/sIp/tTSmVZNuMx+oOeue3ft3r2D4caN42vWGo+KdTd4tgCQvgkemQMAVtS606NJEdLa1SABYd4wJSRyFIz061p2+oJfWDwkpBdyxhFkY4VVPUmirUlJbfqTyu3NFE0xuRbWMJht44Y5NiyoTubqRkY+tRfE2CP+ybFiz7lbHK/Jn1z+dW3jWa2F1cBZCQoTavp3xXP/EsTanottDBIfswjKZBPDepH4n86xpq84lUVerFrocULvyIHa3UXd3kFoww+ck9OD0rsPC1vca54nhZ1UfZ8zzsvPQ4Ax615bouit4UuZdWuLppYYVLOFG0MM5xn1r0T4MeM4NV8SXwtbWZY2Qs5OM9Qcg+ldVdNQbiddecowbtaVj1L4g6nZ2mgS2t1HHO18DAIW43g9c+gxXlHiDwl4f8Mavp1vaXfk3ghLJExLBWPO0H8+tdZ4zxrwOpW0zqtu3kJbyJ8x55cc+4FeH3U2v6j4wt5ry1kNvDMULkH7ucbifXFY4Sk1HR27nFhqTpxi18z0zV7PRfFlrL4b126bT5NQSOWxmB+VZlBGD6k56H19ah8HG48H6OvhbVp4by5SQx2skAJVkY8A57gg9BxW3oem2LPpU2qWq3EbyZVmAJiYMuCR6cVrz2OjjW3aawjvGKJLHNbgK0LBsngke1EpRT5en6hUilNtHDxaFp8Os/aJYrcXJky0xXJ3cDrXlnj3T7iz+KqvYRs4kaKRcLxngEV9CXemaZDBc75WDyfvY45EIYe1ZOqaJbRagbq0t2RxAXVXJ4bb29gcD61rCqm9TfnjUtujH8N6odT8T3FvK5dYYAFyTyc4zx9RVJ7IRfHDQtkjJcKyfMOA2Rzz3yM1d+HOizWF+b7VAltJPvWME5DAZznHABzx9K1bnTI3+KGhX4lYRwzrGEUdyMDn0zROSUpJbWIm7pryPW/E15Bp+gX13dZ8qKJiSByOMce/NeKeCJjriX7JHaWkNkrTWcyALO8icjKk/MDjmvbvEGlxa1o13p05KpOhXcBnaex/OvENb8NX/hGxutR1PToriVVaOG7tZiEUkEKWTGc8nmuHCOPK431MsslSdOVOTtJ2sZFt4mi8R3ct8gQXEX+jysUK7mHfHr7+1TTXAS/jtpFJXdgAj5gWODgepxVfRtYjk/e3UETBIdgliQIzPjhmwOT7962vB2hXfiXVYz5s0McZLS3KLgg4xgHpnmvRk1FNvRI9WcPq0G6nQ7n4Q2e2zv9QdSBLKIkY9wvX8Mn8wa5Tx+8Wo+N7i8lDNaWcYtkBJAlkHzYyDnHPOPSvY9N02303S4bC0XFvEu0BuSfr75rxvWdLuFvriKcNuScvG2PlbjBzj6Vw4eop1ZTPJwc41sRKpJnNX91OximQRq7KVGR8oUcYVewH9aVrc3EcMUaO24bNqHc2T1AxVU2utrrdu7Wwh0iIMXuJm+VwR/CPrXQaffQi6t9O0xreW6lP7wq+xiD2B/hGOOOea73otD25YmEF7i2DwT4b07Q7S5XU7gm1t5QBbK25pHPzYLegJ7dwa2brVbW7As7AiB7hgr3DgBguegPHHFYd+8kUNzLx5EU/lEJwiMo+YD6Z61nfb7iJIzC+1XXAx0xn8qz5OZ8zMKeGdVe0v/AJHrfhbxFZ2Fu9hdXERjjdvJkjYPkFjhTj+LNee+Ip7rUNU1GWQs0jytlCANoBwo9vl5ptn4pvWuorXUGS7tgRhHUZ/BhXf+F9DttRF219ZiSFsGN3PIbngfT1rDljQbm0ckoLAzdaa1Z51ql7Lo+m2ZtpWvLtEyqQHdtLEAKSOvr7ZrLm1h5tQt0u4DBKFVZFUkkuOTz/Wu21ixtrS01zTZ5o49REqyxSTDaJIgOFBHAP5c1yMGiPeEPJLbwpABIW8wZIBGcep56V0QlFq514aVOd5zPUvD+pwtNFa3awu9xK9vHJcNkzIOq+5B498UzxR4ItJ76Ke1nS1ib5ZI3G8DHQrnoPbpXlXjDT7u/n0S6juY0srUzSW8SOS+d/U+4r1qPVbHVNDsI76SRrxIk8x1jZiW28+57GuWdOVNqcHvueXOE6U1Ug7J32MqTwzp+ms0usXX2xIVLRWtrDsz3wQP1P51k65q3lxpZmAW7n/VoCC8anscdOK9F8OSaVc6eLS1vIbuUxES4Yb8Hgggcj0rgvG3gqXRbS81qwcXscCmU20indgc4yDz6VNKqnPlqPUrD4iDq2rN36HEf2daC9S8e0ja5X5TPjkL0/mcVB/bllHq0Gm+XNPcyybJNowA316k1y3g3xPd699sS6UNPGPMXauFwT0wO2a6bQdCiS8j1OZmN5E/yDIwp7H3Ir0mlH4jucvaRU4dTo4ZodP1wGRyIoGy4l42nkDJz24/KuUjt5vE/iWWy8NxDU5wf3kynEMXX5mfp+A610viLwTN430kWun6jDBrkEzy3MVwvM4J4YN9O1eteAvDFl4H8J22nxGMNGu64nC4MjnqT/IVx1MRGkrrWXY46uPnQbVP4ti34X0K28O6XFbxhPMCAzzYx5jeufSuB+KHjO1jidBIRpluw86QLkSvnhR61h/Ev4kfZNXSGSG5GkuTG00JyMf1Oe1dxc+G9H8U/DBbK0uY5LW6iWeK7Ufx9Q39MVzRh7NqrV6nIl7GSqVdZP8AAreE0Yaa1xFCxS6t0uY22EZB7E/wn8K5m5sZF1K+1i2lmV7w+UhZ+gUcjHYHrk12F3LBonhCGzt5NhEKwqEP3uxPqf8A69eVat4oilvJ4baNpfs6gFA3+rXPU981vRi5ybR00G5NzkaFvJM08zFHmKcseTtwc5J7DirFprMN5vitl3SAclSPl45PPXpXKahr9/Db3+n2c/lwahb+aFYKGkYfw7j27475rH8FLcJOl0ZP3SsVwOMEjGPpzXX7K6bZ2OXM9jtxI898okOXbAwx459fSum8O7ZNZs4V+6u9RMM4PHGc+uKxdKFvE8klxLBGYlKjepIZjxnjnjPatjwtGI55bpo5JFhX5G29WI9M/Suepswrv3GdE9ob/wAQQW26TylRjM/cLkfzPFdolnboiqvlAAYHyisnw3aJLaz3UsmZbpjyp+6oyAPbufxrQ2OvyqMgcAmQ5P6V5tSV3bseLVm5PlvseS2819cW1t5sUcU0QaMJJg7S2GJB9e1dEthcxW9vMkpW2kDGVVGCDj7uT7iqtjb3AmjhWFEEjNN5jjkKe+B+HFdLMqw2hiefJ24JUDH1rqqTs0kdlSdrJHD3ZuGiW3RnwGO3ODgE+4HauafxLY2/xE07RdRgkjhkVVRiQFZ+cAj0rpNQuUuUmRJFkvLZm84hhkY6Hn2rjPHXhEeJZ7TUElNtqVmoIG3maMHKnA6EV0wSas9Dd83J7p6xqmrLHcT2wSGWWMfKCQQB61yEOpv9oijlYvCNzKnGAxzg4x/Ouu065V4I5LmBPKdEUSgYGccgY5xXMalZR2mvCRsi3lZlVlXPB6de+eKxpcusWiaKjFuNjlvF2hf2pY2n2ueXyWYsyKe4/hJqPR7mx8I6dNcWriBREwclA5kzxtPTrzW5P5ZtjabnSLI2E/MwYAjJx79eO9c/4z8Fa/rWlxjTZLMWUZHmES8t3HT8a61JNcsnodknHl97c7L4bXul+KDdCxvZrZgqu2CGDkdmBHHODjNV7sTQ6xci4ghEked7qmDJnuQPatD4d6DovgzwMyx3cEurTNvd2YZEmMAKOuAP61m6jqTJqMk0kZuQzMxDjaW4AXnrjOTWEG5TlbY56UnKcnY27SFU0ASCN1mhb98rMMgE+lUPDMWNT1m61y4WNCpmQGPcAATzjoaqWOs20esvpWvyfZ2vLRpIGb5QXU5A/Hn8q201bQhpaW99cLeFh5ACYkPIBJAHI60ndXVtyJSauu5NBqNprE1tEt8t9Ds3qWiCOHPbAxxVi8Xel1IW43hSCx+UDrjPTntVO98LweH49M1HRnIAIYrPydp7/QA1vXT2lxDC0UccZZi8gOAWPqexHfNZtx0cNjLmWjjscN4iv5tN0B7kpud8RRKF+ViW6n2AB6VnXV1M/huz1NXdLiE7nbbzuRs/L+VbWvQDWopIbNoVjjlLR7SNu4H5h78j9atWmhyReF2tJ3V9yncMcLkk8H05roUoqKvvc3UrPXqd94E8TWvivw3a6laSKXZQsyZ5jkHUEVt3VvDdwPBdRJNC4wyOuQR7ivlPw9f634Q8aPJpZYQyNiaE/cIHUn2/yK+nvDuqnWNJivmgMAcH5SwbpwcY7VwYrDOi+aOzPKxGGdJ8y2MK8+HmhTOXhimts/wQylU+mO34V02m2UGm2MNpaRrHFGuAqjiq9hrum3yqbe8iJL7AjHa27OMYPPWud1zx7YWmrf2ZpbxX98ELSIkg2xAHncfXn3rK1ar7juybV6zVOV36nZTP5cTvjO0E4Fc1bWtr4k065d2lSViYzIjbWX2yK4zXta1/VrqGK2uEtkRy5WHK4Uf3ieT34rqtG12OzQQSojySTnBiXaCuBhjz69TWvsJU43W5t9WnShdfEcf8TfhOviF7SSy1u6tbhVEaROS6MwHBznj361y3gb4H6toeqNq2t6jFLLbfPFFbOxLt6sSOB+de/wAd7ayxNJ58WI/vksBs+vpXO6v4he8Ig0OKW5QnDzRJlfoD0/Gqp4is1yomnUrSaj27nE3Wk3VnYahpktm9zFLMzRSKjMd/5fhWJB4T1WQENp92E6K3lNx+Ar2Kxu5bG3ze286KV3dNxHqDgn2/Wp77xDpdgqG8u0iLgEIwO7n1A5H41SxM1pGNzsjmFamnGEb3OC8HfDyWK7ivNYO1YyGSLPzMexPp/npXd6tqthodn5t1+6SJSEQDG7joPWoLrxRpUUEssdwk3lZBC54YDp0478151q2o2/jTV418zyrdchDJIFVCBk4PvjrUKM68uapokZJVcZU58RdRRSPiK71C8SBjbSNJHjayDcOOAGJBOB1ri7+O7k1S3gtISIVY71YnqDyOOvSob7S4pPGdtqGsXq2Gk2rn94gJ8wL0CAcmu8tLDTNSgub/AEHXmeJW81opbcrgk54PbnNen7tK1vyPQVSEHypWRkW8dve3Igj85njR2jMhwCANxVccjjOKyLvxxd29hONOs5YNLj/dT3W7MoUtjI9PfvXSywSWt5FeGGcxKciRQfLOR/e/HrXH3Phyz1OOaJbeUpI3mS7JSioc9cZw35UR5X8RpOCmrwOr1CeTRbyy1DTmkhjUK0MwI2um0E4PTHYj65r2Ialbah4XS9kx5N1bbsAEjleR/OvHpYxpenW1tEXSJkO3c2Q3YHB4/wD116j8OwJ/BVlFKo+QPEQf94/41w4tLlUuzOHMIrkhUa1Wh4V4K8LaTpWqX8ouJrhpw7MQAiRRjLFfr2/GvQvCmlf8JHZTwWpjigt5BulYEsTn7o9OBVq38APHrNzFNPLBpZPmtsYHeM8AkjI+ntmrvizVptE06wsfDNmYFlLRxzADg8jGOpye/wBK0qVvaNKm9fyKqVotclDd/ci5d6vo/hbUXiEUj3JB3SGLLcDhQevP5Vg6hrep+JVYNH9hsFO1mYnBPr9efwq3Dp0mn2qz6yv2rU3TAzyFPoB07mrfim38nwrZ6baxs88rBmCHDLxkn357VlHkTT3fcygoKUWtW+v6mTpWk6ffeSt1Gj20ZJeJgWWTGcN06n/CusmttO0Sxj0/TYo4vNYMEhwiDnngcCsbQNy6PJEEdyIiFLrwQfT3HNaMswtVjRm8zICxjON2O386VS7la4q15T1exynim6eO7ZCpWQjy4lcgiMcHr+Oa868N+Bb2XUNSSzEW5pWlkk38mMdRg9OT6963fG891JBcTMrmSRxIDjopyGYenYfjUPgGO8tYr661VrqVEi/cxXRdWkY8ZyRkqO4+ld1NOFO6OpxSSitzV8TeE7GWSxg1O+GI4PMfyVG6JAoAA+v9K5/SNPsbaO30mG6ihMku2GKXALc8knsTXqOn6Ba6zptt5OnxKqhXeU8bueVXH9fSvC/HmhalH4vuwtodisIrc25yNwOM+3J/Cpoz524N6oKVRO6vqjvbnS7yz1dreeHEaAxoEO5ec46df/rV6DpumW0OhSwLIJJRCcbRghiO4Ncv8PLS9m0qKzu3kleKZXe4ZiSzBeBz6HdXo2oQx2sMaW6qLgrtBOATge1cmIqO/IY4qvKUlF7jPB00EmjRw28gZ4crIvUqcnqK3g+AAVbI44FYXhu1FtNO67mklVWmbb8pfJyB+db/AM3oPzriq253Y8utbndjyu2uLu4iEPmp58MC73izwPT8P6Vz1zqd1agyPKIbcHasrkDblsDP1JroE1LStE0wW9tm7vp9sksjJwD746ewFee/Gyyv/Mkjt4HdZI0a3RUwMjuo7kDvXp0VzS5Wj2KK1enpfyNoyRxCfXLnT0v5GiYJLEq/vW6AAjqeP0rR0PVr25EznQ5LAMg2PNMA3vvUAn8z2rzr4WDV9NgSPUhIbXdhbSRc8fT3r1G5u/7OjhNt5u51BiQvyAf4SMc+lXNa2sXUg7LTc1dOKz2jtdDdhAqEf6teccA5755qrrMd7faTvkREt4m8uSRWyFx3Hr161p6ZCbqANcpgyP8ANHtxnFUY2lt7tooCxhlGxl6q5JPOPWudPW6OeK9526HFXzyNiHGAh+9GuMj6/TNalub230pmaYW9lKdpRfvSYB55ziut1jSI7OaxtgipJd+YgdOMALkg/hV64ttKgh826miKWkJWWJuo464PU/StHXTSsjV4pNLQ8W8JXU9zf6gJv3ltC28O3TJOODXfeFLC3eVr7UYnlhjcKoUZyeck/pxUOira6jJJPptm32ZizKjN2GBn8ya6NrC6sbGBD5WCRmAgbQxHr+FVWqc2i0Kq1dOXa5zfjfwwniLxPbajHMltFYwMsZCbjLJgkAnt6YqWX7Po3hnSILOONNRMv2ieUqM5BzyfTPb0FdV4jh+yeHbeGxYG5bB9unNebeL72DTLJpLiXayoCIxyx3DgAn60qTdRJdEZ4dKold6I1zrNxfy3N3eTSSXMsewIMhYxnPA7Cuzs7LTdW0GePTUMOoeQUyeWUkf4mvJ/COv22uRTr5Twz24IZQQcAjghvwx+NdnYXk3n20zN5cj5VTgAZB65HQe+KKtO2i0sbVqScV7PSwnhnRZNKtri1mQjyMyE4OGY/e59ecn61vPO0Bito4y8TcZHPbp+WKhbWYzdmPVfMy7bVwwwMHocVoJB55CwoWUfMqhiSB3rKcm3eRzTbvea/wAjjdfsIUuo2bDxbFEgJGQ57Z/Cuji1S/8ADmn293OwfSdqRsVAKw84BPf6moLm0tri2nkljeRhMAyjhmPTgfT9abqV/bxeDdd0nXJDFAtnI0UsgwXGCMD3zVyfMkmrlVZc0FG1yn4jvdQ0XX2t/D+Jftqqzz7d53ZyGwMAHmuS034dtompS60lxMCwdvLOGZlPBPqDmpfgX4gOs+Do4b7zLy7juzEsm7DRxgZyT34r1nTLhbmK9n+0iZGH7pCoUxgrkjjrRKpKj7qXr5i9ryJSS/4JxOgw3Qtb6Mb5URcwnAU7+nXqeDVrRozNdCM4LFAAM5zwTn+WatfarWCR7eMwWtzLMQ87sOE+nb0rR8GWUcuhy3cDKJI55vJZSSD0A+o46UpzsnJmtapaMptWuWpLPRdE04Xeuyx7ipOxz98HsF6t9K5K48bX+oxQQ6fHHp8EkvkoqDaxGM5Hpx+HI69vH/F95q/ib4z3CyxXE8dpceSsSKSFVPbnr1/GuqutTkl1nT7HSrCGXVr668iETblFuqgAlh7Y7c8VtDDWXNPV/gjKlCNnOq7/AKFz4a+M9V8QeKNQsHlmvUijL22+VlGeDhvXHNbPiLSL1vtV9cyLOJJSs0y7sROP4SAPu9MHFTR6LB4I17UJ7lIGmv40lM0a7drbvn288ZqHU/EyTXs1rC0VtpynYk+zarE4OAOhz75p/FPmprQ0pSkpKcCpYDfaeRq0cDWeMmTgPn0Ujr9DUkFkRazPFBJHpqyZWWT5SR/u9TWXr88lvFbvpvk39qFUHkjaCO4/qKsxa7pmmz29te3SxLPGHMUsgBJ7D+QyauzaujolNt3SMLVtA1jXdZgNvYT3MbJtiIztQZ556V3Wk6dcaN4cutMms5rSXzULySp8gj4H3hxgH+dYFuuq6z4ils4LiaK1batvbxSkCI4Hp7DrXWW3iaTS7/8AsDXp49T02RfKaV/9YoP9498fnU1ZSaUV62MKiqX0V+tupyFpHqaa5EIllNzvHBOVZe+c8FcZrI8Sa6mjamYra3Msckknlln2KFHcEj/OKp/ETWtX8Ga7qel29nbPak7oJpo8nYw4IbIBxn8xTvBupWviLQYpNdFrczxkxqhiwBjpux1+taxX2nsdEq7rNcq6HT6NNF4jj0yIuILSVQYmYF2ySMqB+Jr3TTLG30nTYrW3G2GFfqT3JPvXkPgzTP7U8Z2r2sKRWFigeTy12rkLgAY9TzXrmtahHpunz3DkZRSQvcmvOxsuaShH7jysc5SnGl+HmeY+INdm1W9uLmJ3hsojhP4SwB7/AI1s6fcGC5XWdWTN48Xl2sOCAi565Pc1zSNayu0uoyxxadGxdlx/rCTnb+ZxW7cSNdyWzwtHHaY3xjqRySTz9a1lFJKKWh11IRSUEtP60HW2oGa9luLp+Yn2pEVwAxPU/qawYvEc3ijxqulaOjTR2xzLPztUdCRisu6tdR8V+IzpNhvtrOGP9/dLk9Sefr/jXp3gvwXYeE7NbKxd2LnzJJG4aRu+SOo6cUqjhSV3vbRGFepGk9NzpLGzgtbVYoU2qV59T+NcHrp+y6vJa+WkgSD5UbIAB4JBHpgmvQ5ZEijaSRgiKMszHAAryHxdriypf30WM3J8iNyv3IV4J9snPNcuGTlNmGCUpzbKc4W80e4vvMVEjcQrGv3iDzk+3SrOmrc23hWfWpY1uGtiVTeMgg8EjjJxxXPLbvcOtzaWssccsQBy2VcKCCQPTtmtzQ7HVLzRG02xvG8mNdzRMcbnHOwE8cn1xXfNWW561aKjBNPr+B294t/b/D1V0mZxerATG4h2E+5U9K8r05bjUNZtYZ1C7wTJFITwT1Jz+demyePrOzv30/UIZTJEoDToNyFsZIIHQ9PzrI8NWUeu+ILnUp0KwF28tH49ev4Vz0pSpqUpLfW5yYapKhGcpxtfr6mz4f0iLT7J4I7oTI7lgY+oIJAPv24rK8S6u1rqSIgSW5JVFOCdvY8f/XrpdUtrDTnacXH2djhFjXHzE9sfX0rJ8MW89x4jlmuLWNPK3EyAjL5Py8fh1rKEk25vUxpzWtWWp1OgG4GnqLs75ixLHbjHt36dKvmFSScnmvM/GnxOh0DWzY7IDLEMlZmILg+nT+tTw/FGKSJH/sxxuUH/AFo/wqPq9WfvpbmEsJWl78Vuc9PZ2ST6q8+4hsRxOmcHA9uByDVLWNbh1QxR3ablhTajnnYMD82znmppFImCLCVYMruhzwx4z+h/OtDwr4SXUb8TXLL5SvuMbAjP9cH8K77xguaXQ9ZSp01zzexJ4W0WCw0248RTlmjRD5Ct05GAxz9aZ4eKapYS7mjlklYiEOTuU9eO3qeat+MNeTUbyTR7BM2VqQJmXgOw42jjgDP+cVf0DTP7DsIRpc8Vyir87Hklj1ArJyfLzS3exzynKS5p7vb0IN0mmWAW5J3x8gbud3b+YqG2dwk3mwlx5RDsDzuxniotRuTPqlvPMypbW4aWTeepwcD86vWqtqdiZIIz5WCHfGASeSAPoMUbK7G/dXvdS/PcpJo1lK0krS2p3RMxyzjGCcnrxXgnizXdY8XeMYotPeS0ti22RFGdoTqzeoAr23UNMGoWr2MF2Y3x+5AbG3g/1xWN8O9Ethqt20kHlar5QEpI6AjnK++evpV0ZQpxlJ7mcbQi5If8NPFmh65eyaJ4duWMlrH8zyxbTs4BxnvnvW14oF6Nat9Lt23iG3a5y3WXLbSSfUV5L8NZtEtvi1eahpyvaG3ElveRMvyZLYyD25WvcdZWJvG+hyJJtWKCYNgZ3DAIH6VnVXs6unYzblCpzb6Mh0eaGeB57ohpYFMYjByeRjj/ABr5W+MOvXz+L5IGDIgx15Ppx9OlfWt1HbxXSGQxNI/KsD8yKDk/UV4f4r0zRNe8S3k1zZiVFm82NgSuPm6H/ZPPFaYSS5mzbDxlPm9mHh+1tdI8OJZQW5W8mPmyT7su4OPlYDp0GBXaeH7R7+8stNtp5HtmxLIp4COBzz3wOPxrGisxeyCG1ixE53Ki5G3HTk8Y616P4J0trWG+uA8R1A4hUkYUHaCf58/Srr1FGLfU68TVjRpu25xXxB0640vXBIwV4Jh8hyQoPT8+K6LwZq8V7DbS297DLJBiOR4mBAzwVP0/wqv8e3a30Gwmj25NztOTzna2MfrXzx8G59e0nxgUtrSe4spZGFyobAAGSW+uKmEfbUU3uc6k62Hg2u6Ponxs76dqdneQLutjOm90zlHU5GfYjitD4jHTbvw2jRGLziwkVMA5DcEEenNPleG80R4IyLiKYbkB+8TnH5iotejF9JaqLdYVgO65UqN3TjH4HP51jHeN+hivihf7Jn/B/S7O0jnFhDFbRDJkjUcNu68fhWnfappljffYo4J7o3cu5fKA2orDGP04rmvD63Gk+NbkQSj7ObdwQe46hhjriuxijh8P+ETeTKs13JGGVm5bJxt56jsadVWnzPW9h1UlUvve1ktP6sU7W90yZ5QljZQsjcq6gvgbuCD7/wAjWvoWvRXLSW9rapHJx5UQ+VccA8gdO9eA+MfG95pmtixgWNyqB5Gkyx57frXefC3xHFqDxalKpt1BeN1C5HAFXVw1ocxpWw8XGS3ZU8Q266Lq2ry5db+6uyZfLbbvXgq3Hsf0rEudc03SNfiudWvGW6RRLG5OZo22kfn2+ma9b+IugjUdMOpaev8Ap1uPMDJ1de/4gV43q3hbSvE2ppJDqN1HqhhGUIG2XIySpPfrwSM1rh6kakbv5mlCrGrR91arcyJvGN1rd5e297m7kuoWW1ugcmJ8ZH4cYqx8L9MuLnxpp41xZhpdkjXEiTtuDzhSflGeRkA49qzPBWjX2j+JJS9jutVjz5p5wy8bl7jJ6jtXqCWkttZx2yyW0d4p88IM5dduSCSMZxzjPtXRVaiuWOlxOPNGz0KvibU4dZ1i4uLeGNbVYvKAA27PfiuW8U+GNL8RT216LV4dsaKZLWUDzAFAIYEH5uDyMUtx8TNa8Ja0kdroenGydijKFO+Qem7ORjOcdOa9sv8AwppOrG31aMvZRPEHlSEKokUjPPHBx3Fc8qnsLXVl0JqV6dOShOPu9Dl/hzaWth4iSNWZEW2CrvfncPk5PGeB+tUbvwNPdzajqyXitYyl5ojvBIAyeTV7xEILbXPO0kgpEqqAiccDGPf1pILDXtf0t9LtbkW9iwILeXt2A8n61m5O/tE7XtuNTnT/AHsZWule/Y7Ow0nR/Enhew/tG1g1CF4lYNMN5zjsTzVFvh3ogmi+xRJa2AyXtYYlCufXdjcD+PatLwH4Wh8HaAml291NcoJGk3y8YLHkAdh7VzWt+PbXSPEctrDN5iFTvjbJ2tnAYHqOh4rki6kpuNF6Hl0/aTk/ZM7S0tNO8O6aUt0W3t15J6ljjqT3NeaeJ9VudfvkREMcC5UoP4hnr7f41Z1TVZtYEdxOxaEorIiZC7mGB+nP51e03Tfs6rPIFdwR8hGMk9PpW1OHs/fnrI7qNL2H7yesmYlzocd82nabJCp2PvcBjj1z16CsXxL4kvE8YWXg7w/awyGZf38mMsit29uBXoEEGLs3MqjYhKFMEZLdRn0x/Ko/CWkWlpc6jrzwxPduzLEQOVQZxk+n+FX7VLWWtvzHOo0ub+rmhbWzaO1tp2irudcNKezNzy3t0/CutjUhFMu3eByR0rhfBXivSdY1i5jt5W8/GcuMA8nPfjkGofiD4smji+w6Iys7kiWUc7BnGB/jXLOlOc1BrU5JUZ1qipperKXxF8VR3LjRNKcM7/NI6ng4PK5/nXONpF5qmjpA8boCY4QGXcshLdAfxz+dRRaQy2aXEiqZnb5SPvHOMj/6xr0Pwd/p00fmK8cVgiqquNpd+dzEex4rrbVCHu9D0p8mFpL2fTc4zX9AfQRZxyXEEcyZdJJ5D5QQDlOgA6dPcVVtr9LsarfRyNDa70ljMGVTaAFyOePSn/HnTtavvKSJVktWOYmTgKMchif8a5Sysbi08InSY7kILmMCR9u7ed2SFHYdq0p3nTUm9S6bnUhGT1b/AMy1b30eoGWSGcSyElmfnqT69+nauwumbw7oUdzLcsI2iDsofG0hc5P6dKwPD3hZLGxjFwhVAA+emcciug8a+GJNd8Cz2cDGK5YK/wA/3n9Ix07frSrSjdRT0FVqrRPYqeCpbfxbINZhf7ajPszLIcxMvIOOPyr1XQ7eW3sR9oLee7lm5zn0B/CuA+D3g658MaBFFPgyM5ldGHO48cYPYAD869P4yuQqscnA7/5zXFiprm5Y7HlYmq5aHBeLvhtoniPW11HUGcOvBVSOccg56jpituLw5oUMSRi2wEUKBnpitDULoW8c0pjaQxrjy1XJJ9KrpPrBRSdMtwSOQZjn+VZqpUcUr6LzBSqOKvL8bHF+H9PebX4L2KEiOJd0zM3yscYAHvnJ/CjULttI8fz3012Chh2G3UHGMZA46c4/Osz4t3Fl4T8KC6mnlF1GoWOFGIDyk9T9ME15X8OfEd/rIv8AUtYllnt4myRwW9/au6FP2i5+j0PQhy1Hdvoz3nwpBG0t/qVykT3FzNulRwDs54x+dM8T6hp8hgstOcC/NyiNHDwf89K4weJbjX9H8rQLaW2iilG+aTG4kk5II9Bj863PDOiW8GswShHFxBiR5HbJZu44qHT5W5yevYz9mk3Uk/kcn4yvpP8AhP10K2WSQxKjSbOSWbn+RrvfDVwvnOLkmK3Xd8gYYY9OlYukwwi58QeIrpkea5uCsLNnO0cKAf6e1Ns51toBJMWbG0bQMAHoSa1muaPL2/Pqa6zhyvodSkaXlsECCCVZd7OuMgZ5x+HavKvhN4g1S2+MfiCHW7x5opLd3VmXgqrDaR6DFer3yJLZwPLuGcbiOwPc1zGoeHNN0/xB/alq5a8fCFxhlWPjj/PpWdNxcZRfUwilNcvc5X4WeHL618d+KH17S5Le11Bzc2rt8pb5zwD9GGRXoNj5sOus8+5obQm3UnnAYZX+gq1qYuiouTOZIsLJaq2NwOMsWqvptzHeTa9ZLu3vCsyM4+8cYb64z+VEpud5MUU1Ft7B4x1qPTdOzGu6e7PkqynGcnGCfqcV5h4aupL6O/N2qmGykAukiAYOTyMP7ZAOK2PirZSyeFLHT7EzSzlnmDklVDZBA+vFU/hVodzomlXV5cXcLSMsjvDI2Ebj06sOB2rekowpX6ndh4+zhdbGl4blAne4txGbWHBe2aTLAZwWGevHJr1DwVc/aUuo4ZBJDDIHVyDzvGcZ/E14xZ6hcW1+j3scSlY2RgqbA2cncPevYfhYB/wi+/nfJMzMCckcAD9AKxxitC7JzWHLT5+5yH7SN0o8M2NqAfNe5BU+nBry34bWt9pmuWt/NA4tOVlOfvqRgj9a9Y+Kumv4n8R6ZYKGW2tld2YHG5s4xz6YrFv9Ik0azSAuXtWcZB64zxzV0LKkovdnRgKkaeFVJ7y/U3/D1xBYp5sfEcUMlyY/vDcCSAD1Ix+uKn0CWXzGuJkOGBklU8kL7+h5rL0SSW6ng+VlNupjEaDJbn26k10+6CIwW1v5cYuYXEjtneW4wBzx34NRPRtdziq2i2t2zmPFOv6f4UvrXWrslrZ2aDKgs2emQM47/oa9E0+S28Q+GElEaz2txHuhLoBkY+U47V5P8RtAj8S+D7fTY5lSdZQySMM7W5yeOxr0X4bmPS/DGl6K04uJ7WAqWQcAKcc+564rOvFezUlujlxKlyqS6f8ABPK/EngPTNTuYJ72YRXigL5Ql2ynk4DKRz0/WtC2hj02xi0ywt32JG5UIDkepJPc47+lcT8WWutR+Ktw1tcuFjkSMYPQdMj6EGu0vBKLO2mw+6VSNw+6SDzk/iDXb73LHme56lFcyUpbs9c8IOsnh2zXkmNdhz2xx/8AWrhdS8DXGn64bzTLP7Uhk3wbZgnlHJOGB6gE9j7VN4J1x7XUYNMgbfbOVGGG0rkZyBn2P5e9ei3F/a288cM8yxySfcVuN30rzpOdCo7dTyqjq4WtLk+1+R84+L4tf0u9WJrWWIFT80ab8t7Htk81v2tvf3VhZSX8bpdGDypZSuEx0yD3wuele5L9nu03DypkzjPDVnHw3pP2kT/Y0DjpgnH5dK2+vJpKUbMqOYWfvLU888L+AI9Y1eLXNeiVreGQyWtuw6nsW9uBXoGq6Z/ad9HDJIVtI1BeMdz2x6f/AF607y6t7GDzJ5EjQcDJx+VZDauyWrTWq/agrfvChGFJ7E1zSq1Ksub7jndWrWn7ReiNG20mwtseTaxAgYyVyf1q4qqi4UBR7cVwd94xu1UpDCDIQDwOhPbrzWRrN/4heBXuJzCr8bYzjb/jTWHnL4mUsHUm/flY7fxFr9vpsRijkVrth8qg5I9zXksvh/TLvVTdmCWS+mJBIbrkHOfxNNS3ma9O53d2OOCSxzW/azQaRq8dkU8tktzcSzNkkdguO3Jrsp0/YL3XqzuhRhQjyx1bNGbS0sIEur24j8hGAijwAu70960klM8RULhuWAYjkeuKyL4y+KBo6ac8i6VZSCSXYgYyyAYABPbrmr11JJGVtYkXLlmJkGduMEg8/Wsnd77mer0luSXs0l5pj+XEYv3e0c8lxjp+VNltS/hi7tDcGJZFB3Mu7J67eoxzipwotLDZcNiNXyvy4Ayf/r1PHJHLsWBy6g8dwCDUN6aEPRWW1zxu10Q+C7W4ae7dppU3ylRtHJzj35966L4bzxeM764gkTyIrGIMSDkybjzn15FanxLgHiLUbXSrUxwyxhVlnPCqdwOD+v510Pgbw5H4cjlsdNRWWfJmu2PzMR1AHYcnFdNSvelzS+Jms6rjSVtGZltocMXjNLmC5kNjZoZWiXlSwzkfy/WkJsfE+v3l3Y3FxataW5eR4H2hyfcfrXo8FlDb2X2eJfk24yx5P1PeuDh8N22ma/c2Nkdsd6C7KXxgY5U98GuWFZTvd6pafqY066qtu+qX4dTmvH92NI0vT7Rb+RoLuPzGSWXOCO4HXbyPrWToTJeXlosgwNqnjqPatD4kaDpt94ksJHjSKVF8s4k3LtHQkHoPak8G2hbVbkSOEWMEKRjAxnmuuDSpc3U9Ck7UnJncJA2qTC1dmEOAzg9MDkfjxVkwSXd5JtkBa2zgf327Y9PSqEN80GmYh2vJPt2BTyTznP4cVl6Qly3iuPSLwZBTzmdAQFYEN1H3ueK5OVu/l/TOPkbTd7W/pne6NZvBCJbgk3MiguN+Qp9BVLxjrC6VodxMziCRhsj3NyXPTH8/wrdICgpIzbR3ryL4hwN4p8UWGkWszmCxlE9zsXKxjaSMkd89vxrGlH2lT3tuvocdFe0nzS2Rq6AbvXkiWa5uYkQqzEEmN8Yxz65xxXXNJru47BYBe2WfpXnmneJ7+2ge20NFe0ts/O65Zxnk/n6VEfiHdAkNKgPceldE6M5P3Vod9ShUnLRKxH+0BFG+mWyOisryYYMM8Y/SvHp4I7D4Zz/Y18nddLnaTz1ooruwv8OBtSS+rp+TPpDwdYWtv4Ms1hgjRZEDOAOp2jmqngyJBfX7YyWZ1OTngAEfzoorgTbjO5yJvkmc3fXEpaG33YhiVmRAAAD6+/WrN7Ei6XCQOWYgn1GKKK7NnE7npy2NgXEsvh+PzH3ZAU5A6AjFaltGn9m6f8i/Og3cdetFFcstNu7OKpotO5HqqhtNgY5y0+089R8w/kKy7B2j8cWECHbF+8+UdPuH/AflRRTj8EvRjj8L9GV/HUEX9mSjYOXDfjuA/DiuAuEVbi8jUYSLCoBxgZoorqw/wHqYB/u/68hl5+9uJJJCWfKck/7Ir2r4ZMf7GaPPyKEYD3I5oorPG/wjLN/4C/rsUPEDMPFMOD3x/MVF4qO2wkIxlWwMjsP/ANQoorGH2Tkpf8u/Q4hLy4tvAviW7t5niuUgdklQ4ZTu7Ht1rkfgpqN5fWOtLeXU04hiJj8xy2w7X6ZoortsuWT/AK6Dn/FZ6lYMZ9LheXDMbOIkkDrha8m+Ems6j/wuZIDdymGeeVZEJyGAB/Kiioil7OYqvwP+uh2Hj23hj8ZazMkaiXzR8wHP3V/xNbYUP8OdIkcbned9xPOeP/rCiih/BD5fkdS+Gj8vyZo+AreIeIrSUIN/ltz/AMBrQ+KErx31kUYqVhkYY7H1oormeuIXp/mc89cbG/b/ADPLvhrr+qweKZIIr+48iSQbo2bcpyfQ19KOcKSOuKKKWYpKasceYpc0WfIvxf8AEusvr9yG1GfbHKYkAOAFOOMV674FvLibwdbiWVmDWwc+5I5J9TRRXVNL2KO6ola3axW04b7tnbljJtz7VU1DV76LxFa2yz5g84LsZFYYz7iiipteWpUtW7nS26qviQlVUFpyDgAdD+lX9OtoW8Ya8WjDFohndz/CfWiiuebsn6fqjlq/p+p5v8d9Vv8AQ9P8ODRrqWwDvlhbHy8nI64+prvtL/0/S7We8/ezKAwZuucUUVo0vYxfW7/MNkmi347lf/hGdP8AmI3thscZwKo+FiTpImZmMshyzEkknI5oorKP8H5hD+AvVnAaxNINQlYO25piCc9cg1658NLiW50TM7l9gQLnsNvaiitsUl7FHRj0vq9/Q6a+YrC20kZU9K87FxLHrPnJI3mozIrE5IHPHNFFceHW5xYFJxZ554hvLifVGkmlZ3IbLNz0bAroPDrFr/yyfk8rJHr9aKK9KaSgj2KqtTt5HZ+SkN/uiXa3nZyD711GnIhu7hyi7vMK5x22j/GiivLqPQ8Ou/d+RB4quZrTQr6e3fZLHC7I2AcEZx/KvOfgVEk/gvUdQmBkvb24ka4mYktIR0yfxNFFKn/Dn8iYfw/mS+AQP7B1kADhCR+tdbBp1jJBG8llas7KGYmFckkfSiitMW2pu39aHTiG1N27/oj/2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Hemolytic uremic syndrome. Light micrograph showing multiple intracapillary glomerular thrombi (arrows) typical of a thrombotic microangiopathy as can be seen in any of the forms of the hemolytic-uremic syndrome.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14277=[""].join("\n");
var outline_f13_60_14277=null;
var title_f13_60_14278="Giant cell arteritis multinuc giant cells";
var content_f13_60_14278=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F83907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F83907&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Multinucleated giant cells in giant cell arteritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 337px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    High-power view of superficial temporal artery involved by giant cell arteritis. Two multinucleated giant cells near the internal elastic lamina have phagocytized small particles of elastic tissue (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gene G Hunder, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14278=[""].join("\n");
var outline_f13_60_14278=null;
var title_f13_60_14279="Overview of the clinical manifestations of hyperthyroidism in adults";
var content_f13_60_14279=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Overview of the clinical manifestations of hyperthyroidism in adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14279/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14279/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14279/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14279/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14279/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14279/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/60/14279/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of hyperthyroidism are largely independent of its cause. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=see_link\">",
"     \"Disorders that cause hyperthyroidism\"",
"    </a>",
"    .) However, the disorder that causes hyperthyroidism may have other effects. In particular, Graves' disease, the most common cause of hyperthyroidism, causes unique problems that are not related to the high serum thyroid hormone concentrations. These include Graves' ophthalmopathy and infiltrative dermopathy (localized or pretibial myxedema). Most patients with Graves' hyperthyroidism have a diffuse goiter, but so do patients with other, less common causes of hyperthyroidism such as painless thyroiditis and thyrotropin (TSH)-secreting pituitary tumors.",
"   </p>",
"   <p>",
"    The major clinical manifestations of hyperthyroidism (thyrotoxicosis) will be briefly reviewed here. More detailed discussions of its effects on specific organ systems as well as the diagnostic approach to patients with hyperthyroidism are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=see_link\">",
"     \"Diagnosis of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     SKIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;The skin is warm (and may rarely be erythematous) in hyperthyroidism due to increased blood flow; it is also smooth because of a decrease in the keratin layer [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/1\">",
"     1",
"    </a>",
"    ]. Other changes include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sweating, which increases due to increased calorigenesis; this is often associated with heat intolerance",
"     </li>",
"     <li>",
"      Onycholysis (loosening of the nails from the nail bed, Plummer's nails) and softening of the nails",
"     </li>",
"     <li>",
"      Hyperpigmentation, which can occur in severe cases; it appears to be mediated by accelerated cortisol metabolism, leading to increased corticotropin (ACTH) secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pruritus and hives, which are occasional findings, primarily in patients with Graves' hyperthyroidism [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/3\">",
"       3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Vitiligo and alopecia areata, which can occur in association with autoimmune disorders",
"     </li>",
"     <li>",
"      Thinning of the hair",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infiltrative dermopathy occurs only in patients with Graves' hyperthyroidism. The most common site is the skin overlying the shins, where it presents as raised, hyperpigmented, violaceous, orange-peel-textured papules. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=see_link\">",
"     \"Pretibial myxedema in autoimmune thyroid disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EYES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Stare and lid lag occur in all patients with hyperthyroidism. They are due to sympathetic overactivity, possibly mediated by increased alpha-adrenergic receptors in some tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/4\">",
"     4",
"    </a>",
"    ]. Lid lag is evaluated by having the patient follow the examiner's finger as it is moved up and down. The patient has lid lag if sclera can be seen above the iris as the patient looks downward.",
"   </p>",
"   <p>",
"    As noted above, only patients with Graves' disease have ophthalmopathy. It is characterized by inflammation of the extraocular muscles and orbital fat and connective tissue, which results in proptosis (exophthalmos), impairment of eye-muscle function, and periorbital and conjunctival edema. Ophthalmopathy is more common in patients who smoke cigarettes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"     \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with ophthalmopathy may have gritty feeling or pain in their eyes, and may have diplopia due to extraocular muscle dysfunction. Corneal ulceration can occur as a result of proptosis and lid retraction, and severe proptosis can cause optic neuropathy and even blindness.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperthyroidism have an increase in cardiac output, due both to increased peripheral oxygen needs and increased cardiac contractility. Heart rate is increased, pulse pressure is widened, and peripheral vascular resistance is decreased [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/5\">",
"     5",
"    </a>",
"    ]. Systolic hypertension is common [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/6\">",
"     6",
"    </a>",
"    ]. The left ventricular ejection fraction does not increase appropriately during exercise, suggesting the presence of a true cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/7\">",
"     7",
"    </a>",
"    ]. High- or normal-output congestive heart failure can occur in patients with severe hyperthyroidism and congestive heart failure worsens in patients who already have it. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"     \"Cardiovascular effects of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Atrial fibrillation occurs in 10 to 20 percent of patients with hyperthyroidism, and is more common in elderly patients. In one study, 8 percent of all patients and 15 percent of patients between ages 70 to 79 developed atrial fibrillation within 30 days of the diagnosis of hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/8\">",
"     8",
"    </a>",
"    ]. Even subclinical hyperthyroidism is associated with an increased rate of atrial ectopy and a threefold increased risk of atrial fibrillation (",
"    <a class=\"graphic graphic_figure graphicRef55024 \" href=\"UTD.htm?19/0/19469\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 60 percent of hyperthyroid patients with atrial fibrillation, the rhythm converts spontaneously to sinus rhythm when the hyperthyroidism is treated; in one study, all who spontaneously converted did so within four months after becoming euthyroid [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/10\">",
"     10",
"    </a>",
"    ]. Among those who do not convert spontaneously to sinus rhythm and who undergo successful electrical cardioversion, the two-year risk of recurrent atrial fibrillation was 59 percent compared with 83 percent of patients whose atrial fibrillation was not associated with hyperthyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of anticoagulation is controversial in hyperthyroid patients with atrial fibrillation. In several studies, 10 to 40 percent of patients with hyperthyroidism and atrial fibrillation had an arterial embolus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/12\">",
"     12",
"    </a>",
"    ]. Left atrial enlargement, which is a risk factor for thrombus formation, is present in about 90 percent of hyperthyroid patients with atrial fibrillation and two percent of hyperthyroid patients with sinus rhythm. Based on these results, we usually anticoagulate hyperthyroid patients with atrial fibrillation. This recommendation is in agreement with guidelines published in 2006 by the American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other abnormalities, including mitral valve prolapse, mitral regurgitation, and an increase in left ventricular mass index have also been reported. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"     \"Cardiovascular effects of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     METABOLIC / ENDOCRINE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Serum lipids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hyperthyroidism tend to have low serum total and high-density lipoprotein (HDL) cholesterol concentrations and a low total",
"    <span class=\"nowrap\">",
"     cholesterol/HDL",
"    </span>",
"    cholesterol ratio. These values increase after treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hyperglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thyroxine is not a counterregulatory hormone, hyperthyroidism can interfere with glucose metabolism. It is associated with both increased sensitivity of pancreatic beta cells to glucose, resulting in increased insulin secretion, and antagonism to the peripheral action of insulin [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/15\">",
"     15",
"    </a>",
"    ]. The latter effect usually predominates, leading to impaired glucose tolerance in untreated patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Adrenal function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interpretation of the cortisol response to ACTH stimulation testing may be misleading in patients with hyperthyroidism because cortisol binding globulin (CBG) levels decrease, resulting in lower total serum cortisol concentrations. In one report of 49 hyperthyroid patients undergoing ACTH testing, 35 percent had subnormal total serum cortisol values (&lt;18",
"    <span class=\"nowrap\">",
"     mcg/dL),",
"    </span>",
"    while only 11 percent had a subnormal free cortisol index (ratio of serum total cortisol to CBG) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     RESPIRATORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dyspnea and dyspnea on exertion may occur for many reasons in hyperthyroidism (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=see_link\">",
"     \"Respiratory function in thyroid disease\"",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Oxygen consumption and CO2 production increase. These changes result in hypoxemia and hypercapnia, respectively, both of which stimulate ventilation.",
"     </li>",
"     <li>",
"      Respiratory muscle weakness is an important cause of dyspnea [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/18\">",
"       18",
"      </a>",
"      ], and reduced exercise capacity may be largely due to respiratory muscle weakness and decreased lung volume [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      There may be tracheal obstruction from a large goiter.",
"     </li>",
"     <li>",
"      Hyperthyroidism may exacerbate underlying asthma.",
"     </li>",
"     <li>",
"      Pulmonary arterial systolic pressure is increased [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     GASTROINTESTINAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Weight loss is due primarily to increased metabolic rate (hypermetabolism), and secondarily to increased gut motility and the associated hyperdefecation and malabsorption; rare patients have steatorrhea. Celiac disease is also more prevalent in patients with Graves' disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/21\">",
"     21",
"    </a>",
"    ]. Most patients have hyperphagia, but an occasional patient with mild hyperthyroidism may have sufficient appetite stimulation that weight is gained (more commonly in younger patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/22\">",
"     22",
"    </a>",
"    ]. Anorexia may be prominent in elderly hyperthyroid patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other changes that may occur include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Vomiting [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/24\">",
"       24",
"      </a>",
"      ] and abdominal pain, rarely",
"     </li>",
"     <li>",
"      Dysphagia due to goiter",
"     </li>",
"     <li>",
"      Abnormalities in liver function tests, particularly high serum alkaline phosphatase concentrations and, rarely, cholestasis",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     HEMATOLOGIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;The red blood cell mass is increased in hyperthyroidism, but the plasma volume is increased more, resulting in a normochromic, normocytic anemia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/25\">",
"     25",
"    </a>",
"    ]. Serum ferritin concentrations may be high.",
"   </p>",
"   <p>",
"    Graves' hyperthyroidism may be associated with autoimmune hematologic disorders such as idiopathic thrombocytopenic purpura and pernicious anemia, and some patients have antineutrophil antibodies.",
"   </p>",
"   <p>",
"    Hyperthyroidism may also be prothrombotic [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. As an example, in a meta-analysis of 51 studies evaluating the effect of thyroid hormone excess (exogenous or endogenous) on the coagulation system, excess thyroid hormone was associated with a rise in prothrombotic factors, including factors VIII, IX, fibrinogen, von Willebrand factor, and plasminogen activator inhibitor-1 [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/27\">",
"     27",
"    </a>",
"    ]. Similar findings were noted in patients with either overt or subclinical hyperthyroidism.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENITOURINARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Urinary frequency and nocturia are common in hyperthyroidism, although the mechanism is uncertain. Possible causes include primary polydipsia [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/28\">",
"     28",
"    </a>",
"    ] and hypercalciuria. Enuresis is common in children.",
"   </p>",
"   <p>",
"    In women, serum sex hormone-binding globulin (SHBG) concentrations are high, which results in high serum estradiol concentrations and low-normal serum free (unbound) estradiol concentrations, high serum luteinizing hormone (LH) concentrations, a reduced mid-cycle surge in LH secretion, oligomenorrhea, and anovulatory infertility [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Amenorrhea can occur in women with severe hyperthyroidism.",
"   </p>",
"   <p>",
"    In men, the increase in serum SHBG concentrations results in high serum total testosterone concentrations, but serum free (unbound) testosterone concentrations are normal or low [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Serum LH concentrations may be slightly high. Extragonadal conversion of testosterone to estradiol is increased, so that serum estradiol concentrations are high. These changes can cause gynecomastia, reduced libido, and erectile dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/29,33\">",
"     29,33",
"    </a>",
"    ]. Spermatogenesis is often decreased or abnormal, eg, more spermatozoa are abnormal or non-motile [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/32\">",
"     32",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     BONE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone stimulates bone resorption, resulting in increased porosity of cortical bone and reduced volume of trabecular bone [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/34\">",
"     34",
"    </a>",
"    ]. The loss in cortical bone density is greater than that of trabecular bone. Serum alkaline phosphatase and osteocalcin concentrations are high, indicative of increased bone turnover. The increase in bone resorption may lead to an increase in serum calcium concentrations, thereby inhibiting parathyroid hormone secretion and the conversion of calcidiol (25-hydroxyvitamin D) to calcitriol (1,25-dihydroxyvitamin D). In addition, the metabolic clearance rate of calcitriol is increased. These changes can result in impaired calcium absorption and an increase in urinary calcium excretion. The net effect is osteoporosis and an increased fracture risk in patients with chronic hyperthyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=see_link\">",
"     \"Bone disease with hyperthyroidism and thyroid hormone therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Graves' disease may also be associated with thyroid acropathy, with clubbing and periosteal new bone formation in the metacarpal bones or phalanges. Patients with thyroid acropachy commonly present with asymptomatic clubbing, severe ophthalmopathy, and dermopathy; a high percentage is cigarette smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     NEUROPSYCHIATRIC",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with thyrotoxicosis may experience behavioral and personality changes, such as psychosis, agitation, and depression. Less overt manifestations that are more common in less severe thyrotoxicosis include anxiety, restlessness, irritability, and emotional lability [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/36\">",
"     36",
"    </a>",
"    ]. Insomnia is also common. Symptoms often worsen in patients with preexisting psychiatric disorders.",
"   </p>",
"   <p>",
"    These behavioral manifestations are accompanied by cognitive impairments, particularly impaired concentration, confusion, poor orientation and immediate recall, amnesia, and constructional difficulties. Other neurologic manifestations are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=see_link\">",
"     \"Neurologic manifestations of hyperthyroidism and Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     GERIATRIC HYPERTHYROIDISM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism in elderly patients may be apathetic, rather than having hyperactivity, tremor, and other symptoms of sympathetic overactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/37\">",
"     37",
"    </a>",
"    ]. However, two-thirds of such patients have symptoms similar to those in younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/38\">",
"     38",
"    </a>",
"    ]. In cross-sectional studies of patients with hyperthyroidism, older patients had a reduced risk for the presence of several classical symptoms (ie, heat intolerance, tremor, nervousness) but a higher prevalence of weight loss and shortness of breath compared with younger patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Older patients also had a higher rate of atrial fibrillation and moderate to severe ophthalmopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14279/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elderly patients with Graves' hyperthyroidism are less likely to have a goiter. Toxic multinodular goiter is more common in the elderly, although the majority of hyperthyroid patients at any age have Graves' hyperthyroidism. In addition, elderly patients often have persistent constipation. Tachycardia of 100 beats per minute is absent in 40 percent of elderly hyperthyroid patients, due primarily to coexistent conduction system disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=see_link\">",
"       \"Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=see_link\">",
"       \"Patient information: Antithyroid drugs (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The classic symptoms of hyperthyroidism include weight loss, heat intolerance, tremor, palpitations, anxiety, increased frequency of bowel movements, and shortness of breath. Goiter is commonly found on physical examination. (See individual sections above.)",
"     </li>",
"     <li>",
"      Elderly patients may have fewer classical manifestations of hyperthyroidism. However, weight loss, shortness of breath, and atrial fibrillation occur more commonly in older than younger patients. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Geriatric hyperthyroidism'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinical manifestations of hyperthyroidism are largely independent of its cause. However, the disorder that causes hyperthyroidism may have other effects. In particular, Graves' disease causes unique problems that are not related to the high serum thyroid hormone concentrations. These include Graves' ophthalmopathy and infiltrative dermopathy (localized or pretibial myxedema). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=see_link\">",
"       \"Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=see_link\">",
"       \"Pretibial myxedema in autoimmune thyroid disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/1\">",
"      Heymann WR. Cutaneous manifestations of thyroid disease. J Am Acad Dermatol 1992; 26:885.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/2\">",
"      KIRKEBY K, HANGAARD G, LINGJAERDE P. THE PIGMENTATION OF THYROTOXIC PATIENTS. Acta Med Scand 1963; 174:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/3\">",
"      Collet E, Petit JM, Lacroix M, et al. [Chronic urticaria and autoimmune thyroid diseases]. Ann Dermatol Venereol 1995; 122:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/4\">",
"      Bilezekian, JP, Loeb, JN. The influence of hyperthyroidism and hypothyroidism on alpha- and beta-adrenergic receptor systems and adrenergic responsiveness. Endocrinol Rev 1983; 4:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/5\">",
"      Klein I, Ojamaa K. Thyroid hormone and the cardiovascular system: from theory to practice. J Clin Endocrinol Metab 1994; 78:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/6\">",
"      Iglesias P, Acosta M, S&aacute;nchez R, et al. Ambulatory blood pressure monitoring in patients with hyperthyroidism before and after control of thyroid function. Clin Endocrinol (Oxf) 2005; 63:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/7\">",
"      Forfar JC, Muir AL, Sawers SA, Toft AD. Abnormal left ventricular function in hyperthyroidism: evidence for a possible reversible cardiomyopathy. N Engl J Med 1982; 307:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/8\">",
"      Frost L, Vestergaard P, Mosekilde L. Hyperthyroidism and risk of atrial fibrillation or flutter: a population-based study. Arch Intern Med 2004; 164:1675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/9\">",
"      Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994; 331:1249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/10\">",
"      Nakazawa HK, Sakurai K, Hamada N, et al. Management of atrial fibrillation in the post-thyrotoxic state. Am J Med 1982; 72:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/11\">",
"      Siu CW, Jim MH, Zhang X, et al. Comparison of atrial fibrillation recurrence rates after successful electrical cardioversion in patients with hyperthyroidism-induced versus non-hyperthyroidism-induced persistent atrial fibrillation. Am J Cardiol 2009; 103:540.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/12\">",
"      Bar-Sela S, Ehrenfeld M, Eliakim M. Arterial embolism in thyrotoxicosis with atrial fibrillation. Arch Intern Med 1981; 141:1191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/13\">",
"      Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation). J Am Coll Cardiol. 2006; 48:e149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/14\">",
"      O'Brien T, Katz K, Hodge D, et al. The effect of the treatment of hypothyroidism and hyperthyroidism on plasma lipids and apolipoproteins AI, AII and E. Clin Endocrinol (Oxf) 1997; 46:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/15\">",
"      Reasner, CA. Autoimmune thyroid disease and type 1 diabetes. Diabetes Reviews 1993; 1:343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/16\">",
"      Andersen OO, Friis T, Ottesen B. Glucose tolerance and insulin secretion in hyperthyroidism. Acta Endocrinol (Copenh) 1977; 84:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/17\">",
"      Mishra SK, Gupta N, Goswami R. Plasma adrenocorticotropin (ACTH) values and cortisol response to 250 and 1 microg ACTH stimulation in patients with hyperthyroidism before and after carbimazole therapy: case-control comparative study. J Clin Endocrinol Metab 2007; 92:1693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/18\">",
"      Ayres J, Rees J, Clark TJ, Maisey MN. Thyrotoxicosis and dyspnoea. Clin Endocrinol (Oxf) 1982; 16:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/19\">",
"      Kahaly G, Hellermann J, Mohr-Kahaly S, Treese N. Impaired cardiopulmonary exercise capacity in patients with hyperthyroidism. Chest 1996; 109:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/20\">",
"      Merc&eacute; J, Ferr&aacute;s S, Oltra C, et al. Cardiovascular abnormalities in hyperthyroidism: a prospective Doppler echocardiographic study. Am J Med 2005; 118:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/21\">",
"      Ch'ng CL, Biswas M, Benton A, et al. Prospective screening for coeliac disease in patients with Graves' hyperthyroidism using anti-gliadin and tissue transglutaminase antibodies. Clin Endocrinol (Oxf) 2005; 62:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/22\">",
"      Nordyke RA, Gilbert FI Jr, Harada AS. Graves' disease. Influence of age on clinical findings. Arch Intern Med 1988; 148:626.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/23\">",
"      Davis PJ, Davis FB. Hyperthyroidism in patients over the age of 60 years. Clinical features in 85 patients. Medicine (Baltimore) 1974; 53:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/24\">",
"      Rosenthal FD, Jones C, Lewis SI. Thyrotoxic vomiting. Br Med J 1976; 2:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/25\">",
"      Nightingale S, Vitek PJ, Himsworth RL. The haematology of hyperthyroidism. Q J Med 1978; 47:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/26\">",
"      Franchini M, Lippi G, Targher G. Hyperthyroidism and venous thrombosis: a casual or causal association? A systematic literature review. Clin Appl Thromb Hemost 2011; 17:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/27\">",
"      Stuijver DJ, van Zaane B, Romualdi E, et al. The effect of hyperthyroidism on procoagulant, anticoagulant and fibrinolytic factors: a systematic review and meta-analysis. Thromb Haemost 2012; 108:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/28\">",
"      Evered DC, Hayter CJ, Surveyor I. Primary polydipsia in thyrotoxicosis. Metabolism 1972; 21:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/29\">",
"      Ridgway EC, Maloof F, Longcope C. Androgen and oestrogen dynamics in hyperthyroidism. J Endocrinol 1982; 95:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/30\">",
"      Koutras DA. Disturbances of menstruation in thyroid disease. Ann N Y Acad Sci 1997; 816:280.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/31\">",
"      Hudson RW, Edwards AL. Testicular function in hyperthyroidism. J Androl 1992; 13:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/32\">",
"      Abalovich M, Levalle O, Hermes R, et al. Hypothalamic-pituitary-testicular axis and seminal parameters in hyperthyroid males. Thyroid 1999; 9:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/33\">",
"      Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab 2005; 90:6472.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/34\">",
"      Ross DS. Hyperthyroidism, thyroid hormone therapy, and bone. Thyroid 1994; 4:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/35\">",
"      Fatourechi V, Ahmed DD, Schwartz KM. Thyroid acropachy: report of 40 patients treated at a single institution in a 26-year period. J Clin Endocrinol Metab 2002; 87:5435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/36\">",
"      Stern RA, Robinson B, Thorner AR, et al. A survey study of neuropsychiatric complaints in patients with Graves' disease. J Neuropsychiatry Clin Neurosci 1996; 8:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/37\">",
"      Thomas FB, Mazzaferri EL, Skillman TG. Apathetic thyrotoxicosis: A distinctive clinical and laboratory entity. Ann Intern Med 1970; 72:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/38\">",
"      Trivalle C, Doucet J, Chassagne P, et al. Differences in the signs and symptoms of hyperthyroidism in older and younger patients. J Am Geriatr Soc 1996; 44:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14279/abstract/39\">",
"      Boelaert K, Torlinska B, Holder RL, Franklyn JA. Older subjects with hyperthyroidism present with a paucity of symptoms and signs: a large cross-sectional study. J Clin Endocrinol Metab 2010; 95:2715.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7833 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-3918385851-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14279=[""].join("\n");
var outline_f13_60_14279=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H17\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      SKIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EYES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CARDIOVASCULAR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      METABOLIC / ENDOCRINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Serum lipids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hyperglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Adrenal function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      RESPIRATORY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      GASTROINTESTINAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      HEMATOLOGIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENITOURINARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      BONE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      NEUROPSYCHIATRIC",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      GERIATRIC HYPERTHYROIDISM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7833\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7833|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/0/19469\" title=\"figure 1\">",
"      Increased incidence of AF in subclinical hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/11/17593?source=related_link\">",
"      Bone disease with hyperthyroidism and thyroid hormone therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/57/26520?source=related_link\">",
"      Diagnosis of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/0/4103?source=related_link\">",
"      Disorders that cause hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/22/30057?source=related_link\">",
"      Neurologic manifestations of hyperthyroidism and Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/22/3432?source=related_link\">",
"      Pathogenesis and clinical features of Graves' ophthalmopathy (orbitopathy)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/15/23794?source=related_link\">",
"      Patient information: Antithyroid drugs (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?3/6/3172?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?22/9/22674?source=related_link\">",
"      Patient information: Hyperthyroidism (overactive thyroid) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/50/1828?source=related_link\">",
"      Pretibial myxedema in autoimmune thyroid disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23701?source=related_link\">",
"      Respiratory function in thyroid disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_60_14280="Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency";
var content_f13_60_14280=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myeloperoxidase deficiency and other enzymatic WBC defects causing immunodeficiency",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14280/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14280/contributors\">",
"     Sergio D Rosenzweig, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14280/contributors\">",
"     Steven M Holland, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14280/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14280/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14280/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14280/contributors\">",
"     Elizabeth TePas, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/60/14280/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are a small number of well-described genetic defects in hematopoietic cell enzymes or transporter proteins that can result in neutrophil dysfunction and immunodeficiency. Two of these, myeloperoxidase deficiency and glucose-6-phosphate dehydrogenase deficiency, are relatively common. The others presented in this review, glutathione reductase deficiency, glutathione synthetase deficiency, and glycogen storage disease type 1b, are rare.",
"   </p>",
"   <p>",
"    This topic review provides an overview of the genetic defects responsible for each of these disorders, as well as their clinical manifestations, diagnosis, and treatment. The focus of this review, however, is the mechanism of neutrophil or leukocyte dysfunction in each condition that leads to immunodeficiency.",
"   </p>",
"   <p>",
"    Some of these conditions are discussed in other contexts elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     MYELOPEROXIDASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloperoxidase (MPO) deficiency (MIM# 254600) is an autosomal recessive inherited disorder, with a variable clinical phenotype. It is also the most common primary phagocyte disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One in 4000 individuals have complete MPO deficiency",
"     </li>",
"     <li>",
"      One in 2000 have a partial defect",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Biology of myeloperoxidase",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myeloperoxidase, encoded by a gene located at 17q23, is synthesized in neutrophils and monocytes, packaged in azurophilic granules, and released either into the phagosome or the extracellular space. Myeloperoxidase is the most abundant enzyme in the azurophilic granules, and plays a critical role in bacterial killing by neutrophils; deficient cells take about twice as long to kill pathogens in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myeloperoxidase catalyses the conversion of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    (H2O2) to hypohalous acid (in neutrophils the halide is Cl- and the acid is bleach) (",
"    <a class=\"graphic graphic_figure graphicRef72548 \" href=\"UTD.htm?39/13/40151\">",
"     figure 1",
"    </a>",
"    ). This reaction is thought to amplify the toxicity of the reactive oxygen species generated during the respiratory burst against bacteria and fungi.",
"   </p>",
"   <p>",
"    Neutrophils release neutrophil extracellular traps (NETs), structures composed of decondensed chromatin and granule proteins that trap and kill pathogens, as part of their extracellular killing tools. Reactive oxygen species are required to initiate NET formation. Neutrophil elastase and myeloperoxidase synergize to drive chromatin decondensation, contributing to this mechanism of extracellular killing of microorganisms [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Myeloperoxidase expression is affected by a promoter polymorphism (SP1 consensus binding site), which confers higher (G allele) or lower (A allele) activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;More than 95 percent of MPO deficient patients are entirely asymptomatic, even though in vitro studies reveal that MPO deficient neutrophils are markedly less efficient than normal neutrophils in killing C. albicans and hyphal forms of A. fumigatus [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/8,9\">",
"     8,9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Candida infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Of the small percentage of MPO-deficient patients with clinical findings, infections due to different Candida strains are the most frequently reported. Mucocutaneous, meningeal, and bone infections, as well as sepsis, have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/4,10-14\">",
"     4,10-14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Diabetes mellitus has also frequently been linked to Candida infections in the context of MPO deficiency, suggesting an interaction between these conditions in susceptibility to Candida [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/1,15,16\">",
"     1,15,16",
"    </a>",
"    ]. Patients with cancer and MPO deficiency also appear to be at increased risk for Candida infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A secondary form of MPO deficiency due to discrete chromosomal rearrangements with gene disruption has been reported in some patients with different hematologic disorders. These include acute myeloid leukemia, Hodgkin&rsquo;s lymphoma, and myelodysplastic syndromes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Non-infectious diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-MPO antibodies are associated with vasculitis (eg, granulomatosis with polyangiitis [Wegener's] and microscopic polyangiitis). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=see_link\">",
"     \"Clinical spectrum of antineutrophil cytoplasmic antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    MPO-derived oxidants have also been associated with atherosclerosis, a disorder in which inflammation appears to play a critical role [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/19\">",
"     19",
"    </a>",
"    ]. Consistent with this, increased MPO plasma levels in patients with chest pain predicted an increased risk of early major adverse cardiac events, including myocardial infarction, need for revascularization, or death [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The role of MPO in the pathogenesis of various inflammatory diseases, and the potential protective effects of MPO deficiency are areas of expanding investigation [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Previously (ie, this is no longer the case), myeloperoxidase deficiency was noted even before the diagnosis was suspected because the machines that performed automated leukocyte differential counts relied upon neutrophil myeloperoxidase activity to stain these cells [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with MPO deficiency had populations of \"large unstained cells\" in their automated differential counts that were not borne out by manual performance of the differential count.",
"   </p>",
"   <p>",
"    Definitive diagnosis is established by histochemical staining of neutrophils for myeloperoxidase, which is available through commercial labs.",
"   </p>",
"   <p>",
"    The clinical relevance of identifying MPO deficiency in a particular patient, however, is less straightforward. Because so many patients with MPO deficiency are asymptomatic, patients with recurrent infections should be carefully evaluated for diabetes mellitus and other immune defects, even if MPO deficiency is identified. The differential diagnosis in a patient with invasive Candida infections, without external immune suppression, includes chronic granulomatous disease (CGD) and the hyper IgE syndrome. Mucocutaneous candidiasis is more common than spontaneous invasive candidiasis, but neither is a common manifestation of MPO deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=see_link\">",
"     \"Hyperimmunoglobulin E syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=see_link\">",
"     \"Chronic mucocutaneous candidiasis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=see_link\">",
"     \"Approach to the child with recurrent infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific treatment for MPO deficiency. Infections should be aggressively treated when they occur, and rigorous control of blood glucose may be beneficial in patients with associated diabetes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucose-6-phosphate dehydrogenase (G6PD, Xq28) deficiency (MIM# 305900), the most common enzymopathy in humans, affects 400 million persons worldwide. The prevalence varies geographically, ranging from 0.1 percent in Japan and northern Europe, to 62 percent among Kurdish Jews. G6PD deficiency is inherited in an X-linked pattern.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Biology",
"    </span>",
"    &nbsp;&mdash;&nbsp;G6PD is required for NADPH generation through the hexose monophosphate pathway. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .) NADPH is necessary for the respiratory burst, and is also crucial in preserving red blood cells from oxidative damage (",
"    <a class=\"graphic graphic_figure graphicRef72548 \" href=\"UTD.htm?39/13/40151\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemolytic anemia is the most frequent clinical manifestation. Triggers include fava beans, drugs (eg, antimalarials, nitrofurans, sulfonamides, and sulfones), infections, or different \"oxidative challenges.\" (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Rarely, patients with severe G6PD deficiency (less than 5 percent of the enzyme activity in neutrophils) have increased susceptibility to infections due to impairment of the neutrophil respiratory burst. Recurrent bacterial pulmonary infections and one death due to Chromobacterium violaceum sepsis have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/25-32\">",
"     25-32",
"    </a>",
"    ]. G6PD deficiency predisposes to septic complications and anemia in patients who have suffered severe traumatic injuries. This is accompanied by increased monocyte oxidative stress, decreased apoptotic response, increased cell adhesion, and diminished IL-10 response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Deficiency of G6PD may also confer some advantages. A significant reduction in the risk of severe malaria has been associated with G6PD deficiency in males and in heterozygous females [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/34\">",
"     34",
"    </a>",
"    ]. A thorough genotype-phenotype correlation has been carried out [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/35\">",
"     35",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=see_link\">",
"     \"Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;G6PD activity should be evaluated in patients with congenital nonspherocytic hemolytic anemia and a high rate of infections. Spherocytes can be seen in G6PD following a hemolytic event, although they are not prominent in the smear at baseline. G6PD activity can be measured in hemolysates or neutrophil homogenates. Neutrophil G6PD activity is significantly higher than that found in erythrocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=see_link\">",
"     \"Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neutrophil dysfunction in G6PD deficiency is less frequent than expected. This may be because most affected patients have more than 20 percent of G6PD activity in neutrophils, a threshold sufficient to maintain the respiratory burst within the normal range [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/26,30\">",
"     26,30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    G6PD deficiency may resemble chronic granulomatous disease because it compromises the function of the NADPH oxidase by limiting the supply of NADPH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=see_link\">",
"     \"Primary disorders of phagocytic function: An overview\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prophylactic antibiotics (eg, cephalosporins, quinolones) may be helpful in the few cases with recurrent infections. Cotrimoxazole should be avoided as it may exacerbate hemolysis in G6PD deficiency. As in other primary phagocyte immunodeficiencies, infections must be aggressively treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GLUTATHIONE PATHWAY ALTERATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reduced form of glutathione (GSH) protects cells from the deleterious effects of reactive oxygen species that are produced during the respiratory burst and the metabolism of uric acid. In neutrophils, GSH is critical for preserving nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity.",
"   </p>",
"   <p>",
"    Glutathione reductase (GR, 8p21.1) and glutathione synthetase (GS, 20q11.2) are involved in maintaining adequate intracellular levels of GSH [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/26\">",
"     26",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_figure graphicRef72548 \" href=\"UTD.htm?39/13/40151\">",
"     figure 1",
"    </a>",
"    ). GR deficiency (MIM #138300) and GS deficiency (MIM #266130, #231900) are rare autosomal recessive inherited diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5399?source=see_link\">",
"     \"Related disorders of the hexose monophosphate shunt and glutathione metabolism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both GR and GS deficiency are associated with hemolysis after increased oxidant stress. GS, but not GR, deficient patients may also be at increased risk of infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     GS deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three different clinical presentations are described for GS deficiency: mild, moderate, and severe. Mutations causing frameshifts, premature stop codons, or aberrant splicing are associated with moderate or severe clinical phenotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Mildly affected patients have isolated hemolytic anemia.",
"     </li>",
"     <li>",
"      Moderately affected patients have hemolytic anemia and metabolic acidosis with increased 5-oxoproline levels.",
"     </li>",
"     <li>",
"      Severely affected patients have hemolytic anemia, metabolic acidosis with increased 5-oxoproline levels, and progressive dysfunction of the central nervous system. These patients also have recurrent bacterial infections, and impairments in phagocytosis and intracellular bacterial killing have been described [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/37,38\">",
"       37,38",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     GR deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premature termination of the respiratory burst is described in GR deficient patients. However, no increased infection rate has been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnoses of GS and GR deficiency are based upon the presence of characteristic clinical manifestations and results of specific laboratory tests:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with GS deficiency present with 5-oxoprolinuria (pyroglutamic aciduria) and low GSH in erythrocytes (as measured by a standard colorimetric test). GS activity in cultured fibroblasts can also be measured.",
"     </li>",
"     <li>",
"      Glutathione reductase activity is low in GR deficiency and can be measured in red cell hemolysates both in the presence or absence of flavin adenine dinucleotide (FAD).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above mentioned tests are commercially available, although the number of laboratories performing them is small [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Neonatal screening for GS deficiency should be considered, since most important determinants for outcome and survival in these patients are early diagnosis and early initiation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exposure to drugs and chemicals with oxidant potential should be avoided, as in patients with G6PD deficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency\", section on 'Drugs and chemicals'",
"    </a>",
"    .) Daily supplementation with vitamin E 400 IU has shown neutrophil functional improvement in vitro and reduced infection rates in GS deficient patients in vivo [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. As in other primary phagocyte immunodeficiencies, infections must be aggressively treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     GLYCOGEN STORAGE DISEASE 1b",
"    </span>",
"    &nbsp;&mdash;&nbsp;The glycogen storage disease (GSD) type 1 or von Gierke disease is characterized by the inability to convert Glucose-6-phosphate to glucose within the liver. The incidence of GSD I is",
"    <span class=\"nowrap\">",
"     1/100,000",
"    </span>",
"    live births [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/43\">",
"     43",
"    </a>",
"    ]. There are four subgroups: 1a, 1b, 1c, and 1d. The following is a brief overview of this disease, with an emphasis upon those aspects related to neutrophil dysfunction. A more comprehensive review is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=see_link\">",
"     \"Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The conversion of glucose-6-phosphate to glucose requires the glucose-6-phosphate transporter 1 (11q23), which is deficient in GSD1b (MIM #232220). GSD1b deficiency is recessively inherited [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/44\">",
"     44",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both GSD1a and GSD1b may present early in life with fasting hypoglycemia, lactic acidosis, hyperuricemia, hyperlipidemia, hepatomegaly, and seizures. GSD1b, unlike GSD1a, also shows neutropenia and neutrophil dysfunction. Neutropenia also occurs in type 1c, which is allelic to GSD1b. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unlike types 1a and 1c, deficient neutrophil chemotaxis and defective respiratory burst have been described in patients with GSD1b deficiency, resulting in an increased incidence of infections [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. In one study, 15 of 21 subjects with GSD1b deficiency had moderate to severe infections, which were primarily due to bacteria affecting the ears, lungs, and skin. Mucosal ulcers of the mouth and anus were also frequently observed, along with an increased rate of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/47\">",
"     47",
"    </a>",
"    ]. However, in a study of 25 GSD1b patients, no correlation was found between individual mutations and the presence of neutropenia, bacterial infections, and systemic complications [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/43\">",
"     43",
"    </a>",
"    ]. Therefore, background genetic and other influences likely modulate neutrophil differentiation, maturation, and apoptosis and thus the severity and frequency of infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Evaluation and diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of GSD1b should be considered in patients with any combination of the characteristic clinical manifestations, including lactic acidosis, hyperlipidemia, neutropenia, neutrophil dysfunction, and an increased rate of infections. Identification of mutations confirms the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/44\">",
"     44",
"    </a>",
"    ]. The most prevalent mutations include 1184G&gt;T and 1211delCT in Caucasians, 521T&gt;C in Japanese, and 338del7 and 1105insA in Pakistanis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=see_link\">",
"     \"Congenital neutropenia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=see_link\">",
"     \"Laboratory evaluation of neutropenia and neutrophil dysfunction\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with GSD 1b, treatment is oriented to maintaining normal blood glucose levels by using nocturnal feeding or complex starches, avoiding infections by keeping the neutrophil number elevated, and controlling inflammatory bowel disease. Recombinant human G-CSF has been used successfully to counter neutropenia and immune dysfunction, as well as improve the symptoms of inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/48-51\">",
"     48-51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study of seven patients with severe",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      recurrent bacterial infections, G-CSF at a median dose of 5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per day increased the absolute neutrophil count in six, and prevented recurrent infection in all seven [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/50\">",
"       50",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The use of G-CSF may also improve phagocytic function through calcium mobilization and superoxide anion generation, although defective neutrophil chemotaxis persisted after G-CSF treatment in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/49\">",
"       49",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The inflammatory bowel disease manifestations of GSD 1b may also respond to G-CSF. A case report and literature review identified six cases treated with G-CSF or GM-CSF [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/51\">",
"       51",
"      </a>",
"      ] who experienced remission of their bowel disease.",
"     </li>",
"     <li>",
"      Splenomegaly is a potential consequence of G-CSF therapy. All 13 patients in one study developed splenomegaly [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14280/abstract/48\">",
"       48",
"      </a>",
"      ], but this was mild in five individuals and none required splenectomy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These findings suggest that G-CSF should be considered for the management of patients with GSD 1b and severe",
"    <span class=\"nowrap\">",
"     neutropenia/severe",
"    </span>",
"    infections, or inflammatory bowel problems. Prospective studies are needed to better clarify the indications for and mechanism of action of G-CSF therapy in GSD 1b.",
"   </p>",
"   <p>",
"    As in other primary phagocyte immunodeficiencies, infections, when present, should be aggressively treated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=see_link\">",
"     \"Medical management of immune deficiency\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Genetic defects in hematopoietic cell enzymes or transporter proteins can cause neutrophil dysfunction and immunodeficiency. Myeloperoxidase deficiency and glucose-6-phosphate dehydrogenase deficiency are relatively common disorders, while others are rare. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Myeloperoxidase deficiency is the most common primary disorder of phagocytes, although the vast majority of affected individuals are asymptomatic. Recurrent Candida infections are seen in the small number of patients who do manifest symptoms, and MPO deficiency may play a role in the development of Candida infections in patients with diabetes mellitus or malignancies. The diagnosis is established by histochemical staining of neutrophils for myeloperoxidase, and there is no specific corrective therapy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Myeloperoxidase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      G6PD deficiency is the most common enzymopathy in humans. Glucose-6-phosphate dehydrogenase (G6PD) is necessary for the neutrophil respiratory burst and also protects red blood cells from oxidative damage. It is an X-linked disorder that most often presents with hemolytic anemia. Patients with severe deficiency may have increased susceptibility to bacterial infections and sepsis. G6PD deficiency may also confer some advantages, such as protection from malarial infection. Treatment of immune dysfunction may include prophylactic antibiotics and aggressive treatment of infections. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Glucose-6-phosphate dehydrogenase deficiency'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Deficiencies of glutathione reductase (GR) and glutathione synthetase (GS) are extremely rare autosomal recessive diseases. Severe GS deficiency may present with hemolytic anemia, metabolic acidosis, progressive CNS defects, and recurrent bacterial infections. Daily vitamin E supplementation can improve neutrophil function in GS deficiency. Infections are not a feature of GR deficiency. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Glutathione pathway alterations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glycogen storage disease 1b is a rare recessive disorder that presents in childhood with fasting hypoglycemia, lactic acidosis, hyperuricemia, hyperlipidemia, hepatomegaly, seizures, neutropenia and neutrophil dysfunction. Sinopulmonary infections and mucosal ulcers are observed and there is associated inflammatory bowel disease. The diagnosis is made with genetic analysis. Treatment involves maintaining normal blood glucose levels, and G-CSF therapy improves immune function. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Glycogen storage disease 1b'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/1\">",
"      Parry MF, Root RK, Metcalf JA, et al. Myeloperoxidase deficiency: prevalence and clinical significance. Ann Intern Med 1981; 95:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/2\">",
"      Kitahara M, Eyre HJ, Simonian Y, et al. Hereditary myeloperoxidase deficiency. Blood 1981; 57:888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/3\">",
"      Nauseef WM, Root RK, Malech HL. Biochemical and immunologic analysis of hereditary myeloperoxidase deficiency. J Clin Invest 1983; 71:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/4\">",
"      Nauseef WM. Myeloperoxidase deficiency. Hematol Oncol Clin North Am 1988; 2:135.",
"     </a>",
"    </li>",
"    <li>",
"     Stiehm ER, Ochs HD, Winkelstein JA. The natural (innate) defense system. In: Immunologic disorders in infants and children, Stiehm ER, Ochs HD, Winkelstein JA (Eds), Elsevier Saunders, Philadelphia 2004. p.258.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/6\">",
"      Hampton MB, Kettle AJ, Winterbourn CC. Inside the neutrophil phagosome: oxidants, myeloperoxidase, and bacterial killing. Blood 1998; 92:3007.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/7\">",
"      Papayannopoulos V, Metzler KD, Hakkim A, Zychlinsky A. Neutrophil elastase and myeloperoxidase regulate the formation of neutrophil extracellular traps. J Cell Biol 2010; 191:677.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/8\">",
"      Rex JH, Bennett JE, Gallin JI, et al. Normal and deficient neutrophils can cooperate to damage Aspergillus fumigatus hyphae. J Infect Dis 1990; 162:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/9\">",
"      Diamond RD, Clark RA, Haudenschild CC. Damage to Candida albicans hyphae and pseudohyphae by the myeloperoxidase system and oxidative products of neutrophil metabolism in vitro. J Clin Invest 1980; 66:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/10\">",
"      Weber ML, Abela A, de Repentigny L, et al. Myeloperoxidase deficiency with extensive candidal osteomyelitis of the base of the skull. Pediatrics 1987; 80:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/11\">",
"      Okuda T, Yasuoka T, Oka N. Myeloperoxidase deficiency as a predisposing factor for deep mucocutaneous candidiasis: a case report. J Oral Maxillofac Surg 1991; 49:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/12\">",
"      Ludviksson BR, Thorarensen O, Gudnason T, Halldorsson S. Candida albicans meningitis in a child with myeloperoxidase deficiency. Pediatr Infect Dis J 1993; 12:162.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/13\">",
"      Nguyen C, Katner HP. Myeloperoxidase deficiency manifesting as pustular candidal dermatitis. Clin Infect Dis 1997; 24:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/14\">",
"      Chiang AK, Chan GC, Ma SK, et al. Disseminated fungal infection associated with myeloperoxidase deficiency in a premature neonate. Pediatr Infect Dis J 2000; 19:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/15\">",
"      Lehrer RI, Cline MJ. Leukocyte myeloperoxidase deficiency and disseminated candidiasis: the role of myeloperoxidase in resistance to Candida infection. J Clin Invest 1969; 48:1478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/16\">",
"      Cech P, Stalder H, Widmann JJ, et al. Leukocyte myeloperoxidase deficiency and diabetes mellitus associated with Candida albicans liver abscess. Am J Med 1979; 66:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/17\">",
"      Koziol-Montewka M, Magrys A, Paluch-Oles J, et al. MPO and cytokines in the serum of cancer patients in the context of Candida colonization and infection. Immunol Invest 2006; 35:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/18\">",
"      Magrys A, Koziol-Montewka M, Staroslawska E, et al. Immunological parameters of candidiasis in cancer patients. New Microbiol 2005; 28:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/19\">",
"      Winterbourn CC, Vissers MC, Kettle AJ. Myeloperoxidase. Curr Opin Hematol 2000; 7:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/20\">",
"      Brennan ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. N Engl J Med 2003; 349:1595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/21\">",
"      Hoy A, Leininger-Muller B, Kutter D, et al. Growing significance of myeloperoxidase in non-infectious diseases. Clin Chem Lab Med 2002; 40:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/22\">",
"      Kutter D, Devaquet P, Vanderstocken G, et al. Consequences of total and subtotal myeloperoxidase deficiency: risk or benefit ? Acta Haematol 2000; 104:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/23\">",
"      Nauseef WM. How human neutrophils kill and degrade microbes: an integrated view. Immunol Rev 2007; 219:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/24\">",
"      Larrocha C, Fern&aacute;ndez de Castro M, Fontan G, et al. Hereditary myeloperoxidase deficiency: study of 12 cases. Scand J Haematol 1982; 29:389.",
"     </a>",
"    </li>",
"    <li>",
"     Lazzato L. Glucose-6-phosphate dehydrogenase deficiency and hemolytic anemia. In: Nathan and Oski's hematology of infancy and childhood, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 1998. p.704.",
"    </li>",
"    <li>",
"     Dinauer M. The phagocyte system and disorders of granulopoiesis and granulocyte function.. In: Nathan and Oski's hematology of infancy and childhood, Nathan DG, Orkin SH (Eds), WB Saunders, Philadelphia 1998. p.889.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/27\">",
"      Vives Corrons JL, Feliu E, Pujades MA, et al. Severe-glucose-6-phosphate dehydrogenase (G6PD) deficiency associated with chronic hemolytic anemia, granulocyte dysfunction, and increased susceptibility to infections: description of a new molecular variant (G6PD Barcelona). Blood 1982; 59:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/28\">",
"      Mamlok RJ, Mamlok V, Mills GC, et al. Glucose-6-phosphate dehydrogenase deficiency, neutrophil dysfunction and Chromobacterium violaceum sepsis. J Pediatr 1987; 111:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/29\">",
"      Gray GR, Stamatoyannopoulos G, Naiman SC, et al. Neutrophil dysfunction, chronic granulomatous disease, and non-spherocytic haemolytic anaemia caused by complete deficiency of glucose-6-phosphate dehydrogenase. Lancet 1973; 2:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/30\">",
"      Ardati KO, Bajakian KM, Tabbara KS. Effect of glucose-6-phosphate dehydrogenase deficiency on neutrophil function. Acta Haematol 1997; 97:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/31\">",
"      Roos D, van Zwieten R, Wijnen JT, et al. Molecular basis and enzymatic properties of glucose 6-phosphate dehydrogenase volendam, leading to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 1999; 94:2955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/32\">",
"      van Bruggen R, Bautista JM, Petropoulou T, et al. Deletion of leucine 61 in glucose-6-phosphate dehydrogenase leads to chronic nonspherocytic anemia, granulocyte dysfunction, and increased susceptibility to infections. Blood 2002; 100:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/33\">",
"      Spolarics Z, Siddiqi M, Siegel JH, et al. Increased incidence of sepsis and altered monocyte functions in severely injured type A- glucose-6-phosphate dehydrogenase-deficient African American trauma patients. Crit Care Med 2001; 29:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/34\">",
"      Ruwende C, Hill A. Glucose-6-phosphate dehydrogenase deficiency and malaria. J Mol Med (Berl) 1998; 76:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/35\">",
"      Mason PJ, Bautista JM, Gilsanz F. G6PD deficiency: the genotype-phenotype association. Blood Rev 2007; 21:267.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/36\">",
"      Nj&aring;lsson R, Ristoff E, Carlsson K, et al. Genotype, enzyme activity, glutathione level, and clinical phenotype in patients with glutathione synthetase deficiency. Hum Genet 2005; 116:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/37\">",
"      Spielberg SP, Boxer LA, Oliver JM, et al. Altered phagocytosis and microtubule function in leukocytes from a patient with severe glutathione synthase deficiency (5-oxoprolinuria). Monogr Hum Genet 1978; 9:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/38\">",
"      Baehner RL, Boxer LA. Role of membrane vitamin E and cytoplasmic glutathione in the regulation of phagocytic functions of neutrophils and monocytes. Am J Pediatr Hematol Oncol 1979; 1:71.",
"     </a>",
"    </li>",
"    <li>",
"     Baylor Research Institute, Institute of Metabolic Disease, Dallas; Duke University Medical Center, Pediatric Biochemical Genetics Laboratory. www.baylorhealth.edu/imd (Accessed on May 11, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/40\">",
"      Simon E, Vogel M, Fingerhut R, et al. Diagnosis of glutathione synthetase deficiency in newborn screening. J Inherit Metab Dis 2009; 32 Suppl 1:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/41\">",
"      Boxer LA, Oliver JM, Spielberg SP, et al. Protection of granulocytes by vitamin E in glutathione synthetase deficiency. N Engl J Med 1979; 301:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/42\">",
"      Ristoff E, Mayatepek E, Larsson A. Long-term clinical outcome in patients with glutathione synthetase deficiency. J Pediatr 2001; 139:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/43\">",
"      Melis D, Fulceri R, Parenti G, et al. Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature. Eur J Pediatr 2005; 164:501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/44\">",
"      Janecke AR, Mayatepek E, Utermann G. Molecular genetics of type 1 glycogen storage disease. Mol Genet Metab 2001; 73:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/45\">",
"      Anderson DC, Mace ML, Brinkley BR, et al. Recurrent infection in glycogenosis type Ib: abnormal neutrophil motility related to impaired redistribution of adhesion sites. J Infect Dis 1981; 143:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/46\">",
"      Kilpatrick L, Garty BZ, Lundquist KF, et al. Impaired metabolic function and signaling defects in phagocytic cells in glycogen storage disease type 1b. J Clin Invest 1990; 86:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/47\">",
"      Ambruso DR, McCabe ER, Anderson D, et al. Infectious and bleeding complications in patients with glycogenosis Ib. Am J Dis Child 1985; 139:691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/48\">",
"      Calderwood S, Kilpatrick L, Douglas SD, et al. Recombinant human granulocyte colony-stimulating factor therapy for patients with neutropenia and/or neutrophil dysfunction secondary to glycogen storage disease type 1b. Blood 2001; 97:376.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/49\">",
"      McCawley LJ, Korchak HM, Douglas SD, et al. In vitro and in vivo effects of granulocyte colony-stimulating factor on neutrophils in glycogen storage disease type 1B: granulocyte colony-stimulating factor therapy corrects the neutropenia and the defects in respiratory burst activity and Ca2+ mobilization. Pediatr Res 1994; 35:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/50\">",
"      Donadieu J, Bader-Meunier B, Bertrand Y, et al. Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. Report of 7 cases. Nouv Rev Fr Hematol 1994; 35:529.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14280/abstract/51\">",
"      Yamaguchi T, Ihara K, Matsumoto T, et al. Inflammatory bowel disease-like colitis in glycogen storage disease type 1b. Inflamm Bowel Dis 2001; 7:128.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3954 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-41.196.66.12-562CF1C545-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14280=[""].join("\n");
var outline_f13_60_14280=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H24\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      MYELOPEROXIDASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Biology of myeloperoxidase",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Candida infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Non-infectious diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Biology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GLUTATHIONE PATHWAY ALTERATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - GS deficiency",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - GR deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      GLYCOGEN STORAGE DISEASE 1b",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Evaluation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3954\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3954|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/13/40151\" title=\"figure 1\">",
"      NADPH oxidase system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/47/30458?source=related_link\">",
"      Approach to the child with recurrent infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/1/22553?source=related_link\">",
"      Chronic mucocutaneous candidiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/25/4505?source=related_link\">",
"      Clinical manifestations of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/28/9674?source=related_link\">",
"      Clinical spectrum of antineutrophil cytoplasmic antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/22/24937?source=related_link\">",
"      Congenital neutropenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/50/39719?source=related_link\">",
"      Diagnosis and treatment of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/62/13289?source=related_link\">",
"      Genetics and pathophysiology of glucose-6-phosphate dehydrogenase deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/48/16136?source=related_link\">",
"      Glucose-6-phosphatase deficiency (glycogen storage disease I, von Gierke disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/25/32153?source=related_link\">",
"      Hyperimmunoglobulin E syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/2/24614?source=related_link\">",
"      Laboratory evaluation of neutropenia and neutrophil dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/27/8633?source=related_link\">",
"      Medical management of immune deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/38/43620?source=related_link\">",
"      Primary disorders of phagocytic function: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/17/5399?source=related_link\">",
"      Related disorders of the hexose monophosphate shunt and glutathione metabolism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_60_14281="Standard and pegylated interferon for chronic hepatitis B virus infection";
var content_f13_60_14281=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Standard and pegylated interferon for chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14281/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14281/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14281/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14281/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?13/60/14281/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?13/60/14281/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?13/60/14281/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 2, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chronic hepatitis B virus (HBV) infection is a serious liver disorder that may result in cirrhosis and hepatocellular carcinoma (HCC). It is an immense health problem globally that affects 300 million individuals or 5 percent of the world's population.",
"   </p>",
"   <p>",
"    Interferons (IFN) have antiviral, antiproliferative, and immunomodulatory effects. IFN-alfa (IFNa) and IFN-beta have predominantly antiviral effects, while IFN-gamma has more marked immunoregulatory but less potent antiviral activity.",
"   </p>",
"   <p>",
"    IFNa was the first treatment approved for chronic HBV infection in most countries. Peginterferon (pegIFN alfa-2a only in the United States and pegIFN alfa-2a as well as pegIFN alfa-2b in many countries outside the US) is also approved for treatment of chronic HBV. This topic review will discuss the treatment of chronic hepatitis B with standard or peginterferon. A general approach to patients with hepatitis B (including other treatment options) is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ENDPOINTS OF THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several endpoints are used to assess the efficacy of hepatitis B treatment (",
"    <a class=\"graphic graphic_table graphicRef63634 \" href=\"UTD.htm?20/6/20587\">",
"     table 1",
"    </a>",
"    ). A report from a NIH workshop on the management of hepatitis B proposes that responses to antiviral therapy of chronic hepatitis B should be categorized as biochemical, virological, or histological, and as on-therapy or sustained off-therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/1\">",
"     1",
"    </a>",
"    ]. A positive response to IFNa is usually defined as the loss of viral replication markers (HBeAg [in patients who were HBeAg-positive] and serum HBV DNA) at the end of treatment or 24 weeks after discontinuation of treatment. A decrease of serum HBV DNA usually occurs during treatment, but loss of HBeAg and seroconversion to HBe antibody (anti-HBe) may be delayed.",
"   </p>",
"   <p>",
"    IFN therapy is associated with flares (at least twofold increase over baseline) in serum alanine aminotransferase (ALT) concentrations in 30 to 50 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/2\">",
"     2",
"    </a>",
"    ]. This response is thought to reflect immune-mediated lysis of infected hepatocytes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=see_link\">",
"     \"Characteristics of the hepatitis B virus and pathogenesis of infection\"",
"    </a>",
"    .) IFN may need to be discontinued or the dose reduced if the flare is severe and accompanied by symptoms or an increase in the serum bilirubin concentration. A successful antiviral response is usually associated with normalization of serum ALT and decreased necroinflammatory activity.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EFFICACY OF STANDARD INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple studies have evaluated the efficacy of standard interferon in HBeAg-positive chronic HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/3\">",
"     3",
"    </a>",
"    ]. The following benefits were found in a meta-analysis of studies comparing treatment with standard interferon for three to six months with placebo (with all estimates reported after 6 to 12 months of post-treatment follow-up) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/3\">",
"     3",
"    </a>",
"    ]. Although standard interferon is no longer used in most countries in which pegylated interferon is available, data from these early studies provide evidence of a beneficial effect of interferon compared with no treatment.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      More frequent loss of viral replication markers (HBeAg) &ndash; 33 versus 12 percent with placebo",
"     </li>",
"     <li>",
"      More frequent loss of HBV DNA (by hybridization assay) &ndash; 37 versus 17 percent",
"     </li>",
"     <li>",
"      More frequent loss of hepatitis B surface antigen (HBsAg) &ndash; 7.8 versus 1.8 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treated patients were also much more likely to seroconvert to anti-HBe and to show normalization in ALT levels.",
"   </p>",
"   <p>",
"    Treatment with standard interferon in patients who are HBeAg-, HBV DNA+, with elevated serum ALT (many of whom are infected with a precore variant) is usually associated with a decrease in serum HBV DNA and ALT levels, but relapse is common after cessation of treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. A longer course of therapy (24 months) may be more effective in inducing a sustained response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Interferon treatment may reduce disease progression, although the beneficial effect is seen mostly among responders [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EFFICACY OF PEGINTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attachment of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/17/4374?source=see_link\">",
"     polyethylene glycol",
"    </a>",
"    to a protein (pegylation) reduces its rate of absorption following subcutaneous injection, reduces renal and cellular clearance, and decreases the immunogenicity of the protein. All of these effects tend to enhance the half-life of the pegylated versus the native protein. Peginterferon (alone and in combination with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    ) has become the treatment of choice for patients with chronic hepatitis C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=see_link\">",
"     \"Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Approval of peginterferon alfa-2a was based upon two studies in HBeAg-positive and HBeAg-negative chronic HBV in which peginterferon was compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or combination therapy with peginterferon plus lamivudine [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Patients were randomly assigned to peginterferon (180 mcg once weekly) or lamivudine (100 mg once daily) or both for 48 weeks followed by a 24-week observation period. All patients were adults with compensated chronic HBV and evidence of HBV replication (serum HBV &gt;500,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    for HBeAg-positive and &gt;100,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    for HBeAg-negative), elevation in serum aminotransferases between 1 and 10 X the upper limit of normal, and liver biopsy findings compatible with chronic hepatitis. The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HBeAg seroconversion was observed significantly more often with pegylated interferon compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      at the end of follow-up (32 versus 19 percent).",
"     </li>",
"     <li>",
"      Persistent suppression of HBV DNA and ALT normalization in HBeAg-negative patients occurred more often with peginterferon compared with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (43 versus 29 percent, and 59 versus 44 percent, respectively).",
"     </li>",
"     <li>",
"      Combination therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      did not increase the rate of sustained response compared with peginterferon monotherapy, although it was associated with the greatest degree of on-treatment virus suppression of the three arms.",
"     </li>",
"     <li>",
"      Serious adverse events occurred in 4, 6, and 2 percent of patients receiving peginterferon monotherapy, combination therapy, or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      monotherapy, respectively. Two patients in the lamivudine monotherapy group developed irreversible liver failure (one received a transplant, and the other died) when treatment was discontinued.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HBeAg seroconversion occurred in some patients a few months after cessation of treatment, underscoring the immune modulatory effects of interferon.",
"   </p>",
"   <p>",
"    The rate of HBeAg seroconversion (32 percent) after 48 weeks of treatment was not substantially higher than what has been observed with shorter courses of standard interferon (see",
"    <a class=\"local\" href=\"#H3\">",
"     'Efficacy of standard interferon'",
"    </a>",
"    above) or lower dose (90 mcg) of pegylated IFN for 24 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/11\">",
"     11",
"    </a>",
"    ]. On the other hand, a later study found that a 90 mcg dose of pegylated IFN given for 24 weeks was inferior to standard dose (180 mcg) of pegylated interferon given for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/12\">",
"     12",
"    </a>",
"    ] The study included 544 patients (mostly Asians with genotypes B or C) with HBeAg+ chronic HBV who were randomly assigned to one of four treatment arms comparing 180 to 90 mcg of peginterferon given for 24 or 48 weeks. The HBeAg seroconversion rate was highest in the 180 mcg 48 week group (36 percent) compared with 26 percent for the 48 week 90 mcg group, 23 percent in the 24 week 180 mcg group, and 14 percent in the 24 week 90 mcg group. The shorter duration of treatment was significantly inferior to the 48 weeks of treatment, and the 90 mcg dose was significantly inferior to the 180 mcg dose. It is unclear if these results will apply to patients with adult-acquired infection or genotype A infection.",
"   </p>",
"   <p>",
"    Other controlled trials have compared peginterferon alone with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in patients with HBeAg-positive or HBeAg-negative chronic hepatitis. The results are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"     \"Combination therapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of peginterferon in patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistant",
"    <span class=\"nowrap\">",
"     M204V/I",
"    </span>",
"    mutations has not been well studied. In a series of 16 such patients (the largest cohort reported), only two patients seroconverted and achieved sustained virologic suppression and biochemical normalization [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Peginterferon alfa-2b (PegIntron",
"    <sup>",
"     TM",
"    </sup>",
"    ) has not been approved for HBV in the United States but probably has similar efficacy as peginterferon alfa-2a. However, the dose and duration of PegIntron",
"    <sup>",
"     TM",
"    </sup>",
"    to be used in chronic HBV, particularly HBeAg-negative patients, are unclear. Two large published trials in HBeAg-positive patients used tapering doses of PegIntron",
"    <sup>",
"     TM",
"    </sup>",
"    for a total of 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In one of these trials, treatment was similarly tolerated in patients with advanced fibrosis and compensated cirrhosis as patients without advanced fibrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/16\">",
"     16",
"    </a>",
"    ]. HBeAg loss after treatment appears to be durable in about 80 percent of patients during follow-up of up to three years. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Long-term outcome'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In treatment of chronic HCV, the rapidity of decline in HCV RNA during treatment with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    correlates with the likelihood of a sustained virologic response. Whether a similar situation exists in treatment of HBeAg-positive chronic HBV with peginterferon has not been as well studied. Changes in HBV DNA were found to be insufficiently accurate in predicting responses in individual patients for routine clinical use in one report [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/17\">",
"     17",
"    </a>",
"    ]. By contrast, another report found that the presence of &ge;10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    HBV DNA at week 8 of peginterferon predicted a low chance of a sustained virological response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/18\">",
"     18",
"    </a>",
"    ]. A decrease in HBeAg titers during treatment was predictive of seroconversion in another study [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/19\">",
"     19",
"    </a>",
"    ], while another report found that a lack of decline in HBsAg by week 12 strongly predicted against a subsequent response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hepatitis flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sixty-seven patients (25 percent) experienced a total of 75 hepatitis flares in the study on peginterferon alfa-2b in HBeAg-positive patients (at an approximately similar rate in the combination and monotherapy groups) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/21\">",
"     21",
"    </a>",
"    ]. Overall, there was no significant difference in the rates of HBeAg loss among those with and without a flare. However, the pattern of HBV DNA surrounding the flare was highly predictive of the likelihood of achieving loss of HBeAg. Flares that occurred after an increase in HBV DNA levels (referred to as \"virus-induced\" flares because they probably reflect increased expression of viral antigens) were not associated with HBeAg loss. By contrast, flares that were followed by a decrease in HBV DNA titers (referred to as \"host-induced\" flares) were significantly associated with HBeAg loss (58 percent compared with 20 percent for virus-induced flares). Loss of HBsAg was observed only in patients with a host-induced flare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Following treatment with nucleos(t)ide analogues",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are relatively few studies evaluating the efficacy of peginterferon following treatment with nucleos(t)ide analogues. One of the largest studies included HBeAg-positive patients with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance who were randomly assigned to pegylated interferon for 48 weeks (n = 155) or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    for 72 weeks (n = 80) [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/22\">",
"     22",
"    </a>",
"    ]. All patients received lamivudine during the first 12 weeks. Six months after treatment, significantly more patients treated with interferon achieved HBeAg seroconversion (15 versus 4 percent). A decline in HBsAg levels was predictive of a response to interferon. These data suggest that peginterferon can be effective in some patients with resistance to nucleos(t)ide analogues.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SELECTION OF PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFNa (whether standard or pegylated) should be considered in patients with chronic HBV infection (HBsAg positive for more than six months) who have evidence of active virus replication (HBeAg",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    high serum HBV DNA levels &gt;20,000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    for HBeAg-positive patients and &gt;2000 int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    for HBeAg-negative patients) and active liver disease (elevated serum ALT concentration and chronic hepatitis on liver biopsy). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=see_link\">",
"     \"Serologic diagnosis of hepatitis B virus infection\"",
"    </a>",
"    .) IFNa treatment is safe and can be effective in patients who have cirrhosis on liver biopsy but no clinical or biochemical evidence of decompensation. The rationale for the selection of interferon versus other options for treatment of chronic HBV is presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The efficacy of IFNa is variable in other clinical settings as summarized below (with most data being derived from studies using standard interferon):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HBeAg+, HBV DNA+, with normal serum ALT &ndash; This profile is frequently seen in Asian patients, particularly in children who were infected perinatally [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/23\">",
"       23",
"      </a>",
"      ]. IFNa treatment is",
"      <strong>",
"       not",
"      </strong>",
"      warranted in these patients since the response rate is less than 10 percent.",
"     </li>",
"     <li>",
"      HBV DNA+ with decompensated cirrhosis &ndash; Some patients with established cirrhosis remain HBV DNA positive. IFNa can inhibit HBV replication, resulting in improvement in the liver disease, but there is a high risk of serious infections and hepatic failure [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. IFN treatment should not be used in these patients.",
"     </li>",
"     <li>",
"      HBeAg-, HBV DNA-, with normal ALT levels &ndash; These inactive carriers do",
"      <strong>",
"       not",
"      </strong>",
"      require treatment since they have no evidence of active virus replication or ongoing liver damage. These patients should be monitored to make sure they are in the inactive carrier state as patients with HBeAg-negative chronic hepatitis may also have intermittently undetectable HBV DNA and normal ALT.",
"     </li>",
"     <li>",
"      Asian patients &ndash; Asian patients who are HBeAg+, HBV DNA+, and have elevated ALT levels and chronic hepatitis should be considered for IFNa treatment. Although initial studies found that Asian patients respond poorly to IFNa therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/26\">",
"       26",
"      </a>",
"      ], a subsequent trial found that Chinese adults with elevated serum ALT levels responded to IFNa at a similar rate as Caucasian patients (39 percent); in comparison, the response rate was only 5 percent in those with normal serum ALT [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/27\">",
"       27",
"      </a>",
"      ]. Response rates among Asian patients were similar to Caucasian patients in the peginterferon studies described above; most patients in these studies had elevated ALT at entry.",
"     </li>",
"     <li>",
"      HBeAg+, HBV DNA+ children with elevated ALT levels &ndash; Issues related to HBV treatment in children are presented separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=see_link\">",
"       \"Overview of hepatitis B virus infection in children\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is also suggestive evidence that IFNa may be beneficial in patients with extrahepatic manifestations of chronic HBV infection such as polyarteritis nodosa and various glomerular diseases. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=see_link\">",
"     \"Renal disease associated with hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     LONG-TERM OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most responders are able to maintain their response after cessation of treatment unless they become immunocompromised [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/28-31\">",
"     28-31",
"    </a>",
"    ]. Furthermore, long-term response is associated with a reduced risk of developing hepatic decompensation, hepatocellular carcinoma, and liver-related deaths.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Eradication of HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;A positive response to IFNa is characterized by the loss of HBeAg from the circulation, followed by loss of HBsAg in some North American and European patients during the course of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/28,32-36\">",
"     28,32-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the largest reports with long-term follow-up focused on 165 patients with HBeAg-positive chronic hepatitis B who were treated with interferon between 1978 and 2002 [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/37\">",
"       37",
"      </a>",
"      ]. Response to treatment was defined as HBeAg loss within 12 months after the end of therapy. Patients were followed for a median of 8.8 years. Fifty-four patients (33 percent) responded. Relapse occurred in only seven of the responders (13 percent). Loss of HBsAg was observed in 52 percent of responders (compared with only 9 percent of nonresponders). In comparison, delayed clearance of HBsAg has not been observed in Asian patients [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/38\">",
"       38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another report focused on 266 patients treated with peginterferon with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , of whom 37 percent lost HBeAg during treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/34\">",
"       34",
"      </a>",
"      ]. Of 172 patients with follow-up data, 81 percent of those who lost HBeAg within 24 weeks of completing a 48-week course of treatment continued to be HBeAg negative up to three years after cessation of treatment. Loss of HBsAg was achieved in 30 percent of patients who lost HBeAg (58 percent of those with genotype A and only 6 percent with non-A genotypes).",
"     </li>",
"     <li>",
"      A third study included a total of 315 patients with HBeAg-negative HBV who were followed for three years after treatment with peginterferon with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      or with lamivudine alone for 48 weeks [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/36\">",
"       36",
"      </a>",
"      ]. One year after treatment, more patients treated with peginterferon (with or without lamivudine) achieved a normal ALT and HBV DNA levels &le;400",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      compared with lamivudine. At three years, the proportion of patients with normal serum ALT levels was significantly higher in patients treated with peginterferon (31 versus 18 percent). Similarly, more patients treated with peginterferon achieved HBV DNA levels of &le;10,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (28 versus 15 percent). Of patients treated with a regimen that included peginterferon (with or without lamivudine), 9 percent cleared HBsAg compared with none who received lamivudine. Thus, these data suggest that about 25 percent of HBeAg-negative patients treated with peginterferon for 48 weeks have a durable response when virologic response was defined as HBV DNA &le;10,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      (and about 14 percent of patients had a durable response when virologic response was defined as HBV DNA &le;400",
"      <span class=\"nowrap\">",
"       copies/mL).",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=see_link\">",
"       \"Combination therapy for chronic hepatitis B virus infection\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Disappearance of HBV DNA in serum as determined by polymerase chain reaction (PCR) assay occurs in 50 to 100 percent of patients who clear both HBeAg and HBsAg, usually occurring at the time the patients become HBsAg negative; in comparison, disappearance of HBV DNA is seldom achieved in patients who clear HBeAg but remain HBsAg positive [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As noted above, the studies on pegylated IFN suggest that the immune modulating effects of IFN may exert a benefit even after therapy is withdrawn since some patients only achieve HBeAg seroconversion after therapy has been stopped and since the response appears to be more durable compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Furthermore, higher rates of HBsAg clearance have been observed in both HBeAg-positive and HBeAg-negative patients compared with lamivudine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Resolution of liver damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;A sustained antiviral response, particularly in those who clear both HBeAg and HBsAg, is almost invariably accompanied by a decrease in necroinflammatory activity. However, residual damage, as manifested by portal inflammation and fibrosis, may be present [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/37,39\">",
"     37,39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Improvement in survival",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data to substantiate the hypothesis that a sustained response can lead to decreased risks of cirrhosis and HCC and improvement in survival are scanty due to the short duration of follow-up in most studies [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/32,35,40-42\">",
"     32,35,40-42",
"    </a>",
"    ]. Although there are exceptions [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/41\">",
"     41",
"    </a>",
"    ], in aggregate, they suggest improved overall survival and survival free of hepatic decompensation among patients who achieve a sustained response [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/7,32,35,37,43\">",
"     7,32,35,37,43",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     DOSE REGIMEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard IFNa is usually administered as subcutaneous injections in doses of 5 million units (MU) daily or 10 MU three times a week for 16 weeks in patients with HBeAg-positive chronic HBV. One controlled trial suggested that extending therapy for up to 32 weeks in patients who remained HBeAg-positive at 16 weeks improved rates of subsequent HBeAg seroconversion [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/42\">",
"     42",
"    </a>",
"    ]. A longer course of treatment (one to two years) has been suggested for HBeAg-negative chronic HBV, but the optimal duration of treatment is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/7\">",
"     7",
"    </a>",
"    ]. As noted above, peginterferon is preferred in settings where it is available.",
"   </p>",
"   <p>",
"    The manufacturer recommends that peginterferon should be given at a dose of 180",
"    <span class=\"nowrap\">",
"     mcg/week",
"    </span>",
"    for 48 weeks for HBeAg-negative or positive chronic HBV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Prednisone priming",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     Prednisone",
"    </a>",
"    enhances HBV replication through a direct stimulatory effect on the glucocorticoid responsive element in the HBV genome and an indirect effect related to immunosuppression. Abrupt withdrawal after a short course of steroids is frequently accompanied by a flare in serum ALT levels, suggesting an enhanced immune response to HBV infected hepatocytes.",
"   </p>",
"   <p>",
"    Initial pilot studies suggested that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    priming followed by IFNa therapy was more effective than IFNa alone. However, this benefit was",
"    <strong>",
"     not",
"    </strong>",
"    confirmed by large-scale randomized controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/27,44,45\">",
"     27,44,45",
"    </a>",
"    ]. Prednisone priming can be with associated hepatitis flares and hepatic decompensation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     PREDICTIVE FACTORS FOR RESPONSE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     HBeAg positive",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several factors have been identified that are associated with a favorable response to standard IFNa treatment of HBeAg-positive patients [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/27,44\">",
"     27,44",
"    </a>",
"    ]. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High pretreatment serum ALT level",
"     </li>",
"     <li>",
"      Low pretreatment serum HBV DNA level",
"     </li>",
"     <li>",
"      Adult acquired HBV infection",
"     </li>",
"     <li>",
"      Active liver histology",
"     </li>",
"     <li>",
"      Female sex",
"     </li>",
"     <li>",
"      HIV antibody negative",
"     </li>",
"     <li>",
"      Delta virus antibody negative",
"     </li>",
"     <li>",
"      HBV genotype B versus C and genotype A versus D (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link\">",
"       \"Clinical significance of hepatitis B virus genotypes\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first two factors, elevated ALT and low serum HBV DNA levels, are generally considered to be the most accurate predictors of response to standard IFNa among HBeAg-positive patients.",
"   </p>",
"   <p>",
"    A number of predictors for response with peginterferon have also been described, but none has been validated sufficiently for routine clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/9,15,20,46-48\">",
"     9,15,20,46-48",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Genotype (genotype A is associated with higher rate of HBeAg seroconversion and HBsAg clearance than genotypes B, C, or D)",
"     </li>",
"     <li>",
"      Low viral load",
"     </li>",
"     <li>",
"      High pretreatment serum ALT level",
"     </li>",
"     <li>",
"      Absence of previous interferon therapy",
"     </li>",
"     <li>",
"      More marked decrease in the titer of HBeAg during treatment",
"     </li>",
"     <li>",
"      Absence of a decline in HBsAg by 12 weeks of treatment",
"     </li>",
"     <li>",
"      IL28B genotype (controversial)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The predictive accuracy of changes in virologic marks (eg, HBeAg and HBsAg) during treatment is described above. (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Efficacy of peginterferon'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    An illustrative study included a total of 721 patients who received peginterferon in two previous trials [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/9,15\">",
"     9,15",
"    </a>",
"    ] concluded that the likelihood of sustained HBeAg loss (defined as undetectable HBeAg and HBV DNA levels &lt;2 X 10",
"    <sup>",
"     3",
"    </sup>",
"    int.",
"    <span class=\"nowrap\">",
"     units/mL",
"    </span>",
"    six months after stopping treatment) could be predicted by pretreatment levels of HBV DNA and ALT and the HBV genotype [",
"    <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/47\">",
"     47",
"    </a>",
"    ]. The likelihood of response varied across these predictors, ranging from as high as 54 percent in patients with genotype A who had an ALT &ge;2 X the upper limit of normal and HBV DNA &lt;9 log",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    to as low as 7 percent in patients with HBV genotype D, an ALT level &le;2 X the upper limit of normal, and HBV DNA of &ge;9 log",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    The predictive accuracy of these observations requires additional validation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     HBeAg negative",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few predictors of response to peginterferon in HBeAg-negative patients have been described, including the degree of elevation of the serum ALT and the HBsAg and HBV DNA levels. Predictive factors for response to interferon in HBeAg-negative patients have not been clearly defined.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study found that a marked elevation in serum ALT (&gt;10 times the upper limit of normal or more than 300 int. units) levels during therapy was predictive of a normal ALT and histologic improvement six months after stopping pegylated IFN therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Several studies found that the change in titer of HBsAg was predictive of response. In one report involving 386 HBeAg-negative patients treated with peginterferon with or without",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , an HBsAg level of &lt;10 int.",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      at week 48 and an on-treatment decline of &gt;1 log",
"      <sub>",
"       10",
"      </sub>",
"      int.",
"      <span class=\"nowrap\">",
"       units/mL",
"      </span>",
"      were significantly associated with sustained HBsAg clearance three years after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/49\">",
"       49",
"      </a>",
"      ]. In another report involving 48 patients treated with peginterferon, a sustained virologic response (defined as undetectable HBV DNA 24 weeks after treatment) was observed only in patients who exhibited a decrease in HBsAg titers during treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/50\">",
"       50",
"      </a>",
"      ]. In a third study, both the degree of decline in HBsAg levels and HBV DNA levels from baseline predicted a sustained response [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/51\">",
"       51",
"      </a>",
"      ]. More data are needed to understand the role of HBsAg and HBV DNA monitoring during treatment with peginterferon, whether treatment duration should be tailored according to the rate of decline in HBsAg titer, and whether a lack of decline in HBsAg titer can be used as a negative predictor of response prompting early termination of treatment.",
"     </li>",
"     <li>",
"      Certain polymorphisms of IL28B predicted HBsAg seroclearance in a report of patients with genotype D infection [",
"      <a class=\"abstract\" href=\"UTD.htm?13/60/14281/abstract/52\">",
"       52",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS TO THE USE OF INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;IFNa should not be used in patients with a history of suicidal tendency, active psychiatric or autoimmune illness, severe leukopenia or thrombocytopenia, concurrent severe systemic disorders, or decompensated cirrhosis. The major side effects of IFNa are discussed separately. They include an initial flu-like syndrome, fatigue, anorexia and nausea, weight loss, hair loss, emotional lability and depression, bone marrow suppression, and induction of autoantibodies with enhancement of autoimmune disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     NONRESPONDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of patients who do not respond to a course of interferon is uncertain. Options include observation or treatment with a",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analog. A second course of interferon is generally not recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;An approach to the use of interferon alfa (IFNa) in the treatment of chronic HBV infection is presented in the figure (",
"    <a class=\"graphic graphic_algorithm graphicRef58668 \" href=\"UTD.htm?6/55/7038\">",
"     algorithm 1",
"    </a>",
"    ). The choice of interferon versus other treatments depends upon the clinical setting. IFNa is most likely to benefit patients with replicative infection and active liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     HBeAg+, HBV DNA+, with elevated ALT levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard IFNa should be used only if pegylated interferon is not available. The approved dose of peginterferon is 180 mcg weekly given for 48 weeks. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients with low HBV DNA and high ALT levels prior to treatment are most likely to respond. These patients are also more likely to respond to oral antiviral therapy. The decision to use",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , or pegylated IFNa as primary therapy should be made after careful discussion with the patient. Recommendations for the selection of agents are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     HBeAg+, HBV DNA+, with normal ALT levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend IFNa",
"    <strong>",
"     NOT",
"    </strong>",
"    be given to these patients since they are unlikely to achieve HBeAg seroconversion (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). However, they should be monitored regularly because immune tolerance may break down later in life, rendering them more responsive to IFNa treatment. These patients are also unlikely to have HBeAg seroconversion with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    therapy (see appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     HBV DNA+ with decompensated cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;These patients should be referred to liver transplant centers. They may benefit from antiviral therapy such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    ,&nbsp;or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . Entecavir or tenofovir are preferred because of the lower rate of drug resistance.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     HBeAg- with elevated ALT levels",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with this profile should be tested for HBV DNA and other causes of liver disease. Those who are HBV DNA positive and have no other causes for the liver disease may be considered for IFNa therapy; they may be infected with precore variants. These patients may require a longer duration of treatment (at least 12 and possibly 24 months) and are more likely to relapse when therapy is discontinued. These patients may also benefit from",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    therapy. (See appropriate topic reviews).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Patients who do not respond to interferon",
"    </span>",
"    &nbsp;&mdash;&nbsp;These patients can be treated with any of the approved",
"    <span class=\"nowrap\">",
"     nucleoside/nucleotide",
"    </span>",
"    analogues. Existing studies indicate that these patients respond just as well as those who are IFN-na&iuml;ve. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link\">",
"     \"Overview of the management of hepatitis B and case examples\"",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/1\">",
"      Lok AS, Heathcote EJ, Hoofnagle JH. Management of hepatitis B: 2000--summary of a workshop. Gastroenterology 2001; 120:1828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/2\">",
"      Nair S, Perrillo RP. Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: is sustained clearance of HBV DNA dependent on levels of pretreatment viremia? Hepatology 2001; 34:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/3\">",
"      Wong DK, Cheung AM, O'Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/4\">",
"      Fattovich G, Farci P, Rugge M, et al. A randomized controlled trial of lymphoblastoid interferon-alpha in patients with chronic hepatitis B lacking HBeAg. Hepatology 1992; 15:584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/5\">",
"      Brunetto MR, Giarin M, Saracco G, et al. Hepatitis B virus unable to secrete e antigen and response to interferon in chronic hepatitis B. Gastroenterology 1993; 105:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/6\">",
"      Lampertico P, Del Ninno E, Manzin A, et al. A randomized, controlled trial of a 24-month course of interferon alfa 2b in patients with chronic hepatitis B who had hepatitis B virus DNA without hepatitis B e antigen in serum. Hepatology 1997; 26:1621.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/7\">",
"      Lampertico P, Del Ninno E, Vigan&ograve; M, et al. Long-term suppression of hepatitis B e antigen-negative chronic hepatitis B by 24-month interferon therapy. Hepatology 2003; 37:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/8\">",
"      Brunetto MR, Oliveri F, Coco B, et al. Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study. J Hepatol 2002; 36:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/9\">",
"      Lau GK, Piratvisuth T, Luo KX, et al. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352:2682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/10\">",
"      Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/11\">",
"      Cooksley WG, Piratvisuth T, Lee SD, et al. Peginterferon alpha-2a (40 kDa): an advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 2003; 10:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/12\">",
"      Liaw YF, Jia JD, Chan HL, et al. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/13\">",
"      Leemans WF, Flink HJ, Janssen HL, et al. The effect of pegylated interferon-alpha on the treatment of lamivudine resistant chronic HBeAg positive hepatitis B virus infection. J Hepatol 2006; 44:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/14\">",
"      Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/15\">",
"      Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/16\">",
"      Buster EH, Hansen BE, Buti M, et al. Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/17\">",
"      ter Borg MJ, van Zonneveld M, Zeuzem S, et al. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: relation to treatment response. Hepatology 2006; 44:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/18\">",
"      Chan HL, Wong VW, Wong GL, et al. Early hepatitis B virus DNA suppression can predict virologic response to peginterferon and lamivudine treatment. Clin Gastroenterol Hepatol 2008; 6:1022.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/19\">",
"      Fried MW, Piratvisuth T, Lau GK, et al. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 2008; 47:428.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/20\">",
"      Sonneveld MJ, Rijckborst V, Boucher CA, et al. Prediction of sustained response to peginterferon alfa-2b for hepatitis B e antigen-positive chronic hepatitis B using on-treatment hepatitis B surface antigen decline. Hepatology 2010; 52:1251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/21\">",
"      Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005; 54:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/22\">",
"      Sun J, Hou JL, Xie Q, et al. Randomised clinical trial: efficacy of peginterferon alfa-2a in HBeAg positive chronic hepatitis B patients with lamivudine resistance. Aliment Pharmacol Ther 2011; 34:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/23\">",
"      Lok AS. Antiviral therapy of the Asian patient with chronic hepatitis B. Semin Liver Dis 1993; 13:360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/24\">",
"      Hoofnagle JH, Di Bisceglie AM, Waggoner JG, Park Y. Interferon alfa for patients with clinically apparent cirrhosis due to chronic hepatitis B. Gastroenterology 1993; 104:1116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/25\">",
"      Perrillo R, Tamburro C, Regenstein F, et al. Low-dose, titratable interferon alfa in decompensated liver disease caused by chronic infection with hepatitis B virus. Gastroenterology 1995; 109:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/26\">",
"      Lok AS, Lai CL, Wu PC, Leung EK. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/27\">",
"      Lok AS, Wu PC, Lai CL, et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102:2091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/28\">",
"      Korenman J, Baker B, Waggoner J, et al. Long-term remission of chronic hepatitis B after alpha-interferon therapy. Ann Intern Med 1991; 114:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/29\">",
"      Lau DT, Everhart J, Kleiner DE, et al. Long-term follow-up of patients with chronic hepatitis B treated with interferon alfa. Gastroenterology 1997; 113:1660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/30\">",
"      Yuen MF, Hui CK, Cheng CC, et al. Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/31\">",
"      Wong VW, Wong GL, Yan KK, et al. Durability of peginterferon alfa-2b treatment at 5 years in patients with hepatitis B e antigen-positive chronic hepatitis B. Hepatology 2010; 51:1945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/32\">",
"      Niederau C, Heintges T, Lange S, et al. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334:1422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/33\">",
"      Moucari R, Korevaar A, Lada O, et al. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol 2009; 50:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/34\">",
"      Buster EH, Flink HJ, Cakaloglu Y, et al. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 2008; 135:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/35\">",
"      Papatheodoridis GV, Manesis E, Hadziyannis SJ. The long-term outcome of interferon-alpha treated and untreated patients with HBeAg-negative chronic hepatitis B. J Hepatol 2001; 34:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/36\">",
"      Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/37\">",
"      van Zonneveld M, Honkoop P, Hansen BE, et al. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39:804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/38\">",
"      Lok AS, Chung HT, Liu VW, Ma OC. Long-term follow-up of chronic hepatitis B patients treated with interferon alfa. Gastroenterology 1993; 105:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/39\">",
"      Fong TL, Di Bisceglie AM, Gerber MA, et al. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B. Hepatology 1993; 18:1313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/40\">",
"      Fattovich G, Giustina G, Realdi G, et al. Long-term outcome of hepatitis B e antigen-positive patients with compensated cirrhosis treated with interferon alfa. European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1997; 26:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/41\">",
"      Lin SM, Sheen IS, Chien RN, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29:971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/42\">",
"      Janssen HL, Gerken G, Carre&ntilde;o V, et al. Interferon alfa for chronic hepatitis B infection: increased efficacy of prolonged treatment. The European Concerted Action on Viral Hepatitis (EUROHEP). Hepatology 1999; 30:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/43\">",
"      Lin SM, Yu ML, Lee CM, et al. Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/44\">",
"      Perrillo RP, Schiff ER, Davis GL, et al. A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 1990; 323:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/45\">",
"      Mellerup MT, Krogsgaard K, Mathurin P, et al. Sequential combination of glucocorticosteroids and alfa interferon versus alfa interferon alone for HBeAg-positive chronic hepatitis B. Cochrane Database Syst Rev 2002; :CD000345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/46\">",
"      Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with Peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006; 101:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/47\">",
"      Buster EH, Hansen BE, Lau GK, et al. Factors that predict response of patients with hepatitis B e antigen-positive chronic hepatitis B to peginterferon-alfa. Gastroenterology 2009; 137:2002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/48\">",
"      Lampertico P, Liaw YF. New perspectives in the therapy of chronic hepatitis B. Gut 2012; 61 Suppl 1:i18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/49\">",
"      Brunetto MR, Moriconi F, Bonino F, et al. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology 2009; 49:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/50\">",
"      Moucari R, Mackiewicz V, Lada O, et al. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients. Hepatology 2009; 49:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/51\">",
"      Rijckborst V, Hansen BE, Cakaloglu Y, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology 2010; 52:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?13/60/14281/abstract/52\">",
"      Lampertico P, Vigan&ograve; M, Cheroni C, et al. IL28B polymorphisms predict interferon-related hepatitis B surface antigen seroclearance in genotype D hepatitis B e antigen-negative patients with chronic hepatitis B. Hepatology 2013; 57:890.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3661 Version 13.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-427C511A25-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14281=[""].join("\n");
var outline_f13_60_14281=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ENDPOINTS OF THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EFFICACY OF STANDARD INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EFFICACY OF PEGINTERFERON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hepatitis flares",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Following treatment with nucleos(t)ide analogues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SELECTION OF PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      LONG-TERM OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Eradication of HBV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Resolution of liver damage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Improvement in survival",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      DOSE REGIMEN",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Prednisone priming",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      PREDICTIVE FACTORS FOR RESPONSE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      HBeAg positive",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      HBeAg negative",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CONTRAINDICATIONS TO THE USE OF INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      NONRESPONDERS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      HBeAg+, HBV DNA+, with elevated ALT levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      HBeAg+, HBV DNA+, with normal ALT levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      HBV DNA+ with decompensated cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      HBeAg- with elevated ALT levels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Patients who do not respond to interferon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"GAST/3661\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3661|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?6/55/7038\" title=\"algorithm 1\">",
"      Use of IFNa in chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"GAST/3661|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?20/6/20587\" title=\"table 1\">",
"      Efficacy of IFNa in chronic HBV",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/35/21045?source=related_link\">",
"      Characteristics of the hepatitis B virus and pathogenesis of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12760?source=related_link\">",
"      Combination therapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/23/41337?source=related_link\">",
"      Mechanism of action and efficacy of peginterferon for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/41/31386?source=related_link\">",
"      Overview of hepatitis B virus infection in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/28/44488?source=related_link\">",
"      Renal disease associated with hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/18/42279?source=related_link\">",
"      Serologic diagnosis of hepatitis B virus infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f13_60_14282="SLE CT scan showing ground glass";
var content_f13_60_14282=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F88483%7ERADIOL%2F88484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F88483%7ERADIOL%2F88484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 610px\">",
"   <div class=\"ttl\">",
"    Ground glass pulmonary changes on computerized tomography imaging in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 590px; height: 489px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The axial CT image from a 40-year-old female with systemic lupus erythematosus shows a subsegmental region of ground glass change (arrow) in the posterior segment of the right lower lobe. In the posterior segment of the left lower lobe, there is a focal parenchymal infiltrate with an air bronchogram (arrowhead).",
"    <div class=\"footnotes\">",
"     CT: computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 619px\">",
"   <div class=\"ttl\">",
"    Acute pneumonitis on chest radiography and computerized tomography imaging in systemic lupus erythematosus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 599px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The chest x-ray performed on this 41-year-old female shows a diffuse interstitial pattern, and the CT scan through the chest shows multicentric ground glass changes centered around the bronchovascular bundle compatible with acute lupus pneumonitis.",
"    <div class=\"footnotes\">",
"     CT: computerized tomography.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14282=[""].join("\n");
var outline_f13_60_14282=null;
var title_f13_60_14283="Sensitivity of human organs or tissues to ionizing radiation";
var content_f13_60_14283=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F68401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F68401&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Sensitivity of human organs or tissues to ionizing radiation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Relative radiosensitivity",
"       </td>",
"       <td class=\"subtitle1\">",
"        Organ or tissue",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very high",
"       </td>",
"       <td>",
"        Embryonic tissue, lymphoid organs, bone marrow, blood, testes and ovaries, small intestines",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        High",
"       </td>",
"       <td>",
"        Skin, lens and cornea of eye, most gastrointestinal organs (oral cavity, esophagus, stomach, rectum), bladder, uterus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Medium",
"       </td>",
"       <td>",
"        Growing cartilage, growing bones, blood vessels",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low",
"       </td>",
"       <td>",
"        Mature cartilage or bone, pituitary gland, lungs, thyroid, pancreas, kidneys, adrenal glands",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Very low",
"       </td>",
"       <td>",
"        Brain, spinal cord, muscles",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Rubin P, Casarett GW. Clinical Radiation Pathology. Philadelphia; W.B. Saunders; 1968.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14283=[""].join("\n");
var outline_f13_60_14283=null;
var title_f13_60_14284="Boston criteria CAA";
var content_f13_60_14284=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F53541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F53541&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Boston criteria for CAA-related hemorrhage",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Classic Boston criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        <strong>",
"         Definite CAA",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Full postmortem examination demonstrating:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lobar, cortical, or corticosubcortical hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Severe CAA with vasculopathy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absence of other diagnostic lesion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Probable CAA with supporting pathology",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Clinical data and pathologic tissue (evacuated hematoma or cortical biopsy) demonstrating:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lobar, cortical, or corticosubcortical hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Some degree of CAA in specimen",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absence of other diagnostic lesion",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Probable CAA",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Clinical data and MRI or CT demonstrating:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Multiple hemorrhages restricted to lobar, cortical, or corticosubcortical regions (cerebellar hemorrhage allowed)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age &ge;55 y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absence of other cause of hemorrhage",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        <strong>",
"         Possible CAA",
"        </strong>",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Clinical data and MRI or CT demonstrating:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Single lobar, cortical, or corticosubcortical hemorrhage",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Age &ge;55 y",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Absence of other cause of hemorrhage",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CAA: cerebral amyloid angiopathy.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Linn J, Halpin A, Demaerel P, et al. Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy. Neurology 2010; 74:1346. Copyright &copy; 2010 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14284=[""].join("\n");
var outline_f13_60_14284=null;
var title_f13_60_14285="Abx prophylaxis regimens";
var content_f13_60_14285=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F54121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F54121&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Antibiotic regimens: Prophylaxis for endoscopic procedures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Procedure",
"       </td>",
"       <td class=\"subtitle1\">",
"        Condition(s)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Antibiotic and dose*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        PEG placement",
"       </td>",
"       <td>",
"        MRSA risk absent",
"       </td>",
"       <td>",
"        Cefazolin 1 gram (pediatric dose 50 mg/kg) IV within&nbsp;30 minutes before procedure.",
"        <strong>",
"         If penicillin or cephalosporin hypersensitivity:",
"        </strong>",
"        Clindamycin 600 mg (pediatric dose 20 mg/kg) IV within 30 minutes before procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        MRSA risk present",
"       </td>",
"       <td>",
"        Pre-procedural MRSA screening and attempt decolonization. (If successful decolonization not completed: Vancomycin 1 gram [pediatric dose 15 mg/kg] IV infused over 60 to 90 minutes to conclude within 30 minutes prior to procedure.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        ERCP",
"       </td>",
"       <td rowspan=\"4\">",
"        <p>",
"         - Biliary obstruction AND cholangitis",
"        </p>",
"        <p>",
"         - Biliary obstruction unlikely to be successfully drained at ERCP (including malignant hilar obstruction and primary sclerosing cholangitis)",
"        </p>",
"        <p>",
"         - Inadequate biliary drainage following ERCP",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Ciprofloxacin 500 mg (pediatric dose 15 mg/kg&loz;) orally given 30 to 60 minutes prior to procedure or 400 mg (pediatric dose 15 mg/kg&loz;) IV within 30 minutes prior to procedure",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         Amoxicillin-clavulate 1750 mg (pediatric dose 45 mg/kg) orally 30 to 60 minutes prior to procedure or ampicillin-sulbactam 3 grams (pediatric dose 50 mg/kg ampicillin component) IV within 30 minutes prior to procedure",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin 2 grams (pediatric dose 50 mg/kg) IV",
"        <strong>",
"         plus",
"        </strong>",
"        gentamicin 1.5 mg/kg (maximum 120 mg) IV 30 minutes before procedure.",
"        <strong>",
"         If penicillin hypersensitivity:",
"        </strong>",
"        Substitute vancomycin 1 gram (pediatric dose 15 mg/kg) IV infused over 60 to 90 minutes to conclude within 30 minutes prior to procedure plus gentamicin 1.5 mg/kg IV (maximum 120 mg) 30 minutes before procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         ALL",
"        </strong>",
"        above regimens are discontinued post-procedure when drainage is established absent evidence of cholangitis. For post-procedure dosing, see each drug information topic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        ERCP or EUS-FNA of cystic lesion(s)",
"       </td>",
"       <td>",
"        <p>",
"         - Sterile pancreatic cysts",
"        </p>",
"        <p>",
"         - Cysts outside pancreas (excluding solid lesions)",
"        </p>",
"       </td>",
"       <td>",
"        Ciprofloxacin 500 mg orally (pediatric dose 15 mg/kg&loz;) 30 to 60 minutes prior to procedure or 400 mg (pediatric dose 15 mg/kg&loz;) IV given within 30 minutes prior to procedure. Continue 3 to 5 days post-procedure.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        All endoscopic procedures with high risk of bacteremia",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         - Immunocompromised patients",
"        </p>",
"        <p>",
"         - Cirrhosis with ascites&bull;",
"        </p>",
"        <p>",
"         - Synthetic vascular graft during first six months after graft placement&Delta; (antibiotic prophylaxis is NOT recommended for nonvalvular cardiovascular devices)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Amoxicillin 2 grams (pediatric dose 50 mg/kg) orally 30 to 60 minutes before procedure",
"        </p>",
"        <p>",
"         <strong>",
"          OR",
"         </strong>",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ampicillin 2 grams (pediatric dose 50 mg/kg) IV or IM within 30 minutes prior to procedure.",
"        <strong>",
"         If penicillin hypersensitivity:",
"        </strong>",
"        Clindamycin 600 mg (pediatric dose 20 mg/kg) orally 30 to 60 minutes before procedure or IV within 30 minutes prior to procedure.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PEG: percutaneous endoscopic gastrostomy; MRSA: methicillin resistant Staphylococcus aureus; ERCP: endoscopic retrograde cholangiopancreatography; EUS-FNA: endoscopic ultrasound-guided fine-needle aspiration; GI: gastrointestinal.",
"     <br>",
"      * Pediatric dose should generally not exceed adult dose.",
"      <br>",
"       &bull; In patients with cirrhosis and upper gastrointestinal bleeding, antibiotics are indicated even if endoscopy is not planned.",
"       <br>",
"        &Delta; American Heart Association recommendation only. Antimicrobial prophylaxis for synthetic vascular grafts is not recommended by the American Society for Gastrointestinal Endoscopy (ASGE) even if recent (&lt;6 months) graft placement.",
"        <br>",
"         &loz; Use fluoroquinolones cautiously in children.",
"         <br/>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14285=[""].join("\n");
var outline_f13_60_14285=null;
var title_f13_60_14286="XELOX regimen";
var content_f13_60_14286=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F61781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F61781&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Capecitabine and oxaliplatin (XELOX) for colorectal cancer",
"    <sup>",
"     [1,2]",
"    </sup>",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr class=\"divider_bottom\">",
"       <td colspan=\"4\">",
"        Cycle length: 21 days.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Drug",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose and route",
"       </td>",
"       <td class=\"subtitle1\">",
"        Administration",
"       </td>",
"       <td class=\"subtitle1\">",
"        Given on days",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Oxaliplatin",
"        </strong>",
"       </td>",
"       <td>",
"        130 mg/m",
"        <sup>",
"         2",
"        </sup>",
"        IV",
"       </td>",
"       <td>",
"        Dilute in 250 mL 5 percent dextrose in water (D5W)* and administer over two hours.",
"       </td>",
"       <td>",
"        Day 1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         Capecitabine",
"        </strong>",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        850 mg/m",
"        <sup>",
"         2&loz;",
"        </sup>",
"        per dose by mouth",
"       </td>",
"       <td>",
"        Twice daily; take with water within 30 minutes after a meal.",
"       </td>",
"       <td>",
"        Evening of Day 1 to morning of Day 15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Pretreatment considerations:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Emesis risk:",
"        </strong>",
"        Oxaliplatin: MODERATE. Oral capecitabine: LOW. Refer to UpToDate topic on \"Prevention and treatment of chemotherapy-induced nausea and vomiting\").",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Prophylaxis for infusion reactions:",
"        </strong>",
"        There is no standard premedication regimen for oxaliplatin. Refer to UpToDate topic on \"Infusion reactions to systemic chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Vesicant/irritant properties:",
"        </strong>",
"        Oxaliplatin is an irritant but can cause significant tissue damage; avoid extravasation. Refer to UpToDate topic on \"Extravasation injury from chemotherapy and other non-neoplastic vesicants\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Infection prophylaxis:",
"        </strong>",
"        Primary prophylaxis with granulocyte colony stimulating factors not indicated (estimated risk of febrile neutropenia less than 5 percent",
"        <sup>",
"         [1]",
"        </sup>",
"        ). Refer to UpToDate topic on \"Use of granulocyte colony stimulating factors in patients with chemotherapy-induced neutropenia\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Dose adjustment for baseline liver or renal dysfunction:",
"        </strong>",
"        Lower starting doses of oxaliplatin and capecitabine may be needed for renal impairment. Refer to UpToDate topic on \"Chemotherapy-related nephrotoxicity and dose modification in patients with renal insufficiency\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Maneuvers to prevent neurotoxicity:",
"        </strong>",
"        Pharmacologic methods to prevent/delay the onset of oxaliplatin-related neuropathy are controversial due to the absence of large clinical trials proving benefit. Counsel patients to avoid exposure to cold during and for approximately 48 hours after each infusion. Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Monitoring parameters:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; CBC with differential and platelet count weekly during treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess electrolytes and liver and renal function every three weeks prior to treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; Assess changes in neurologic function prior to each treatment.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull; More frequent anticoagulant response (INR or prothrombin time) monitoring is necessary for patients receiving concomitant capecitabine and oral coumarin-derivative anticoagulant therapy.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"4\">",
"        Suggested dose alterations for toxicity:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Myelotoxicity:",
"        </strong>",
"        The treatment cycle should be delayed one week if the total white blood cell count is less than 3000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , absolute neutrophil count is less than 1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        , or the platelets count is less than 100,000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        on day 1. If treatment is delayed for two weeks or delayed for one week on two separate occasions, reduce the doses of oxaliplatin and capecitabine by 10 to 20 percent. Subsequent treatment cycles should be delayed until neutrophils are &ge;1500 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        and platelets are &ge;75,000 cells/mm",
"        <sup>",
"         3",
"        </sup>",
"        .",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Neurologic toxicity:",
"        </strong>",
"        In the original trial, for grade 3 paresthesias and dysethesias lasting longer than seven days, the oxaliplatin dose was decreased by 25 percent, and oxaliplatin was discontinued for grade 4 or persistent grade 3 paresthesia/dysesthesias",
"        <sup>",
"         [1]",
"        </sup>",
"        . The US FDA-approved product information suggests dose reduction for persistent NCI-CTC grade 2 neurosensory events (sensory alteration or paresthesias including tingling but not interfering with activities of daily living [ADLs]) and discontinuation of oxaliplatin for persistent grade 3 (objective sensory loss or paresthesias including tingling interfering with function but not ADLs) or grade 4 neurosensory events",
"        <sup>",
"         [3]",
"        </sup>",
"        . Refer to UpToDate topic on \"Neurologic complications of platinum-based chemotherapy\".",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"4\">",
"        &bull;",
"        <strong>",
"         Other toxicity:",
"        </strong>",
"        A dose reduction in oxaliplatin is recommended after recovery from grade 3 to 4 gastrointestinal toxicity",
"        <sup>",
"         [3]",
"        </sup>",
"        . Recommended dose modification guidelines for capecitabine are available in the US FDA-approved manufacturer's package insert",
"        <sup>",
"         [4]",
"        </sup>",
"        . Doses of capecitabine that are omitted for toxicity are not replaced. The patient should resume the planned treatment cycles at the modified dose.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         If there is a change in body weight of at least 10 percent, doses should be recalculated.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <strong>",
"     This table is provided as an example of how to administer this regimen; there may be other acceptable methods. This regimen must be administered by a clinician trained in the use of chemotherapy. The clinician is expected to use his or her independent medical judgment in the context of individual circumstances to make adjustments, as necessary.",
"    </strong>",
"    <div class=\"footnotes\">",
"     IV: intravenous; CBC: complete blood count; INR: international normalized ratio; NCI-CTC: National Cancer Institute Common Toxicity Criteria.",
"     <br/>",
"     * Diluent solutions should not be modified without consulting a detailed reference due to potential incompatibility(ies).",
"     <br/>",
"     &Delta; Capecitabine should be administered within 30 minutes of a meal, with each dose given as close to 12 hours apart as possible.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     In the setting of metastatic disease, American patients are usually started on capecitabine 850 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily, as per TREE-2, while Asian and European patients are more often started at capecitabine 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     twice daily, per TREE-1",
"     <sup>",
"      [1]",
"     </sup>",
"     . In the adjuvant setting, the N16968 trial used capecitabine 1000 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     in conjunction with oxaliplatin",
"     <sup>",
"      [2]",
"     </sup>",
"     . While this dose is appropriate for robust patients, others are started at 850 mg/m",
"     <sup>",
"      2",
"     </sup>",
"     with dose escalation as tolerated.",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <br/>",
"     <ol>",
"      <li>",
"       Hochster HS, et al. J Clin Oncol. 2008; 26:3523.",
"      </li>",
"      <li>",
"       Haller DG, et al. J Clin Oncol 2011; 29:1465.",
"      </li>",
"      <li>",
"       Eloxatin (oxaliplatin). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).",
"      </li>",
"      <li>",
"       Xeloda (capecitabine). US FDA-approved manufacturer's package insert. US National Library of Medicine. (Available online at dailymed.nlm.nih.gov, accessed on November 28, 2011).",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14286=[""].join("\n");
var outline_f13_60_14286=null;
var title_f13_60_14287="Erythema toxicum trunk";
var content_f13_60_14287=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F78577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F78577&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Erythema toxicum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 323px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Multiple erythematous macules with central pustules are present.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Photo courtesy of Esther K Chung, MD. From Visual Diagnosis and Treatment in Pediatrics, 1st Ed. Philadelphia: Lippincott Williams &amp; Wilkins, 2006. Copyright &copy; 2006.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f13_60_14287=[""].join("\n");
var outline_f13_60_14287=null;
